NUCLEOTIDE AND PROTEIN SEQUENCES OF VERTEBRATE SERRATE GENES AND METHODS BASED THEREON

Abstract: The present invention relates to nucleotide sequences of vertebrate Serrate genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the Serrate protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of a vertebrate Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, cysteine rich domain, transmembrane region, membrane-associated region, or one or more EGF-like repeats of a Serrate protein, or any combination of the foregoing. Antibodies to vertebrate Serrate, its derivatives and analogs, are additionally provided. Methods of production of the vertebrate Serrate proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.In specific examples, isolated Serrate genes, from chick, mouse, Xenopus and human, are provided.

Description: NUCLEOTIDE AND PROTEIN SEQUENCES OF VERTEBRATE SERRATE GENES AND METHODS BASED THEREON This invention was made in part with government support under Grant numbers GM 29093 and NS 26084 awarded by the Department of Health and Human Services. The government has certain rights in the invention. 1. INTRODUCTION The present invention relates to vertebrate Serrate genes and their encoded protein products, as well as derivatives and analogs thereof. Production of vertebrate Serrate proteins, derivatives, and antibodies is also provided. The invention further relates to therapeutic compositions and methods of diagnosis and therapy. 2. BACKGROUND OF THE INVENTION Genetic analyses in Drosophila have been extremely useful in dissecting the complexity of developmental pathways and identifying interacting loci. However, understanding the precise nature of the processes that underlie genetic interactions requires a knowledge of the protein products of the genes in question. Embryological, genetic and molecular evidence indicates that the early steps of ectodermal differentiation in Drosophila depend on cell interactions (Doe and Goodman, 1985, Dev. Biol. 111:206-219; Technau and Campos-Ortega, 1986, Dev. Biol. 195:445-454; Vassin et al., 1985, J. Neurogenet. 2:291-308; de la Concha et al. , 1988, Genetics 118:499-508; Xu et al., 1990, Genes Dev. 4:464-475; Artavanis-Tsakonas, 1988, Trends Genet. 4:95-100). Mutational analyses reveal a small group of zygotically- acting genes, the so called neurogenic loci, which affect the choice of ectodermal cells between epidermal and neural pathways (Poulson, 1937, Proc. Natl. Acad. Sci. 23:133-137; Lehmann et al., 1983, Wilhelm Roux's Arch. Dev. Biol. 192:62- 74; Jϋrgens et al., 1984, Wilhelm Roux's Arch. Dev. Biol. 193:283-295; Wieschaus et al., 1984, Wilhelm Roux's Arch. Dev. Biol. 193:296-307; Nϋsslein-Volhard et al., 1984, Wilhelm Roux's Arch. Dev. Biol. 193:267-282) . Null mutations in any one of the zygotic neurogenic loci — Notch (N) , Delta (Dl ) , mastermind (mam) , Enhancer of Split (E (spl ) , neuralized (neu ) , and big brain (bib) — result in hypertrophy of the nervous system at the expense of ventral and lateral epidermal structures. This effect is due to the misrouting of epidermal precursor cells into a neuronal pathway, and implies that neurogenic gene function is necessary to divert cells within the neurogenic region from a neuronal fate to an epithelial fate. Serrate has been identified as a genetic unit capable of interacting with the Notch locus (Xu et al., 1990, Genes Dev. 4:464-475) . These genetic and developmental observations have led to the hypothesis that the protein products of the neurogenic loci function as components of a cellular interaction mechanism necessary for proper epidermal development (Artavanis-Tsakonas, S., 1988, Trends Genet. 4:95-100) . Mutational analyses also reveal that the action of the neurogenic genes is pleiotropic and is not limited solely to embryogenesis. For example, ommatidial, bristle and wing formation, which are known also to depend upon cell interactions, are affected by neurogenic mutations (Morgan et al., 1925, Bibliogr. Genet. 2:1-226; Welshons, 1956, Dros. Inf. Serv. 30:157-158; Preiss et al., 1988, EMBO J. 7:3917- 3927; Shellenbarger and Mohler, 1978, Dev. Biol. 62:432-446; Technau and Campos-Ortega, 1986, Wilhelm Roux's Dev. Biol. 195:445-454; Tomlison and Ready, 1987, Dev. Biol. 120:366- 376; Cagan and Ready, 1989, Genes Dev. 3:1099-1112) . Sequence analyses (Wharton et al., 1985, Cell 43:567-581; Kidd and Young, 1986, Mol. Cell. Biol. 6:3094- 3108; Vassin, et al., 1987, EMBO J. 6:3431-3440; Kopczynski, et al., 1988, Genes Dev. 2:1723-1735) have shown that two of the neurogenic loci, Notch and Delta , appear to encode transmembrane proteins that span the membrane a single time. The Notch gene encodes a -300 kd protein (we use "Notch" to denote this protein) with a large N-terminal extracellular domain that includes 36 epidermal growth factor (EGF)-like tandem repeats followed by three other cysteine-rich repeats, designated Notch/lin-12 repeats (Wharton, et al., 1985, Cell 43:567-581; Kidd and Young, 1986, Mol. Cell. Biol. 6:3094- 3108; Yochem, et al., 1988, Nature 335:547-550) . Delta encodes a -100 kd protein (we use "Delta" to denote DLZM, the protein product of the predominant zygotic and maternal transcripts; Kopczynski, et al., 1988, Genes Dev. 2:1723- 1735) that has nine EGF-like repeats within its extracellular domain (Vassin, et al., 1987, EMBO J. 6:3431-3440; Kopczynski, et al., 1988, Genes Dev. 2:1723-1735) . Molecular studies have lead to the suggestion that Notch and Delta constitute biochemically interacting elements of a cell communication mechanism involved in early developmental decisions (Fehon et al., 1990, Cell 61:523-534) . The EGF-like motif has been found in a variety of proteins, including those involved in the blood clotting cascade (Furie and Furie, 1988, Cell 53: 505-518). In particular, this motif has been found in extracellular proteins such as the blood clotting factors IX and X (Rees et al., 1988, EMBO J. 7:2053-2061; Furie and Furie, 1988, Cell 53: 505-518) , in other Drosophila genes (Knust et al., 1987 EMBO J. 761-766; Rothberg et al., 1988, Cell 55:1047-1059), and in some cell-surface receptor proteins, such as thrombomodulin (Suzuki et al., 1987, EMBO J. 6:1891-1897) and LDL receptor (Sudhof et al., 1985, Science 228:815-822) . A protein binding site has been mapped to the EGF repeat domain in thrombomodulin and urokinase (Kurosawa et al., 1988, J. Biol. Chem 263:5993-5996; Appella et al., 1987, J. Biol. Chem. 262:4437-4440) . The Drosophila Serrate gene has been cloned and characterized (PCT Publication WO 93/12141 dated June 24, 1993) . However, prior to the present invention, despite attempts to achieve the same, no vertebrate Serrate gene was available. Citation of references hereinabove shall not be construed as an admission that such references are prior art to the present invention. 3. SUMMARY OF THE INVENTION The present invention relates to nucleotide sequences of vertebrate Serrate genes (human Serrate and related genes of other species) , and amino acid sequences of their encoded proteins, as well as derivatives (e . g . , fragments) and analogs thereof. Nucleic acids hybridizable to or complementary to the foregoing nucleotide sequences are also provided. In a specific embodiment, the Serrate protein is a human protein. The invention relates to vertebrate Serrate derivatives and analogs of the invention which are functionally active, i.e., they are capable of displaying one or more known functional activities associated with a full- length (wild-type) Serrate protein. Such functional activities include but are not limited to antigenicity [ability to bind (or compete with Serrate for binding) to an anti-Serrate antibody] , immunogenicity (ability to generate antibody which binds to Serrate) , ability to bind (or compete with Serrate for binding) to Notch or other toporythmic proteins or fragments thereof ("adhesiveness") , ability to bind (or compete with Serrate for binding) to a receptor for Serrate. "Toporythmic proteins" as used herein, refers to the protein products of Notch , Del ta , Serrate , Enhancer of split , and Deltex, as well as other members of this interacting gene family which may be identified, e . g . , by virtue of the ability of their gene sequences to hybridize, or their homology to Delta, Serrate, or Notch, or the ability of their genes to display phenotypic interactions. The invention further relates to fragments (and derivatives and analogs thereof) of vertebrate Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, transmembrane domain, membrane- associated region, or one or more EGF-like (homologous) repeats of a Serrate protein, or any combination of the foregoing. Antibodies to vertebrate Serrate, its derivatives and analogs, are additionally provided. Methods of production of the vertebrate Serrate proteins, derivatives and analogs, e . g. , by recombinant means, are also provided. The present invention also relates to therapeutic and diagnostic methods and compositions based on vertebrate Serrate proteins and nucleic acids. The invention provides for treatment of disorders of cell fate or differentiation by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include: vertebrate Serrate proteins and analogs and derivatives (including fragments) thereof; antibodies thereto; nucleic acids encoding the vertebrate Serrate proteins, analogs, or derivatives; and vertebrate Serrate antisense nucleic acids. In a preferred embodiment, a Therapeutic of the invention is administered to treat a cancerous condition, or to prevent progression from a pre- neoplastic or non-malignant state into a neoplastic or a malignant state. In other specific embodiments, a Therapeutic of the invention is administered to treat a nervous system disorder or to promote tissue regeneration and repair. In one embodiment, Therapeutics which antagonize, or inhibit, Notch and/or Serrate function (hereinafter "Antagonist Therapeutics") are administered for therapeutic effect. In another embodiment, Therapeutics which promote Notch and/or Serrate function (hereinafter "Agonist Therapeutics") are administered for therapeutic effect. Disorders of cell fate, in particular hyperproliferative (e . g. , cancer) or hypoproliferative disorders, involving aberrant or undesirable levels of expression or activity or localization of Notch and/or Serrate protein can be diagnosed by detecting such levels, as described more fully infra . In a preferred aspect, a Therapeutic of the invention is a protein consisting of at least a fragment (termed herein "adhesive fragment") of a vertebrate Serrate which mediates binding to a Notch protein or a fragment thereof. 3.1. DEFINITIONS As used herein, underscoring or italicizing the name of a gene shall indicate the gene, in contrast to its encoded protein product which is indicated by the name of the gene in the absence of any underscoring. For example, "Serrate" shall mean the Serrate gene, whereas "Serrate" shall indicate the protein product of the Serrate gene. 4. DESCRIPTION OF THE FIGURES Figure 1. Nucleotide sequence (SEQ ID NO:l) and protein sequence (SEQ ID NO:2) of Human Serrate-1 (also known as Human Jagged-1 (HJ1 ) ) . Figure 2. "Complete" nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4) of Human Serrate-2 (also known as Human Jagged-2 (HJ2) ) generated on the computer by combining the sequence of clones pBS15 and pBS3-2 isolated from human fetal brain cDNA libraries. There is a deletion of approximately 120 nucleotides in the region of this sequence which encodes the portion of Human Serrate-2 between the signal sequence and the beginning of the DSL domain. Figure 3. Nucleotide sequence (SEQ ID NO:5) of chick Serrate (C-Serrate) cDNA. Figure 4. Amino acid sequence (SEQ ID NO:6) of C-Serrate (lacking the amino-terminus of the signal sequence) . The putative cleavage site following the signal sequence (marking the predicted amino-terminus of the mature protein) is marked with an arrowhead; the DSL domain is indicated by asterisks; the EGF-like repeats (ELRs) are underlined with dashed lines; the cysteine rich region between the ELRs and the transmembrane domain is marked between arrows, and the single transmembrane domain (between amino acids 1042 and 1066) is shown in bold. Figure 5. Alignment of the amino terminal sequences of Drosophila melanogaster Delta (SEQ ID NO:7) and Serrate (SEQ ID NO:8) with C-Serrate (SEQ ID NO:6). The region shown extends from the end of the signal sequence to the end of the DSL domain. The DSL domain is indicated. Identical amino acids in all three proteins are boxed. Figure 6. Diagram showing the domain structures of Drosophila Delta and Drosophila Serrate compared with C-Serrate. The second cysteine-rich region just downstream of the EGF repeats, present only in C-Serrate and Drosophila Serrate, is not shown. Hydrophobic regions are shown in black; DSL domains are checkered and EGF-like repeats are hatched. 5. DETAILED DESCRIPTION OF THE INVENTION The present invention relates to nucleotide sequences of vertebrate Serrate genes, and amino acid sequences of their encoded proteins. The invention further relates to fragments and other derivatives, and analogs, of vertebrate Serrate proteins. Nucleic acids encoding such fragments or derivatives are also within the scope of the invention. The invention provides vertebrate Serrate genes and their encoded proteins of many different species. The Serrate genes of the invention include human Serrate and related genes (homologs) in vertebrate species. In specific embodiments, the Serrate genes and proteins are from mammals. In a preferred embodiment of the invention, the Serrate protein is a human protein. In most preferred embodiments, the Serrate protein is Human Serrate-1 or Human Serrate-2. Production of the foregoing proteins and derivatives, e . g . , by recombinant methods, is provided. The invention relates to vertebrate Serrate derivatives and analogs of the invention which are functionally active, i.e., they are capable of displaying one or more known functional activities associated with a full- length (wild-type) Serrate protein. Such functional activities include but are not limited to antigenicity [ability to bind (or compete with Serrate for binding) to an anti-Serrate antibody] , immunogenicity (ability to generate antibody which binds to Serrate) , ability to bind (or compete with Serrate for binding) to Notch or other toporythmic proteins or fragments thereof ("adhesiveness") , ability to bind (or compete with Serrate for binding) to a receptor for Serrate. "Toporythmic proteins" as used herein, refers to the protein products of Notch , Delta , Serrate , Enhancer of split , and Deltex, as well as other members of this interacting gene family which may be identified, e . g . , by virtue of the ability of their gene sequences to hybridize, or their homology to Delta, Serrate, or Notch, or the ability of their genes to display phenotypic interactions. The invention further relates to fragments (and derivatives and analogs thereof) of a vertebrate Serrate which comprise one or more domains of the Serrate protein, including but not limited to the intracellular domain, extracellular domain, transmembrane domain, membrane- associated region, or one or more EGF-like (homologous) repeats of a Serrate protein, or any combination of the foregoing. Antibodies to Serrate, its derivatives and analogs, are additionally provided. As demonstrated infra , Serrate plays a critical role in development and other physiological processes, in particular, as a ligand to Notch, which is involved in cell fate (differentiation) determination. In particular, Serrate is believed to play a major role in determining cell fates in the central nervous system. The nucleic acid and amino acid sequences and antibodies thereto of the invention can be used for the detection and quantitation of Serrate mRNA and protein of human and other species, to study expression thereof, to produce Serrate and fragments and other derivatives and analogs thereof, in the study and manipulation of differentiation and other physiological processes. The present invention also relates to therapeutic and diagnostic methods and compositions based on Serrate proteins and nucleic acids. The invention provides for treatment of disorders of cell fate or differentiation by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include: vertebrate Serrate proteins and analogs and derivatives (including fragments) thereof; antibodies thereto; nucleic acids encoding the vertebrate Serrate proteins, analogs, or derivatives; and vertebrate Serrate antisense nucleic acids. In a preferred embodiment, a Therapeutic of the invention is administered to treat a cancerous condition, or to prevent progression from a pre- neoplastic or non-malignant state into a neoplastic or a malignant state. In other specific embodiments, a Therapeutic of the invention is administered to treat a nervous system disorder or to promote tissue regeneration and repair. In one embodiment, Therapeutics which antagonize, or inhibit, Notch and/or Serrate function (hereinafter "Antagonist Therapeutics") are administered for therapeutic effect. In another embodiment, Therapeutics which promote Notch and/or Serrate function (hereinafter "Agonist Therapeutics") are administered for therapeutic effect. Disorders of cell fate, in particular hyperproliferative (e.g., cancer) or hypoproliterative disorders, involving aberrant or undesirable levels of expression or activity or localization of Notch and/or Serrate protein can be diagnosed by detecting such levels, as described more fully infra . In a preferred aspect, a Therapeutic of the invention is a protein consisting of at least a fragment (termed herein "adhesive fragment") of a vertebrate Serrate which mediates binding to a Notch protein or a fragment thereof. The invention is illustrated by way of examples infra which disclose, inter alia , the cloning of a mouse Serrate homolog (Section 6) , the cloning of a Xenopus (frog) Serrate homolog (Section 7) , the cloning of a chick Serrate homolog (Section 8) , and the cloning of the human Serrate homologs Human Serrate-1 (HJ1 ) and Human Serrate-2 (HJ2 ) (Section 9) . For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the sub-sections which follow. 5.1. ISOLATION OF THE SERRATE GENES The invention relates to the nucleotide sequences of vertebrate Serrate nucleic acids. In specific embodiments, vertebrate Serrate nucleic acids comprise the cDNA sequences shown in Figure 1 (SEQ ID NO:l), Figure 2 (SEQ ID NO:3), Figure 3 (SEQ ID NO:6) or the coding regions thereof, or nucleic acids encoding a vertebrate Serrate protein (e.g., having the sequence of SEQ ID NO:2, 4, or 6). The invention provides nucleic acids consisting of at least 8 nucleotides (i.e., a hybridizable portion) of a vertebrate Serrate sequence; in other embodiments, the nucleic acids consist of at least 10 (continuous) nucleotides, 25 nucleotides, 50 nucleotides, 100 nucleotides, 150 nucleotides, or 200 nucleotides of a vertebrate Serrate sequence, or a full-length vertebrate Serrate coding sequence. The invention also relates to nucleic acids hybridizable to or complementary to the foregoing sequences. In specific aspects, nucleic acids are provided which comprise a sequence complementary to at least 10, 25, 50, 100, or 200 nucleotides or the entire coding region of a Serrate gene. In a specific embodiment, a nucleic acid which is hybridizable to a vertebrate Serrate nucleic acid (e.g., having sequence SEQ ID N0:1), or to a nucleic acid encoding a vertebrate Serrate derivative, under conditions of low stringency is provided. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10 6 cpm 32 P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film. Other conditions of low stringency which may be used are well known in the art (e.g., as employed for cross- species hybridizations) . In another specific embodiment, a nucleic acid which is hybridizable to a vertebrate Serrate nucleic acid under conditions of high stringency is provided. By way of example and not limitation, procedures using such conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 X 10 6 cpm of 3 P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art. Nucleic acids encoding fragments and derivatives of vertebrate Serrate proteins (see Section 5.6) , and vertebrate Serrate antisense nucleic acids (see Section 5.11) are additionally provided. As is readily apparent, as used herein, a "nucleic acid encoding a fragment or portion of a Serrate protein" shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of the Serrate protein and not the other contiguous portions of the Serrate protein as a continuous sequence. Fragments of vertebrate Serrate nucleic acids comprising regions of homology to other toporythmic proteins are also provided. The DSL regions (regions of homology with Drosophila Delta and Serrate) of Serrate proteins of other species are also provided. Nucleic acids encoding conserved regions between Delta and Serrate, such as those represented by Serrate amino acids 63-73, 124-134, 149-158, 195-206, 214- 219, and 250-259 of SEQ ID NO:8, or by the DSL domains are also provided. Specific embodiments for the cloning of a vertebrate Serrate gene, presented as a particular example but not by way of limitation, follows: For expression cloning (a technique commonly known in the art) , an expression library is constructed by methods known in the art. For example, mRNA (e.g., human) is isolated, cDNA is made and ligated into an expression vector (e.g., a bacteriophage derivative) such that it is capable of being expressed by the host cell into which it is then introduced. Various screening assays can then be used to select for the expressed Serrate product. In one embodiment, anti-Serrate antibodies can be used for selection. In another preferred aspect, PCR is used to amplify the desired sequence in a genomic or cDNA library, prior to selection. Oligonucleotide primers representing known Serrate sequences can be used as primers in PCR. In a preferred aspect, the oligonucleotide primers encode at least part of the Serrate conserved segments of strong homology between Serrate and Delta . The synthetic oligonucleotides may be utilized as primers to amplify by PCR sequences from a source (RNA or DNA) , preferably a cDNA library, of potential interest. PCR can be carried out, e . g . , by use of a Perkin- Elmer Cetus thermal cycler and Taq polymerase (Gene Amp") . The DNA being amplified can include mRNA or cDNA or genomic DNA from any eukaryotic species. One can choose to synthesize several different degenerate primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the known Serrate nucleotide sequence and the nucleic acid homolog being isolated. For cross species hybridization, low stringency conditions are preferred. For same species hybridization, moderately stringent conditions are preferred. After successful amplification of a segment of a Serrate homolog, that segment may be cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described infra . In this fashion, additional genes encoding Serrate proteins may be identified. Such a procedure is presented by way of example in various examples sections infra . The above-methods are not meant to limit the following general description of methods by which clones of vertebrate Serrate may be obtained. Any vertebrate cell potentially can serve as the nucleic acid source for the molecular cloning of the Serrate gene. The nucleic acid sequences encoding Serrate can be isolated from human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. For example, we have amplified fragments of the appropriate size in mouse, Xenopus , and human, by PCR using cDNA libraries with Drosophila Serrate primers. The DNA may be obtained by standard procedures known in the art from cloned DNA (e . g . , a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell. (See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be olecularly cloned into a suitable vector for propagation of the gene. In the molecular cloning of the gene from genomic DNA, DNA fragments are generated, some of which will encode the desired gene. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography. Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired gene may be accomplished in a number of ways. For example, if a Serrate (of any species) gene or its specific RNA, or a fragment thereof, e .g. , an extracellular domain (see Section 5.6), is available and can be purified and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R. , 1977, Science 196:180; Grunstein, M. And Hogness, D. , 1975, Proc. Natl. Acad. Sci. U.S.A. 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. It is also possible to identify the appropriate fragment by restriction enzyme digestion(s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection can be carried out on the basis of the properties of the gene. Alternatively, the presence of the gene may be detected by assays based on the physical, chemical, or immunological properties of its expressed product. For example, cDNA clones, or DNA clones which hybrid-select the proper mRNAs, can be selected which produce a protein that, e . g. , has similar or identical electrophoretic migration, isolectric focusing behavior, proteolytic digestion maps, receptor binding activity, in vitro aggregation activity ("adhesiveness") or antigenic properties as known for Serrate. If an antibody to Serrate is available, the Serrate protein may be identified by binding of labeled antibody to the putatively Serrate synthesizing clones, in an ELISA (enzyme-linked immunosorbent assay)-type procedure. The Serrate gene can also be identified by mRNA selection by nucleic acid hybridization followed by in vitro translation. In this procedure, fragments are used to isolate complementary RNAs by hybridization. Such DNA fragments may represent available, purified Serrate DNA of another species (e.g., human, chick). Immunoprecipitation analysis or functional assays (e . g . , aggregation ability in vitro ; binding to receptor; see infra ) of the in vitro translation products of the isolated products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against Serrate protein. A radiolabeled Serrate cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabeled mRNA or cDNA may then be used as a probe to identify the Serrate DNA fragments from among other genomic DNA fragments. Alternatives to isolating the Serrate genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the Serrate protein. For example, RNA for cDNA cloning of the Serrate gene can be isolated from cells which express Serrate . Other methods are possible and within the scope of the invention. The identified and isolated gene can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives. The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and Serrate gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc. , so that many copies of the gene sequence are generated. In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionization, can be done before insertion into the cloning vector. In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated Serrate gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA. The Serrate sequences provided by the instant invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in native Serrate proteins, and those encoded amino acid sequences with functionally equivalent amino acids, all as described in Section 5.6 infra for Serrate derivatives. 5.2. EXPRESSION OF THE SERRATE GENES The nucleotide sequence coding for a vertebrate Serrate protein or a functionally active fragment or other derivative thereof (see Section 5.6), can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native vertebrate Serrate gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e . g . , vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e . g . , baculovirus) ; microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cos id DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host- vector system utilized, any one of a number of suitable transcription and translation elements may be used. In a specific embodiment, the adhesive portion of the Serrate gene is expressed. In other specific embodiments, a Human Serrate gene or a sequence encoding a functionally active portion of a human Serrate gene, such as Human Serrate-1 (HJ2 ) or Human Serrate-2 (HJ2 ) , is expressed. In yet another embodiment, a fragment of Serrate comprising the extracellular domain, or other derivative, or analog of Serrate is expressed. Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (genetic recombination) . Expression of nucleic acid sequence encoding a Serrate protein or peptide fragment may be regulated by a second nucleic acid sequence so that the Serrate protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a Serrate protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control toporythmic gene expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304- 310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yama oto, et al., 1980, Cell 22:787- 797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42); prokaryotic expression vectors such as the β-lactamase promoter (Villa-Kamaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tae promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., Nature 303:209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner, et al., 1981, Nucl. Acids Res. 9:2871), and the promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, Nature 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444) , mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276) , alpha-fetoprotein gene control region which is active in liver (Kru lauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1- antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta- globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain- 2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378). Expression vectors containing Serrate gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a foreign gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted toporythmic gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e . g . , thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of foreign genes in the vector. For example, if the Serrate gene is inserted within the marker gene sequence of the vector, recombinants containing the Serrate insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the foreign gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the Serrate gene product in vitro assay systems, e .g . , aggregation (binding) with Notch, binding to a receptor, binding with antibody. Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenoviruε; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e .g . , lambda) , and plasmid and cosmid DNA vectors, to name but a few. In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered Serrate protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, cleavage [e.g., of signal sequence]) of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous mammalian toporythmic protein. Furthermore, different vector/host expression systems may effect processing reactions such as proteolytic cleavages to different extents. In other specific embodiments, the Serrate protein, fragment, analog, or derivative may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein) ) . Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e . g . , by use of a peptide synthesizer. Both cDNA and genomic sequences can be cloned and expressed. 5.3. IDENTIFICATION AND PURIFICATION OF THE SERRATE GENE PRODUCTS In particular aspects, the invention provides amino acid sequences of a vertebrate Serrate, preferably a human Serrate homolog, and fragments and derivatives thereof which comprise an antigenic determinant (i . e . , can be recognized by an antibody) or which are otherwise functionally active, as well as nucleic acid sequences encoding the foregoing. "Functionally active" material as used herein refers to that material displaying one or more known functional activities associated with a full-length (wild-type) Serrate protein, e.g., binding to Notch or a portion thereof, binding to any other Serrate ligand, antigenicity (binding to an anti- Serrate antibody) , etc. In specific embodiments, the invention provides fragments of a vertebrate Serrate protein consisting of at least 6 amino acids, 10 amino acids, 25 amino acids, 50 amino acids, or of at least 75 amino acids. In other embodiments, the proteins comprise or consist essentially of an extracellular domain, DSL domain, epidermal growth factor- like repeat (ELR) domain, one or any combination of ELRs, cysteine-rich region, transmembrane domain, or intracellular (cytoplasmic) domain, or a portion which binds to Notch, or any combination of the foregoing, of a Serrate protein. Fragments, or proteins comprising fragments, lacking some or all of the foregoing regions of a vertebrate Serrate protein are also provided. Nucleic acids encoding the foregoing are provided. Once a recombinant which expresses the vertebrate Serrate gene sequence is identified, the gene product can be analyzed. This is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay, etc. Once the Serrate protein is identified, it may be isolated and purified by standard methods including chromatography (e . g . , ion exchange, affinity, and sizing column chromatography) , centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.7) . Alternatively, once a Serrate protein produced by a recombinant is identified, the amino acid sequence of the protein can be deduced from the nucleotide sequence of the chimeric gene contained in the recombinant. As a result, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M. , et al., 1984, Nature 310:105-111) . In a specific embodiment of the present invention, such Serrate proteins, whether produced by recombinant DNA techniques or by chemical synthetic methods, include but are not limited to those containing, as a primary amino acid sequence, all or part of the amino acid sequence substantially as depicted in Figures 1, 2, or 3 (SEQ ID NO:2, 4, or 6, respectively), as well as fragments and other derivatives, and analogs thereof. 5.4. STRUCTURE OF THE SERRATE GENES AND PROTEINS The structure of the Serrate genes and proteins can be analyzed by various methods known in the art. 5.4.1. GENETIC ANALYSIS The cloned DNA or cDNA corresponding to the vertebrate Serrate gene can be analyzed by methods including but not limited to Southern hybridization (Southern, E.M. , 1975, J. Mol. Biol. 98:503-517), Northern hybridization (see e . g . , Freeman et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:4094-4098), restriction endonuclease mapping (Maniatis, T. , 1982, Molecular Cloning, A Laboratory, Cold Spring Harbor, New York), and DNA sequence analysis. Polymerase chain reaction (PCR; U.S. Patent Nos. 4,683,202, 4,683,195 and 4,889,818; Gyllenstein et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7652-7656; Ochman et al., 1988, Genetics 120:621-623; Loh et al., 1989, Science 243:217-220) followed by Southern hybridization with a Serrate-specific probe can allow the detection of the Serrate gene in DNA from various cell types. Methods of amplification other than PCR are commonly known and can also be employed. In one embodiment, Southern hybridization can be used to determine the genetic linkage of Serrate . Northern hybridization analysis can be used to determine the expression of the Serrate gene. Various cell types, at various states of development or activity can be tested for Serrate expression. Examples of such techniques and their results are described in Section 6, infra . The stringency of the hybridization conditions for both Southern and Northern hybridization can be manipulated to ensure detection of nucleic acids with the desired degree of relatedness to the specific Serrate probe used. Restriction endonuclease mapping can be used to roughly determine the genetic structure of the Serrate gene. In a particular embodiment, cleavage with restriction enzymes can be used to derive the restriction map shown in Figure 2, infra . Restriction maps derived by restriction endonuclease cleavage can be confirmed by DNA sequence analysis. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, Meth. Enzymol. 65:499- 560) , the Sanger dideoxy method (Sanger, F., et al., 1977, Proc. Natl. Acad. Sci. U.S.A. 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699) , or use of an automated DNA sequenator (e . g . , Applied Biosystems, Foster City, CA) . The cDNA sequence of a representative Serrate gene comprises the sequence substantially as depicted in Figures 1 and 2, and is described in Section 9, infra . 5.4.2. PROTEIN ANALYSIS The amino acid sequence of the Serrate proteins can be derived by deduction from the DNA sequence, or alternatively, by direct sequencing of the protein, e . g . , with an automated amino acid sequencer. The amino acid sequence of a representative Serrate protein comprises the sequence substantially as depicted in Figure 1, and detailed in Section 9, infra , with the representative mature protein that shown by amino acid numbers 30-1219. The Serrate protein sequence can be further characterized by a hydrophilicity analysis (Hopp, T. and Woods, K. , 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824). A hydrophilicity profile can be used to identify the hydrophobic and hydrophilic regions of the Serrate protein and the corresponding regions of the gene sequence which encode such regions. Secondary, structural analysis (Chou, P. and Fasman, G., 1974, Biochemistry 13:222) can also be done, to identify regions of Serrate that assume specific secondary structures. 5 Manipulation, translation, and secondary structure prediction, as well as open reading frame prediction and plotting, can also be accomplished using computer software programs available in the art. Other methods of structural analysis can also be 10 employed. These include but are not limited to X-ray crystallography (Engstom, A., 1974, Biochem. Exp. Biol. ll:7- 13) and computer modeling (Fletterick, R. and Zoller, M. (eds.), 1986, Computer Graphics and Molecular Modeling, in Current Communications in Molecular Biology, Cold Spring 15 Harbor Laboratory, Cold Spring Harbor, New York) . 5.5. GENERATION OF ANTIBODIES TO SERRATE PROTEINS AND DERIVATIVES THEREOF According to the invention, a vertebrate Serrate 2 protein, its fragments or other derivatives, or analogs thereof, may be used as an immunogen to generate antibodies which recognize such an immunogen. Such antibodies include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. __ In a specific embodiment, antibodies to human Serrate are produced. In another embodiment, antibodies to the extracellular domain of Serrate are produced. In another embodiment, antibodies to the intracellular domain of Serrate are produced. Various procedures known in the art may be used for the production of polyclonal antibodies to a Serrate protein or derivative or analog. In a particular embodiment, rabbit polyclonal antibodies to an epitope of the Serrate protein encoded by a sequence depicted in Figure 1, or a subsequence thereof, can be obtained. For the production of antibody, various host animals can be immunized by injection with the native Serrate protein, or a synthetic version, or derivative (e.g., fragment) thereof, including but not limited to rabbits, mice, rats, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete) , mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. For preparation of monoclonal antibodies directed toward a vertebrate Serrate protein sequence or analog thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) , and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96) . In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (PCT/US90/02545) . According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B cells with EBV virus in vitro (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy. Alan R. Liss, pp. 77-96) . In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851-6855; Neuberger et al., 1984, Nature 312:604-608; Takeda et al., 1985, Nature 314:452-454) by splicing the genes from a mouse antibody molecule specific for Serrate together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce Serrate-specific single chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, Science 246:1275- 1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for Serrate proteins, derivatives, or analogs. Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab 1 fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, and the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent. In the production of antibodies, screening for the desired antibody can be accomplished by techniques known in the art, e.g. ELISA (enzyme-linked immunosorbent assay) . For example, to select antibodies which recognize a specific domain of a Serrate protein, one may assay generated hybridomas for a product which binds to a Serrate fragment containing such domain. For selection of an antibody specific to vertebrate (e.g., human) Serrate, one can select on the basis of positive binding to vertebrate Serrate and a lack of binding to Drosophila Serrate. In another embodiment, one can select for binding to human Serrate and not to Serrate of other species. The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the protein sequences of the invention (e.g., see Section 5.7, infra) , e . g. , for imaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc. Antibodies specific to a domain of a Serrate protein are also provided. In a specific embodiment, antibodies which bind to a Notch-binding fragment of Serrate are provided. In another embodiment of the invention (see infra ) , anti-Serrate antibodies and fragments thereof containing the binding domain are Therapeutics. 5.6. SERRATE PROTEINS. DERIVATIVES AND ANALOGS The invention further relates to vertebrate Serrate proteins, and derivatives (including but not limited to fragments) and analogs of Serrate proteins. Nucleic acids encoding vertebrate Serrate protein derivatives and protein analogs are also provided. In one embodiment, the Serrate proteins are encoded by the vertebrate Serrate nucleic acids described in Section 5.1 supra . In particular aspects, the proteins, derivatives, or analogs are of frog, mouse, rat, pig, cow, dog, monkey, or human Serrate proteins. The production and use of derivatives and analogs related to vertebrate Serrate are within the scope of the present invention. In a specific embodiment, the derivative or analog is functionally active, i.e., capable of exhibiting one or more functional activities associated with a full- length, wild-type Serrate protein. As one example, such derivatives or analogs which have the desired immunogenicity or antigenicity can be used, for example, in immunoassays, for immunization, for inhibition of Serrate activity, etc. Such molecules which retain, or alternatively inhibit, a desired Serrate property, e.g., binding to Notch or other toporythmic proteins, binding to a cell-surface receptor, can be used as inducers, or inhibitors, respectively, of such property and its physiological correlates. A specific embodiment relates to a Serrate fragment that can be bound by an anti-Serrate antibody but cannot bind to a Notch protein or other toporythmic protein. Derivatives or analogs of Serrate can be tested for the desired activity by procedures known in the art, including but not limited to the assays described in Section 5.7. In particular, Serrate derivatives can be made by altering Serrate sequences by substitutions, additions or deletions that provide for functionally equivalent molecules. Due to the degeneracy of nucleotide coding sequences, other DNA sequences which encode substantially the same amino acid sequence as a Serrate gene may be used in the practice of the present invention. These include but are not limited to nucleotide sequences comprising all or portions of Serrate genes which are altered by the substitution of different codons that encode a functionally equivalent amino acid residue within the sequence, thus producing a silent change. Likewise, the Serrate derivatives of the invention include, but are not limited to, those containing, as a primary amino acid sequence, all or part of the amino acid sequence of a Serrate protein including altered sequences in which functionally equivalent amino acid residues are substituted for residues within the sequence resulting in a silent change. For example, one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a silent alteration. Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. In a specific embodiment of the invention, proteins consisting of or comprising a fragment of a vertebrate Serrate protein consisting of at least 10 (continuous) amino acids of the Serrate protein is provided. In other embodiments, the fragment consists of at least 20 or 50 amino acids of the Serrate protein. In specific embodiments, such fragments are not larger than 35, 100 or 200 amino acids. Derivatives or analogs of vertebrate Serrate include but are not limited to those peptides which are substantially homologous to a vertebrate Serrate or a fragment thereof (e.g., at least 30% identity over an amino acid sequence of identical size) or whose encoding nucleic acid is capable of hybridizing to a coding vertebrate Serrate sequence. The Serrate derivatives and analogs of the invention can be produced by various methods known in the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned Serrate gene sequence can be modified by any of numerous strategies known in the art (Maniatis, T. , 1990, Molecular Cloning, A Laboratory Manual, 2d ed. , Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) . The sequence can be cleaved at appropriate sites with restriction endonuclease(s) , followed by further enzymatic modification if desired, isolated, and ligated in vitro . In the production of the gene encoding a derivative or analog of Serrate, care should be taken to ensure that the modified gene remains within the same translational reading frame as Serrate , uninterrupted by translational stop signals, in the gene region where the desired Serrate activity is encoded. Additionally, the Serrate-encoding nucleic acid sequence can be mutated in vitro or in vivo , to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further in vitro modification. Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site- directed mutagenesis (Hutchinson, C. , et al., 1978, J. Biol. Chem 253:6551), use of TAB® linkers (Pharmacia) , etc. Manipulations of the Serrate sequence may also be made at the protein level. Included within the scope of the invention are Serrate protein fragments or other derivatives or analogs which are differentially modified during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH 4 ; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc. In addition, analogs and derivatives of Serrate can be chemically synthesized. For example, a peptide corresponding to a portion of a Serrate protein which comprises the desired domain (see Section 5.6.1), or which mediates the desired aggregation activity in vitro , or binding to a receptor, can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the Serrate sequence. Non- classical amino acids include but are not limited to the D- isomers of the common amino acids, α-amino isobutyric acid, 4-aminobutyric acid, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, 3-alanine, designer amino acids such as β- methyl amino acids, Cα-methyl amino acids, and Nα-methyl amino acids. In a specific embodiment, the Serrate derivative is a chimeric, or fusion, protein comprising a vertebrate Serrate protein or fragment thereof (preferably consisting of at least a domain or motif of the Serrate protein, or at least 10 amino acids of the Serrate protein) joined at its amino- or carboxy-terminus via a peptide bond to an amino acid sequence of a different protein. In one embodiment, such a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (comprising a Serrate- coding sequence joined in-frame to a coding sequence for a different protein) . Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric nucleic acid encoding a mature vertebrate Serrate protein with a heterologous signal sequence is expressed such that the chimeric protein is expressed and processed by the cell to the mature Serrate protein. As another example, and not by way of limitation, a recombinant molecule can be constructed according to the invention, comprising coding portions of both Serrate and another toporythmic gene, e.g., Delta. The encoded protein of such a recombinant molecule could exhibit properties associated with both Serrate and Delta and portray a novel profile of biological activities, including agonists as well as antagonists. The primary sequence of Serrate and Delta may also be used to predict tertiary structure of the molecules using computer simulation (Hopp and Woods, 1981, Proc. Natl. Acad. Sci. U.S.A. 78:3824-3828); Serrate/Delta chimeric recombinant genes could be designed in light of correlations between tertiary structure and biological function. Likewise, chimeric genes comprising portions of a vertebrate Serrate fused to any heterologous protein-encoding sequences may be constructed. A specific embodiment relates to a chimeric protein comprising a fragment of a vertebrate Serrate of at least ten amino acids. In another specific embodiment, the Serrate derivative is a fragment of Serrate comprising a region of homology with another toporythmic protein. As used herein, a region of a first protein shall be considered "homologous" to a second protein when the amino acid sequence of the region is at least 30% identical or at least 75% either identical or involving conservative changes, when compared to any sequence in the second protein of an equal number of amino acids as the number contained in the region. For example, such a 5 Serrate fragment can comprise one or more regions homologous to Delta, or DSL domains or portions thereof. Other specific embodiments of derivatives and analogs are described in the subsections below and examples sections infra . 10 5.6.1. DERIVATIVES OF SERRATE CONTAINING ONE OR MORE DOMAINS OF THE PROTEIN In a specific embodiment, the invention relates to vertebrate Serrate derivatives and analogs, in particular 15 vertebrate Serrate fragments and derivatives of such fragments, that comprise, or alternatively consist of, one or more domains of the Serrate protein, including but not limited to the extracellular domain, DSL domain, ELR domain, cysteine rich domain, transmembrane domain, intracellular __ domain, membrane-associated region, and one or more of the EGF-like repeats (ELR) of the Serrate protein, or any combination of the foregoing. In particular examples relating to the human and chick Serrate proteins, such domains are identified in Examples Section 9 and 8, 2 _ respectively. In a specific embodiment, the molecules comprising specific fragments of vertebrate Serrate are those comprising fragments in the respective Serrate protein most homologous to specific fragments of the Drosophila Serrate and/or Delta 30 proteins. In particular embodiments, such a molecule comprises or consists of the amino acid sequences homologous to SEQ ID NO:10, 12, or 18. Alternatively, a fragment comprising a domain of a Serrate homolog can be identified by protein analysis methods as described in Section 5.3.2. 35 5.6.2. DERIVATIVES OF SERRATE THAT MEDIATE BINDING TO TOPORYTHMIC PROTEIN DOMAINS The invention also provides for vertebrate Serrate fragments, and analogs or derivatives of such fragments, which mediate binding to toporythmic proteins (and thus are termed herein "adhesive") , and nucleic acid sequences encoding the foregoing. In a specific embodiment, the adhesive fragment of Serrate is that comprising the portion of Serrate most homologous to about amino acid numbers 85-283 or 79-282 of the Drosophila Serrate sequence (see PCT Publication WO 93/12141 dated June 24, 1993) . In a particular embodiment, the adhesive fragment of a Serrate protein comprises the DSL domain, or a portion thereof. Subfragments within the DSL domain that mediate binding to Notch can be identified by analysis of constructs expressing deletion mutants. The ability to bind to a toporythmic protein (preferably Notch) can be demonstrated by in vitro aggregation assays with cells expressing such a toporythmic protein as well as cells expressing Serrate or a Serrate derivative (See Section 5.7). That is, the ability of a Serrate fragment to bind to a Notch protein can be demonstrated by detecting the ability of the Serrate fragment, when expressed on the surface of a first cell, to bind to a Notch protein expressed on the surface of a second cell. The nucleic acid sequences encoding toporythmic proteins or adhesive domains thereof, for use in such assays, can be isolated from human, porcine, bovine, feline, avian, equine, canine, or insect, as well as primate sources and any other species in which homologs of known toporythmic genes can be identified. 5.7. ASSAYS OF SERRATE PROTEINS, DERIVATIVES AND ANALOGS The functional activity of vertebrate Serrate proteins, derivatives and analogs can be assayed by various methods. For example, in one embodiment, where one is assaying for the ability to bind or compete with wild-type Serrate for binding to anti-Serrate antibody, various immunoassays known in the art can be used, including but not limited to competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay) , "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example) , western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays) , complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention. In another embodiment, where one is assaying for the ability to mediate binding to a toporythmic protein, e.g., Notch, one can carry out an in vitro aggregation assay such as described in PCT Publication WO 93/12141 dated June 24, 1993 (see also Fehon et al., 1990, Cell 61:523-534; Rebay et al., 1991, Cell 67:687-699). In another embodiment, where a receptor for Serrate is identified, receptor binding can be assayed, e.g., by means well-known in the art. In another embodiment, physiological correlates of Serrate binding to cells expressing a Serrate receptor (signal transduction) can be assayed. In another embodiment, in insect or other model systems, genetic studies can be done to study the phenotypic effect of a Serrate mutant that is a derivative or analog of wild-type vertebrate Serrate . Other methods will be known to the skilled artisan and are within the scope of the invention. 5.8. THERAPEUTIC USES The invention provides for treatment of disorders of cell fate or differentiation by administration of a therapeutic compound of the invention. Such therapeutic compounds (termed herein "Therapeutics") include: vertebrate Serrate proteins and analogs and derivatives (including fragments) thereof (e.g., as described hereinabove) ; antibodies thereto (as described hereinabove) ; nucleic acids encoding the vertebrate Serrate proteins, analogs, or derivatives (e.g., as described hereinabove); and Serrate antisense nucleic acids. As stated supra , the Antagonist Therapeutics of the invention are those Therapeutics which antagonize, or inhibit, a vertebrate Serrate function and/or Notch function (since Serrate is a Notch ligand) . Such Antagonist Therapeutics are most preferably identified by use of known convenient in vitro assays, e.g., based on their ability to inhibit binding of Serrate to another protein (e.g., a Notch protein) , or inhibit any known Notch or Serrate function as preferably assayed in vitro or in cell culture, although genetic assays (e.g., in Drosophila) may also be employed. In a preferred embodiment, the Antagonist Therapeutic is a protein or derivative thereof comprising a functionally active fragment such as a fragment of Serrate which mediates binding to Notch, or an antibody thereto. In other specific embodiments, such an Antagonist Therapeutic is a nucleic acid capable of expressing a molecule comprising a fragment of Serrate which binds to Notch, or a Serrate antisense nucleic acid (see Section 5.11 herein) . It should be noted that preferably, suitable in vitro or in vivo assays, as described infra , should be utilized to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue, since the developmental history of the tissue may determine whether an Antagonist or Agonist Therapeutic is desired. In addition, the mode of administration, e.g., whether administered in soluble form or administered via its encoding nucleic acid for intracellular recombinant expression, of the Serrate protein or derivative can affect whether it acts as an agonist or antagonist. In another embodiment of the invention, a nucleic acid containing a portion of a vertebrate Serrate gene is used, as an Antagonist Therapeutic, to promote Serrate inactivation by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra et al., 1989, Nature 342:435-438). The Agonist Therapeutics of the invention, as described supra , promote Serrate function. Such Agonist Therapeutics include but are not limited to proteins and derivatives comprising the portions of Notch that mediate binding to Serrate, and nucleic acids encoding the foregoing (which can be administered to express their encoded products in vivo) . Further descriptions and sources of Therapeutics of the inventions are found in Sections 5.1 through 5.7 herein. Molecules which retain, or alternatively inhibit, a desired Serrate property, e.g., binding to Notch, binding to an intracellular ligand, can be used therapeutically as inducers, or inhibitors, respectively, of such property and its physiological correlates. In a specific embodiment, a peptide (e.g., in the range of 10-50 or 15-25 amino acids; and particularly of about 10, 15, 20 or 25 amino acids) containing the sequence of a portion of a vertebrate Serrate which binds to Notch is used to antagonize Notch function. In a specific embodiment, such an Antagonist Therapeutic is used to treat or prevent human or other malignancies associated with increased Notch expression (e.g., cervical cancer, colon cancer, breast cancer, squamous adenocarcimas (see infra ) ) . Derivatives or analogs of Serrate can be tested for the desired activity by procedures known in the art, including but not limited to the assays described in the examples infra . For example, molecules comprising vertebrate Serrate fragments which bind to Notch EGF-repeats (ELR) 11 and 12 and which are smaller than a DSL domain, can be obtained and selected by expressing deletion mutants and assaying for binding of the expressed product to Notch by any of the several methods (e . g . , in vitro cell aggregation assays, interaction trap system) , some of which are described in the Examples Sections infra . In one specific embodiment, peptide libraries can be screened to select a peptide with the desired activity; such screening can be carried out by assaying, e.g., for binding to Notch or a molecule containing the Notch ELR 11 and 12 repeats. The Agonist and Antagonist Therapeutics of the invention have therapeutic utility for disorders of cell fate. The Agonist Therapeutics are administered therapeutically (including prophylactically) : (1) in diseases or disorders involving an absence or decreased (relative to normal, or desired) levels of Notch or Serrate function, for example, in patients where Notch or Serrate protein is lacking, genetically defective, biologically inactive or underactive, or underexpressed; and (2) in diseases or disorders wherein in vitro (or in vivo) assays (see infra) indicate the utility of Serrate agonist administration. The absence or decreased levels in Notch or Serrate function can be readily detected, e.g., by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for protein levels, structure and/or activity of the expressed Notch or Serrate protein. Many methods standard in the art can be thus employed, including but not limited to immunoassays to detect and/or visualize Notch or Serrate protein (e.g., Western blot, immunoprecipitation followed by sodium dodecyl sulfate polyacryla ide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect Notch or Serrate expression by detecting and/or visualizing respectively Notch or Serrate mRNA (e.g., Northern assays, dot blots, in situ hybridization, etc.) In vitro assays which can be used to determine whether administration of a specific Agonist Therapeutic or Antagonist Therapeutic is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a Therapeutic, and the effect of such Therapeutic upon the tissue sample is observed. In one embodiment, where the patient has a malignancy, a sample of cells from such malignancy is plated out or grown in culture, and the cells are then exposed to a Therapeutic. A Therapeutic which inhibits survival or growth of the malignant cells (e.g., by promoting terminal differentiation) is selected for therapeutic use in vivo . Many assays standard in the art can be used to assess such survival and/or growth; for example, cell proliferation can be assayed by measuring 3 H-thymidine incorporation, by direct cell count, by detecting changes in transcriptional activity of known genes such as proto- oncogenes (e.g., foε, myc) or cell cycle markers; cell viability can be assessed by trypan blue staining, differentiation can be assessed visually based on changes in morphology, etc. In a specific aspect, the malignant cell cultures are separately exposed to (1) an Agonist Therapeutic, and (2) an Antagonist Therapeutic; the result of the assay can indicate which type of Therapeutic has therapeutic efficacy. In another embodiment, a Therapeutic is indicated for use which exhibits the desired effect, inhibition or promotion of cell growth, upon a patient cell sample from tissue having or suspected of having a hyper- or hypoproliferative disorder, respectively. Such hyper- or hypoproliferative disorders include but are not limited to those described in Sections 5.8.1 through 5.8.3 infra . In another specific embodiment, a Therapeutic is indicated for use in treating nerve injury or a nervous system degenerative disorder (see Section 5.8.2) which exhibits in vitro promotion of nerve regeneration/neurite extension from nerve cells of the affected patient type. In addition, administration of an Antagonist Therapeutic of the invention is also indicated in diseases or disorders determined or known to involve a Notch or Serrate dominant activated phenotype ("gain of function" mutations.) Administration of an Agonist Therapeutic is indicated in diseases or disorders determined or known to involve a Notch or Serrate dominant negative phenotype ("loss of function" mutations) . The functions of various structural domains of the Notch protein have been investigated in vivo , by ectopically expressing a series of Drosophila Notch deletion mutants under the hsp70 heat-shock promoter, as well as eye- specific promoters (see Rebay et al., 1993, Cell 74:319-329) . Two classes of dominant phenotypes were observed, one suggestive of Notch loss-of function mutations and the other of Notch gain-of-function mutations. Dominant "activated" phenotypes resulted from overexpression of a protein lacking most extracellular sequences, while dominant "negative" phenotypes resulted from overexpression of a protein lacking most intracellular sequences. The results indicated that Notch functions as a receptor whose extracellular domain mediates ligand-binding, resulting in the transmission of developmental signals by the cytoplasmic domain. We have shown that Serrate binds to the Notch ELR 11 and 12 (see PCT Publication WO 93/12141) . In various specific embodiments, in vitro assays can be carried out with representative cells of cell types involved in a patient's disorder, to determine if a Therapeutic has a desired effect upon such cell types. In another embodiment, cells of a patient tissue sample suspected of being pre-neoplastic are similarly plated out or grown in vitro , and exposed to a Therapeutic. The Therapeutic which results in a cell phenotype that is more normal (i.e., less representative of a pre-neoplastic state, neoplastic state, malignant state, or transformed phenotype) is selected for therapeutic use. Many assays standard in the art can be used to assess whether a pre-neoplastic state, neoplastic state, or a transformed or malignant phenotype, is present. For example, characteristics associated with a transformed phenotype (a set of in vitro characteristics associated with a tumorigenic ability in vivo) include a more rounded cell morphology, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, release of proteases such as plasminogen activator, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton surface protein, etc. (see Luria et al., 1978, General Virology, 3d Ed., John Wiley & Sons, New York pp. 436-446) . In other specific embodiments, the in vitro assays described supra can be carried out using a cell line, rather than a cell sample derived from the specific patient to be treated, in which the cell line is derived from or displays characteristic(s) associated with the malignant, neoplastic or pre-neoplastic disorder desired to be treated or prevented, or is derived from the neural or other cell type upon which an effect is desired, according to the present invention. The Antagonist Therapeutics are administered therapeutically (including prophylactically) : (1) in diseases or disorders involving increased (relative to normal, or desired) levels of Notch or Serrate function, for example, where the Notch or Serrate protein is overexpressed or overactive; and (2) in diseases or disorders wherein in vitro (or in vivo) assays indicate the utility of Serrate antagonist administration. The increased levels of Notch or Serrate function can be readily detected by methods such as those described above, by quantifying protein and/or RNA. In vitro assays with cells of patient tissue sample or the appropriate cell line or cell type, to determine therapeutic utility, can be carried out as described above. 5.8.1. MALIGNANCIES Malignant and pre-neoplastic conditions which can be tested as described supra for efficacy of intervention with Antagonist or Agonist Therapeutics, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to those described below in Sections 5.8.1 and 5.9.1. Malignancies and related disorders, cells of which type can be tested in vitro (and/or in vivo) , and upon observing the appropriate assay result, treated according to the present invention, include but are not limited to those listed in Table 1 (for a review of such disorders, see Fishman et al., 1985, Medicine , 2d Ed., J.B. Lippincott Co., Philadelphia) : TABLE 1 MALIGNANCIES AND RELATED DISORDERS Leukemia acute leukemia acute lymphocytic leukemia acute myelocytic leukemia myeloblastic promyelocytic myelomonocytic monocytic erythroleukemia chronic leukemia chronic myelocytic (granulocytic) leukemia chronic lymphocytic leukemia Polycythemia vera Lymp o a Hodgkin's disease non-Hodgkin's disease Multiple myeloma Waldenstrδm's macroglobulinemia Heavy chain disease Solid tumors sarcomas and carcinomas fibrosarcoma myxosarcoma liposarcoma chondrosarcoma osteogenic sarcoma chordoma angiosarcoma endotheliosarcoma lymphangiosarcoma lymphangioendotheliosarcoma synovioma mesothelioma Ewing's tumor leiomyosarcoma rhabdomyosarcoma colon carcinoma pancreatic cancer breast cancer ovarian cancer 10 prostate cancer squamous cell carcinoma basal cell carcinoma adenocarcinoma sweat gland carcinoma sebaceous gland carcinoma papillary carcinoma papillary adenocarcinomas 15 cystadenocarcinoma medullary carcinoma bronchogenic carcinoma renal cell carcinoma hepatoma bile duct carcinoma choriocarcinoma 20 seminoma embryonal carcinoma Wilms' tumor cervical cancer testicular tumor lung carcinoma small cell lung carcinoma bladder carcinoma 25 epithelial carcinoma glioma astrocytoma edulloblastoma craniopharyngioma ependymoma pinealoma 30 hemangioblastoma acoustic neuroma oligodendroglioma menangioma melanoma neuroblastoma retinoblastoma 35 In specific embodiments, malignancy or dysproliferative changes (such as metaplasias and dysplasias) are treated or prevented in epithelial tissues such as those in the cervix, esophagus, and lung. Malignancies of the colon and cervix exhibit increased expression of human Notch relative to such non- malignant tissue (see PCT Publication no. WO 94/07474 published April 14, 1994, incorporated by reference herein in its entirety) . Thus, in specific embodiments, malignancies or premalignant changes of the colon or cervix are treated or prevented by administering an effective amount of an Antagonist Therapeutic, e.g., a Serrate derivative, that antagonizes Notch function. The presence of increased Notch expression in colon, and cervical cancer suggests that many more cancerous and hyperproliferative conditions exhibit upregulated Notch. Thus, in specific embodiments, various cancers, e.g., breast cancer, squamous adenocarcinoma, seminoma, melanoma, and lung cancer, and premalignant changes therein, as well as other hyperproliferative disorders, can be treated or prevented by administration of an Antagonist Therapeutic that antagonizes Notch function. 5.8.2. NERVOUS SYSTEM DISORDERS Nervous system disorders, involving cell types which can be tested as described supra for efficacy of intervention with Antagonist or Agonist Therapeutics, and which can be treated upon thus observing an indication of therapeutic utility, include but are not limited to nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the invention include but are not limited to the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (i) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (ii) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (iϋ) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (iv) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (v) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis; (vi) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum) , and alcoholic cerebellar degeneration; (vii) neurological lesions associated with systemic diseases including but not limited to diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (viii) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (ix) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including but not limited to multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis. Therapeutics which are useful according to the invention for treatment of a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons (see also Section 5.8). For example, and not by way of limitation, Therapeutics which elicit any of the following effects may be useful according to the invention: (i) increased survival time of neurons in culture; (ii) increased sprouting of neurons in culture or in vivo; (iii) increased production of a neuron-associated molecule in culture or in vivo , e . g . , choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (iv) decreased symptoms of neuron dysfunction in vivo. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may be measured by the method set forth in Arakawa et al. (1990, J. Neurosci. 10:3507-3515); increased sprouting of neurons may be detected by methods set forth in Pestronk et al. (1980, Exp. Neurol. 70:65-82) or Brown et al. (1981, Ann. Rev. Neurosci. 4:17-42); increased production of neuron- associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability. In a specific embodiments, motor neuron disorders that may be treated according to the invention include but are not limited to disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including but not limited to progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome) , poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot- Marie-Tooth Disease) . 5.8.3. TISSUE REPAIR AND REGENERATION In another embodiment of the invention, a Therapeutic of the invention is used for promotion of tissue regeneration and repair, including but not limited to treatment of benign dysproliferative disorders. Specific embodiments are directed to treatment of cirrhosis of the liver (a condition in which scarring has overtaken normal liver regeneration processes) , treatment of keloid (hypertrophic scar) formation (disfiguring of the skin in which the scarring process interferes with normal renewal) , psoriasis (a common skin condition characterized by excessive proliferation of the skin and delay in proper cell fate determination) , and baldness (a condition in which terminally differentiated hair follicles (a tissue rich in Notch) fail to function properly) . In another embodiment, a Therapeutic of the invention is used to treat degenerative or traumatic disorders of the sensory epithelium of the inner ear. 5.9. PROPHYLACTIC USES 5.9.1. MALIGNANCIES The Therapeutics of the invention can be administered to prevent progression to a neoplastic or malignant state, including but not limited to those disorders listed in Table 1. Such administration is indicated where the Therapeutic is shown in assays, as described supra , to have utility for treatment or prevention of such disorder. Such prophylactic use is indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 68-79.) Hyperplasia is a form of controlled cell proliferation involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. As but one example, endometrial hyperplasia often precedes endometrial cancer. Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplasia can occur in epithelial or connective tissue cells. Atypical metaplasia involves a somewhat disorderly metaplastic epithelium. Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation, and is often found in the cervix, respiratory passages, oral cavity, and gall bladder. Alternatively or in addition to the presence of abnormal cell growth characterized as hyperplasia, metaplasia, or dysplasia, the presence of one or more characteristics of a transformed phenotype, or of a malignant phenotype, displayed in vivo or displayed in vitro by a cell sample from a patient, can indicate the desirability of prophylactic/therapeutic administration of a Therapeutic of the invention. As mentioned supra , such characteristics of a transformed phenotype include morphology changes, looser substratum attachment, loss of contact inhibition, loss of anchorage dependence, protease release, increased sugar transport, decreased serum requirement, expression of fetal antigens, disappearance of the 250,000 dalton cell surface protein, etc. (see also id . , at pp. 84-90 for characteristics associated with a transformed or malignant phenotype) . In a specific embodiment, leukoplakia, a benign- appearing hyperplastic or dysplastic lesion of the epithelium, or Bowen's disease, a carcinoma in situ , are pre- neoplastic lesions indicative of the desirability of prophylactic intervention. In another embodiment, fibrocystic disease (cystic hyperplasia, mammary dysplasia, particularly adenosis (benign epithelial hyperplasia) ) is indicative of the desirability of prophylactic intervention. In other embodiments, a patient which exhibits one or more of the following predisposing factors for malignancy is treated by administration of an effective amount of a Therapeutic: a chromosomal translocation associated with a malignancy (e.g., the Philadelphia chromosome for chronic myelogenous leukemia, t(14;18) for follicular lymphoma, etc.), familial polyposis or Gardner's syndrome (possible forerunners of colon cancer) , benign monoclonal gammopathy (a possible forerunner of multiple myeloma) , and a first degree kinship with persons having a cancer or precancerous disease showing a Mendelian (genetic) inheritance pattern (e.g., familial polyposis of the colon, Gardner's syndrome, hereditary exostosis, polyendocrine adenomatosis, medullary thyroid carcinoma with amyloid production and pheochromocytoma, Peutz-Jeghers syndrome, neurofibromatosis of Von Recklinghausen, retinoblastoma, carotid body tumor, cutaneous melanocarcinoma, intraocular melanocarcinoma, xeroderma pigmentosum, ataxia telangiectasia, Chediak-Higashi syndrome, albinism, Fanconi's aplastic anemia, and Bloom's syndrome; see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W.B. Saunders Co., Philadelphia, pp. 112-113) etc.) In another specific embodiment, an Antagonist Therapeutic of the invention is administered to a human patient to prevent progression to breast, colon, or cervical cancer. 5.9.2. OTHER DISORDERS In other embodiments, a Therapeutic of the invention can be administered to prevent a nervous system disorder described in Section 5.8.2, or other disorder (e.g., liver cirrhosis, psoriasis, keloids, baldness) described in Section 5.8.3. 5.10. DEMONSTRATION OF THERAPEUTIC OR PROPHYLACTIC UTILITY The Therapeutics of the invention can be tested in vivo for the desired therapeutic or prophylactic activity. For example, such compounds can be tested in suitable animal model systems prior to testing in humans, including but not limited to rats, mice, chicken, cows, monkeys, rabbits, etc. For in vivo testing, prior to administration to humans, any animal model system known in the art may be used. 5.11. ANTISENSE REGULATION OF SERRATE EXPRESSION The present invention provides the therapeutic or prophylactic use of nucleic acids of at least six or of at least ten nucleotides that are antisense to a gene or cDNA encoding a vertebrate Serrate or a portion thereof. "Antisense" as used herein refers to a nucleic acid capable of hybridizing to a portion of a vertebrate Serrate RNA (preferably mRNA) by virtue of some sequence complementarity. Such antisense nucleic acids have utility as Antagonist Therapeutics of the invention, and can be used in the treatment or prevention of disorders as described supra in Section 5.8 and its subsections. The antisense nucleic acids of the invention can be oligonucleotides that are double-stranded or single-stranded, RNA or DNA or a modification or derivative thereof, which can be directly administered to a cell, or which can be produced intracellularly by transcription of exogenous, introduced sequences. In a specific embodiment, the Serrate antisense nucleic acids provided by the instant invention can be used for the treatment of tumors or other disorders, the cells of which tumor type or disorder can be demonstrated (in vitro or in vivo) to express a Serrate gene or a Notch gene. Such demonstration can be by detection of RNA or of protein. The invention further provides pharmaceutical compositions comprising an effective amount of the Serrate antisense nucleic acids of the invention in a pharmaceutically acceptable carrier, as described infra in Section 5.12. Methods for treatment and prevention of disorders (such as those described in Sections 5.8 and 5.9) comprising administering the pharmaceutical compositions of the invention are also provided. In another embodiment, the invention is directed to methods for inhibiting the expression of a Serrate nucleic acid sequence in a prokaryotic or eukaryotic cell comprising providing the cell with an effective amount of a composition comprising an antisense vertebrate Serrate nucleic acid of the invention. Serrate antisense nucleic acids and their uses are described in detail below. 5.11.1. VERTEBRATE SERRATE ANTISENSE NUCLEIC ACIDS The vertebrate Serrate antisense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging preferably from 10 to about 50 oligonucleotides) . In specific aspects, the oligonucleotide contains at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 200 nucleotides antisense to a Serrate gene. The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO 88/09810, published December 15, 1988) or blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134, published April 25, 1988) , hybridization-triggered cleavage agents (see, e.g., Krol et al., 1988, BioTechniques 6:958-976) or intercalating agents (see, e.g., Zon, 1988, Pharm. Res. 5:539-549). In a preferred aspect of the invention, a vertebrate Serrate antisense oligonucleotide is provided, preferably of single-stranded DNA. In a most preferred aspect, such an oligonucleotide comprises a sequence antisense to the sequence encoding an SH3 binding domain or a Notch-binding domain of Serrate, most preferably, of a human Serrate homolog. The oligonucleotide may be modified at any position on its structure with substituents generally known in the art. The Serrate antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D- galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v) , wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil- 5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v) , 5-methy1-2-thiouraci1, 3-(3-amino-3-N-2-carboxypropy1) uracil, (acp3)w, and 2,6-diaminopurine. In another embodiment, the oligonucleotide comprises at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose. In yet another embodiment, the oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof. In yet another embodiment, the oligonucleotide is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual 0-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross- linking agent, transport agent, hybridization-triggered cleavage agent, etc. Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448- 7451) , etc. In a specific embodiment, the Serrate antisense oligonucleotide comprises catalytic RNA, or a ribozyme (see, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al., 1990, Science 247:1222-1225). In another embodiment, the oligonucleotide is a 2'-0- methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330) . In an alternative embodiment, the Serrate antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector can be introduced in vivo such that it is taken up by a cell, within which cell the vector or a portion thereof is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the Serrate antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the Serrate antisense RNA can be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive. Such promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304- 310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell 22:787- 797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), etc. The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript specific to a vertebrate Serrate gene, preferably a human Serrate gene. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded Serrate antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a Serrate RNA it may contain and still form a stable duplex (or triplex, as the case may be) . One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex. 5.11.2. THERAPEUTIC UTILITY OF VERTEBRATE SERRATE ANTISENSE NUCLEIC ACIDS The vertebrate Serrate antisense nucleic acids can be used to treat (or prevent) malignancies or other disorders, of a cell type which has been shown to express Serrate or Notch . In specific embodiments, the malignancy is cervical, breast, or colon cancer, or squamous adenocarcinoma. Malignant, neoplastic, and pre-neoplastic cells which can be tested for such expression include but are not limited to those described supra in Sections 5.8.1 and 5.9.1. In a preferred embodiment, a single-stranded DNA antisense Serrate oligonucleotide is used. Malignant (particularly, tumor) cell types which express Serrate or Notch RNA can be identified by various methods known in the art. Such methods include but are not limited to hybridization with a Serrate or Notch-specific nucleic acid (e.g. by Northern hybridization, dot blot hybridization, in situ hybridization) , observing the ability of RNA from the cell type to be translated in vitro into Notch or Serrate, immunoassay, etc. In a preferred aspect, primary tumor tissue from a patient can be assayed for Notch or Serrate expression prior to treatment, e.g., by immunocytochemistry or in situ hybridization. Pharmaceutical compositions of the invention (see Section 5.12) , comprising an effective amount of a vertebrate Serrate antisense nucleic acid in a pharmaceutically acceptable carrier, can be administered to a patient having a malignancy which is of a type that expresses Notch or Serrate RNA or protein. The amount of Serrate antisense nucleic acid which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the antisense cytotoxicity of the tumor type to be treated in vitro, and then in useful animal model systems prior to testing and use in humans. In a specific embodiment, pharmaceutical compositions comprising vertebrate Serrate antisense nucleic acids are administered via liposomes, microparticles, or microcapsules. In various embodiments of the invention, it may be useful to use such compositions to achieve sustained release of the Serrate antisense nucleic acids. In a specific embodiment, it may be desirable to utilize liposomes targeted via antibodies to specific identifiable tumor antigens (Leonetti et al., 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2448-2451; Renneisen et al., 1990, J. Biol. Chem. 265:16337-16342) . 5.12. THERAPEUTIC/PROPHYLACTIC ADMINISTRATION AND COMPOSITIONS The invention provides methods of treatment (and prophylaxis) by administration to a subject of an effective _ amount of a Therapeutic of the invention. In a preferred aspect, the Therapeutic is substantially purified. The subject is preferably an animal, including but not limited to animals such as cows, pigs, chickens, etc., and is preferably a mammal, and most preferably human. 10 Various delivery systems are known and can be used to administer a Therapeutic of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, expression by recombinant cells, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a Therapeutic nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds may be __ administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral ucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be __ systemic or local. In addition, it may be desirable to introduce the pharmaceutical compositions of the invention into the central nervous system by any suitable route, including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an _ intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent. __ In a specific embodiment, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre- neoplastic tissue. In another embodiment, the Therapeutic can be delivered in a vesicle, in particular a liposo e (see Langer, Science 249:1527-1533 (1990); Treat et al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.) , Liss, New York, pp. 353-365 (1989) ; Lopez-Berestein, ibid . , pp. 317-327; see generally ibid . ) In yet another embodiment, the Therapeutic can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, supra ; Sefton, CRC Crit. Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980); Saudek et al., N. Engl. J. Med. 321:574 (1989)) . In another embodiment, polymeric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); Controlled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.) , Wiley, New York (1984) ; Ranger and Peppas, J. Macro ol. Sci. Rev. Macro ol. Chem. 23:61 (1983); see also Levy et al., Science 228:190 (1985) ; During et al., Ann. Neurol. 25:351 (1989); Howard et al., J. Neurosurg. 71:105 (1989)) . In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i . e . , the brain, thus requiring only a fraction of the systemic dose (see , e . g . , Goodson, in Medical Applications of Controlled Release, supra , vol. 2, pp. 115-138 (1984) ) . Other controlled release systems are discussed in the review by Langer (Science 249:1527-1533 (1990)) . In a specific embodiment where the Therapeutic is a nucleic acid encoding a protein Therapeutic, the nucleic acid can be administered in vivo to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont) , or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot et al., 1991, Proc. Natl. Acad. Sci. USA 88:1864-1868), etc. Alternatively, a nucleic acid Therapeutic can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination. In specific embodiments directed to treatment or prevention of particular disorders, preferably the following forms of administration are used: Preferred Forms of Disorder Administration Cervical cancer Topical Gastrointestinal cancer Oral; intravenous Lung cancer Inhaled; intravenous Leukemia Intravenous; extracorporeal Metastatic carcinomas Intravenous; oral Brain cancer Targeted; intravenous;intrathecal Liver cirrhosis Oral; intravenous Psoriasis Topical Keloids Topical Baldness Topical Spinal cord injury Targeted; intravenous; intrathecal Parkinson's disease Targeted; intravenous; intrathecal Motor neuron disease Targeted; intravenous; intrathecal Alzheimer's disease Targeted; intravenous; intrathecal The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a Therapeutic, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the Therapeutic, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should suit the mode of administration. In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration. The Therapeutics of the invention can be formulated as neutral or salt forms. Pharmaceutically acceptable salts include those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc. The amount of the Therapeutic of the invention which will be effective in the treatment of a particular disorder or condition will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 micrograms of active compound per kilogram body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 g/kg body weight. Effective doses may be extrapolated from dose- response curves derived from in vitro or animal model test systems. Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient. The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. 5.13. DIAGNOSTIC UTILITY Vertebrate Serrate proteins, analogues, derivatives, and subsequences thereof, vertebrate Serrate nucleic acids (and sequences complementary thereto) , anti- vertebrate Serrate antibodies, have uses in diagnostics. Such molecules can be used in assays, such as immunoassays, to detect, prognose, diagnose, or monitor various conditions, diseases, and disorders affecting Serrate expression, or monitor the treatment thereof. In particular, such an immunoassay is carried out by a method comprising contacting a sample derived from a patient with an anti-Serrate antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody. In a specific aspect, such binding of antibody, in tissue sections, preferably in conjunction with binding of anti-Notch antibody can be used to detect aberrant Notch and/or Serrate localization or aberrant levels of Notch-Serrate colocalization in a disease state. In a specific embodiment, antibody to Serrate can be used to assay in a patient tissue or serum sample for the presence of Serrate where an aberrant level of Serrate is an indication of a diseased condition. Aberrant levels of Serrate binding ability in an endogenous Notch protein, or aberrant levels of binding ability to Notch (or other Serrate ligand) in an endogenous Serrate protein may be indicative of a disorder of cell fate (e.g., cancer, etc.) By "aberrant levels," is meant increased or decreased levels relative to that present, or a standard level representing that present, in an analogous sample from a portion of the body or from a subject not having the disorder. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay) , "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement- fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Vertebrate Serrate genes and related nucleic acid sequences and subsequences, including complementary sequences, and other toporythmic gene sequences, can also be used in hybridization assays. Vertebrate Serrate nucleic acid sequences, or subsequences thereof comprising about at least 8 nucleotides, can be used as hybridization probes. Hybridization assays can be used to detect, prognose, diagnose, or monitor conditions, disorders, or disease states associated with aberrant changes in Serrate expression and/or activity as described supra . In particular, such a hybridization assay is carried out by a method comprising contacting a sample containing nucleic acid with a nucleic acid probe capable of hybridizing to Serrate DNA or RNA, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization. Additionally, since Serrate binds to Notch, vertebrate Serrate or a binding portion thereof can be used to assay for the presence and/or amounts of Notch in a sample, e.g., in screening for malignancies which exhibit increased Notch expression such as colon and cervical cancers. 6. ISOLATION AND CHARACTERIZATION OF A MOUSE SERRATE HOMOLOG A mouse Serrate homolog, termed M-Serrate-1, was isolated as follows: Mouse Serrate-1 gene Tissue origin: 10.5-day mouse embryonic RNA Isolation method: a) random primed cDNA against above RNA b) PCR of above cDNA using PCR primer 1: CGI (C/T)TTTGC(C/T)TIAA(A/G) (G/C)AITA(C/T)CA (SEQ ID NO: 9) {encoding RLCCK(H/E)YQ (SEQ ID NO: 10)}: PCR primer 2: TCIATGCAIGTICCICC(A/G)TT (SEQ ID NO: 11) {encoding NGGTCID (SEQ ID N0:12)} Amplification conditions: 50 ng cDNA, 1 μg each primer, 0.2 mM dNTP's, 1.8 U Taq (Perkin-Elmer) in 50 μl of supplied buffer, 40 cycles of: 94°C/30 sec, 45°C/2 min, 72°C/1 min extended by 2 sec each cycle. Yielded a 1.8 kb fragment which was sequenced at both ends and identified as corresponding to C-Serrate-1 Partial DNA sequence of M-Serrate-1 : From 5' end: GTCCCGCGTCACTGCCGGGGGACCCTGCAGCTTCGGCTCAGGGTCTACGCCTGTCATCGGG GGTAACACCTTCAATCTCAAGGCCAGCCGTGGCAACGACCGTAATCGCATCGTACTGCCTT TCAGTTTCACCTGGCCGAGGTCCTACACTTTGCTGGTGGAG (SEQ ID NO: 13) Protein translation of above: SRVTAGGPCSFGSGSTPVIGGNTFNLKASRGNDRNRIVLPFSFTWPRSYTLLVE (SEQ ID NO: 14) (corresponds to amino-terminal sequence upstream of the DSL domain) 5 From 3' end (but coding strand) TCTTCTAACGTCTGTGGTCCCCATGGCAAGTGCAAGAGCCAGTCGGCAGGCAAATTCACCT GTGACTGTAACAAAGGCTTCACCGGCACCTACTGCCATGAAAATATCAACGACTGCGAGAG CAACCCCTGTAAA (SEQ ID NO: 15) 10 Protein translation of above: SSNVCGPHGKCKSQSAGKFTCDCNKGFTGTYCHENINDCESNPCK (SEQ ID NO: 16) (within tandemly arranged EGF-like repeats) Expression pattern: The expression pattern was determined to 15 be the same as that observed for C-Serrate-1 (chicken Serrate) (see Section 11 infra) , including expression in the developing central nervous system, peripheral nervous system, limb, kidney, lens, and vascular system. 20 7. ISOLATION AND CHARACTERIZATION OF A XENOPUS SERRATE HOMOLOG A Xenopus Serrate homolog, termed Xenopus Serrate-1 was isolated as follows: Xenopus Serrate-1 gene __ Tissue origin: neurula-stage embryonic RNA Isolation method: a) random primed cDNA against above RNA b) PCR using: Primer 1: CGI (C/T)TTTGC(C/T)TIAA(A/G) (G/C)AITA(C/T)CA 3Q (SEQ ID NO:9) {encoding RLCCK(H/E)YQ (SEQ ID NO: 10)}: PCR primer 2: TCIATGCAIGTICCICC(A/G)TT (SEQ ID NO: 11) {encoding NGGTCID (SEQ ID NO:12)} Amplification conditions: 50 ng cDNA, 1 μg each primer, 0.2 mM dNTP's, 1.8 U Taq (Perkin-Elmer) in 50 μl of supplied 3 buffer. 40 cycles of: 94°C/30 sec, 45°C/2 min, 72°C/1 min extended by 2 sec each cycle. Yielded a -700 bp fragment which was partially sequenced to confirm its relationship to C-Serrate-1 . 8. ISOLATION AND CHARACTERIZATION OF A CHICK SERRATE HOMOLOG In the example herein, we report the cloning and sequence of a chick Serrate homolog, C-Serrate , and of fragments of two chick Notch homologs, C-Notch-1 and C-Notch-2 , together with their expression patterns during early embryogenesis. The patterns of transcription of C-Serrate overlaps with that of C-Notch-1 in many regions of the embryo, suggesting that C-Notch-1, like Notch in Drosophila , is a receptor for Serrate. In particular, Notch and Serrate are expressed in the neurogenic regions of the developing central and peripheral nervous system. Our data show that Serrate, a known ligand of Notch, has been conserved from arthropods to chordates. The overlapping expression patterns suggest conservation of its functional relationship with Notch and imply that development of the chick and in particular of its central nervous system involves the interaction of C-Notch-1 with Serrate at several specific locations. Materials and Methods Embryos White Leghorn chicken eggs were obtained from University Park Farm and incubated at 38°C. Embryos were staged according to Hamburger and Hamilton (1951, J. Exp. Zool. 88:49-92). Cloning of chicken homologs of Notch Approximately 1000 base pair PCR fragments of the chicken Notch 1 and Notch 2 genes were amplified from otic explant RNA (see below) using degenerate primers and PCR conditions as outlined in Lardelli and Lendahl (1993, Exp. Cell Res. 204:364-372). The PCR fragment was subcloned into Bluescript KS-, sequenced and used as a template for making a DIG antisense RNA probe (RNA Transcription Kit, Stratagene; DIG RNA labelling mix, Boehringer Mannheim) . Cloning of a chicken homologue of Drosophila Serrate 5 Otic explants were dissected from embryos of stages 8 to 13. Each otic explant consisted of the two otic cups, a short section of intervening hindbrain and pharynx and the associated head ectoderm and esenchyme. RNA was extracted using a modification of standard protocols (Sambrook et al., 10 1989, in Molecular Cloning: A Laboratory Manual, 2nd ed. , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York) and polyA + mRNA was isolated from total RNA using the PolyATtract mRNA Isolation System (Promega) . First strand cDNA was synthesized using the Superscript Preamplification 15 System (Gibco) . PCR and degenerate primers were used to amplify a fragment of a chicken gene homologous to the Drosophila gene Serrate from the otic explant cDNA. The primers were designed to recognize peptide motifs found in both the fly 20 Delta and Serrate proteins: 1) primer 1, 5-CGI(T/C)TITGC(T/C)TIAA(G/A) (G/C)AITA(C/T)CA- 3' (SEQ ID N0:17), corresponds to the motif RLCLK(E/H)YQ (SEQ ID NO:18) located at the amino-terminus of the fly Delta and Serrate proteins. 25 2) primer 2, 5'-TCIATGCAIGTICCICC(A/G)TT-3 ' (SEQ ID N0:11), corresponds to the motif NGGTCID (SEQ ID NO:12) found in several of the EGF-like repeats. The PCR conditions were as follows: 35 cycles of 94°C for 1 minute, 45°C for 1.5 minutes and 72°C for 2 minutes; followed by a final extension step of 30 72°C for 10 minutes. A PCR product of approximately 900 base pairs in length was purified, subcloned into Bluescript KS- (Stratagene) and its DNA sequence partially determined to confirm that it was a likely Serrate homolog. It was then used to recover larger cDNA clones by screening two cDNA 35 libraries: 1) a stage 8-13 otic explant random primed cDNA library 2) a stage 17 chick spinal cord oligo dT primed cDNA library Overlapping cDNAs were isolated, and two (termed 9 and 3A.1) that together cover almost the entire coding region of the gene were subcloned into Bluescript KS-. DNA sequence was determined from nested deletion series generated using the double-stranded Nested Deletion Kit (Pharmacia) and Sanger dideoxy chain termination method with the Sequenase enzyme (US Biochemical Corporation) . Sequences were aligned and analyzed using Geneworks 2.3 and Intelligenetics. Homology searches were done using the program Sharq. To obtain the most 5' end of the open reading frame, a number of other PCR based strategies were used including the screening of a number of other libraries (CDNA and genomic) using the method of Lardelli et al. (1994, Mechanisms of Development 46:123-136). In situ hybridization Patterns of gene transcription were determined by in situ hybridization using DIG-labeled RNA probes and: 1) a high-stringency wholemount in situ hybridization protocol, and 2) in situ hybridization on cryostat sections based on the protocol of Strahle et al. (1994, Trends in Genet. 10:7). Results To obtain insight into the likely role of chick Serrate in the vertebrate embryo, we examined its expression in relation to that of chick Notch, since functional coupling of Notch and Serrate occurs in Drosophila . Two chick Notch homologs were obtained as described below. C-Notch-1 and C-Notch-2 are apparent counterparts of the rodent Notch-l and Notch-2 genes, respectively We searched for Notch homologs in the chick by PCR, using cDNA prepared from two-day chick embryos and degenerate primers based on conserved regions common to the known rodent Notch homologs. in this way, we obtained fragments, each approximately 1000 nucleotides long, of two distinct genes, which we have called C-Notch-1 and C-Notch-2. The fragments extend from the third Notch/linl2 repeat up to and including the last five or so EGF-like repeats. EGF-like repeats are present in a large number of proteins, most of which are otherwise unrelated to Notch. The three Notch/linl2 repeats, however, are peculiar to the Notch family of genes and are found in all its known members. C-Notch-1 shows the highest degree of amino-acid identity with rodent Notchl (Weinmaster et al., 1991, Development 113:199-205), and is expressed in broadly similar domains to rodent Notchl (see below) . Of the rodent Notch genes, C-Notσh-2 appears most similar to Notch2 (Weinmaster et al., 1992, Development 116:931-941). We examined the expression patterns of C-Notch-1 in early embryos by in situ hybridization. C-Notch-1 was expressed in the 1- to 2-day chick embryo in many well- defined domains, including the neural tube, the presomitic mesoderm, the nephrogenic mesoderm (the prospective mesonephros) , the nasal placode, the otic placode/vesicle, the lens placode, the epibranchial placodes, the endothelial lining of the vascular system, in the heart, and the apical ectodermal ridges (AER) of the limb buds. These sites match the reported sites of Notchl expression in rodents at equivalent stages (Table II) . Taking the sequence data together with the expression data, we conclude that C-Notch-1 is either the chick ortholog of rodent Notchl , or a very close relative of it. Table II COMPARISON OF DOMAINS OF RODENT-NOTCH1 AND CHICK NOTCH-1 EXPRESSION THROUGHOUT EMBRYOGENESIS Body Region R-Notchl' C-Notchl primitive streak + + Hensen's node neural tube retina + + lens + + otic placode/vesicle + + epibranchial placodes + + nasal placode + + dorsal root ganglia + + preso itic mesoderm + + somites + + notochord ? + mesonephric kidney + + metanephric kidney + + blood vessels + + heart + + whisker follicles + N/A thymus + ? toothbuds + N/A salivary gland + ? limb bud (AER) ? + from Weinmaster et al., 1991, Development 113:199-205; Franco del Amo et al., 1992, Development 115:737-744; Reaume et al., 1992, Dev. Biol. 154:377-387; Kopan and Weintraub, 1993, J. Cell. Biol. 121:631-641; Lardelli et al., 1994, Mech. of Dev. 46:123-126. C-Serrate is a homolog of Drosophila Serrate, and codes for a candidate ligand for a receptor belonging to the Notch family In Drosophila , two ligands for Notch are known, encoded by the two related genes Del ta and Serrate . The amino-acid sequences corresponding to these genes are homologous at their 5' ends, including a region, the DSL motif, which is necessary and sufficient for in vitro binding to Notch. To isolate a fragment of a chicken homolog of Serrate , we used PCR and degenerate primers designed to recognize sequences on either side of the DSL motif (see Materials and methods) . A 900 base pair PCR fragment was recovered and used to screen a library, allowing us to isolate overlapping cDNA clones. The DNA sequence of the cDNA clones revealed an almost complete single open reading frame of 3582 nucleotides, lacking only a few 5' bases. Comparison with the amino acid sequences of Drosophila Delta and Serrate suggests that we are missing only the portion of the coding sequence that encodes part of the signal sequence of the chick Serrate protein. Translation of the nucleotide sequence (SEQ ID NO:5) (Fig. 3) predicts a protein of 1230 amino acids (SEQ ID NO:6) (Fig. 4). A hydropathy plot reveals a single hydrophobic region characteristic of a transmembrane domain (Kyte and Doolittle, 1982, J. Mol. Biol. 157:105-132). In addition, the protein has sixteen EGF-like repeats organized in a tandem array in its extracellular domain. Comparison of the chick sequence with sequences of D . melanogaster Delta and Serrate suggests that the clones encode a chicken homolog of Serrate (Fig. 5; Fig. 6) . Whereas Drosophila Serrate contains 14 EGF-like repeats with large insertions in repeats 4, 6 and 10, the chicken homolog has an extra two EGF-like repeats and only one small insertion of 16 amino acids in the 10th repeat. Both proteins have a second cysteine-rich region between the EGF-like repeats and the transmembrane domain; the spacing of the cysteines in this region is almost identical in the two proteins (compare CX 2 CXCX 6 CX 4 CX„CX 5 CX 7 CX 4 CX S C in Drosophila Serrate with CX 2 CXCX 6 CX 4 CX 9 CX 5 CX 7 CX 4 CX 5 C in C-Serrate) . The intracellular domain of C-Serrate bears no significant homology to the intracellular domains of either Drosophila Delta or Serrate . C-Serrate is expressed in the central nervous system, cranial placodes, nephric mesoderm, vascular system, and limb bud mesenchyme In situ hybridization was performed to examine the expression of C-Serrate in whole-mount preparations during early embryogenesis, from stage 4 to stage 21, at intervals of roughly 12 hours. Later stages were studied by in situ hybridization on cryosections. The main sites of early expression of C-Serrate , as seen in whole mounts, can be grouped under five headings: central nervous system, cranial placodes, nephric mesoderm, vascular system, and limb bud mesenchyme. Central nervous system The first detectable expression of C-Serrate was seen in the central nervous system at stage 6 (O somites/24 hrs) , within the posterior portion of the neural plate. By stage 10 (9-11 somites/35.5 hrs), a strong stripe of expression was seen in the prospective diencephalon. Additional faint staining was seen in the hindbrain and in the prospective spinal cord. At stage 13, there were several patches of expression in the neural tube. In the diencephalon, there was a strong triangular stripe of expression that appeared to correspond to neuromere D2. There were two patches (one on either side of the midline) on the floor of the anterior mesencephalon as well as diffuse staining in the dorsal mesencephalon. In the hindbrain and rostral spinal cord, there were two longitudinal stripes of expression on either side of the midline: one along the dorsal edge of the neural tube and a second more ventral one, adjacent to the floor plate. Both were located within the domain of (rat) Notch 1 expression. The anterior limit of the ventral stripe was at the midbrain/hindbrain boundary. The dorsal stripe was continuous with the expression in the dorsal mesencephalon. In the anterior spinal cord, expression was more spotty, the stripes being replaced by isolated scattered cells expressing C-Serrate . At stage 17 (58 hrs) , expression in the diencephalon and midbrain was unchanged. In the hindbrain and spinal cord, there were an additional two longitudinal stripes: one midway along the dorsoventral axis and a second wider more ventral stripe; the anterior limits of these stripes coincided with the anterior border of rhombomere 2. All four longitudinal stripes in the hindbrain continued into the spinal cord of the embryo; decreasing towards its posterior end. These stripes of expression were maintained at least up to and including stage 31 (E7) . By stage 21 (84 hrs) , additional expression was seen in the cerebral hemispheres and strong expression in a salt and pepper distribution of cells in the optic tectum. Cranial placodes It is striking that C-Serrate is expressed in all the cranial placodes - the lens placode, the nasal placode, the otic placode/vesicle and the epibranchial placodes, as well as a patch of cranial ectoderm anterior to the otic placode that may correspond to the trigeminal placode (which is not well-defined morphologically) . In the lens placode, expression was already seen at stage 11, rapidly became very strong, and persisted at least to stage 21. Expression was weaker in the nasal placode and was only detected from stage 13. Again, expression was maintained at least until stage 21. Likewise for the otic placode, expression began to be visible at stage 10 and was strong by early stage 11 (12- 14 somites, 42.5 hours). Curiously, there was a "hole" in the otic expression domain - an anteroventral region of the placode in which the gene was not expressed. Subsequently, as the placode invaginates to form an otic vesicle, the strongest expression was seen at the anterolateral and postero edial poles. Later still, as the otic vesicle becomes transformed into the membranous labyrinth of the inner ear, C-Serrate expression became restricted to the sensory patches. The epibranchial expression was seen at stage 13/14 as strong staining in the ectoderm around the dorsal margins of the first and second branchial clefts. It was accompanied by expression of the gene in the deep part of the lining of the clefts and in the endodermal lining of the branchial pouches, where the two epithelia abut one another. Lastly, a large and strong but transient patch of expression was seen in the cranial ectoderm just anterior and ventral to the ear rudiment at stage 11. From its location, we suspect this to be, or to include, the region of the trigeminal placode. Nephric mesoderm Expression was detectable in the cells of the intermediate mesoderm from stage 10 and in older embryos (stage 17 to 21) in the developing mesonephric tubules. Limb buds C-Serrate mRNA was localized to a patch of mesenchyme at the distal end of the developing limb bud. This may suggest a role in limb growth. Other sites Expression was also seen in the tail bud, allantoic stalk, and possibly other tissues at late stages. All major sites of C-Serrate expression lie within domains of C-Notch-1 expression The conservation of the DSL domain and adjacent N- terminal region in C-Serrate suggests that it functions as a ligand for a receptor belonging to the Notch family. We thus expected to find sites where C-Serrate expression is accompanied by expression of a Notch gene. At such sites, overlapping or contiguous expression of the two genes can be taken as an indication that cells are communicating by Serrate-Notch signalling. We have compared the expression pattern of C-Serrate , as shown by in situ hybridization, with that of C-Notch-1, to discover what overlaps in fact occur, over a range of stages up to 8 days of incubation (E8) . All the observed sites of C-Serrate expression indeed lay within, or very closely adjacent to, domains of expression of C-Notch-1 (Table III). Table III COMPARISON OF C-NOTCH-1 AND C-SERRATE EXPRESSION AT STAGE 17a C-Serrate ++ (specific regions) ++ ++ ++ ++ ++ (furrows) ++ (tips of pouches) ++ ++ ++ ++ ++ (distal mesenchyme) a Hamburger and Hamilton, 1951, J. Exp. Zool. 88:49-92. Because of the importance of Notch and its partners in insect neurogenesis, it was of particular interest to us to see whether the homologous genes are involved in the development of the vertebrate CNS. C-Serrate is expressed in the CNS, and its pattern of expression shows a remarkable relationship to that of the Notch homologs. We analyzed transverse sections through the spinal cord of a six day chicken embryo hybridized with C-Notch-1 and C-Serrate antisense RNA probes. C-Notch-1 was expressed throughout the luminal region as described previously; within this region, there were two small patches in which Serrate was strongly expressed. Discussion In Drosophila development, cell-cell signalling via the product of the Notch gene plays a cardinal role in the final cell-fate decisions that specify the detailed pattern of differentiated cell types. This signalling pathway, in which the Notch protein has been identified as a transmembrane receptor, is best known for its role in neurogenesis: loss-of-function mutations in Notch or any of a set of other genes required for signal transmission via Notch alter cell fates in the neuroectoderm, causing cells that should have remained epidermal to become neural instead. Notch-dependent signalling is, however, as important in non- neural as in neural tissues. It regulates choices of mode of differentiation in oogenesis, in myogenesis, in formation of the Malpighian tubules and in the gut, for example, as well as in development of the retina, the peripheral sensilla, and the central nervous system. In most of these cases the signal delivered via Notch appears to mediate lateral inhibition, a type of interaction by which a cell that becomes committed to differentiate in a particular way - for example, as a neuroblast - inhibits its immediate neighbors from doing likewise. This forces adjacent cells to behave in contrasting ways, creating a fine-grained pattern of different cell types. There are, however, good reasons to believe that this is not the only function of signals delivered via Notch. Two direct ligands of Notch have been identified. These are the products of the Delta and Serrate genes. Both of them, like Notch itself, code for transmembrane proteins with tandem arrays of EGF-like repeats in their extracellular domain. Both the Delta and the Serrate protein have been shown to bind to Notch in a cell adhesion assay, and they share a large region of homology at their amino-termini including a motif that is necessary and sufficient for interaction with Notch in vitro, the so-called EBD or DSL domain. Yet despite these biochemical similarities, they seem to have quite different developmental functions. Although Serrate is expressed in many sites in the fly, it is apparently required only in the humeral, wing and halteres disks. When Serrate function is lost by mutation, these structures fail to grow. Studies on the wing disc have indicated that it is specifically the wing margin that depends on Serrate; when Serrate is lacking, this critical signaling region and growth centre fails to form, and when Serrate is expressed ectopically under a GAL4-UAS promoter in the ventral part of the wing disc, ectopic wing margin tissue is induced, leading to ectopic outgrowths. Notch appears to be the receptor for Serrate at the wing margin, since some mutant alleles of Notch cause similar disturbances of wing margin development and allele-specific interactions are seen in the effects of the two genes. Here we describe the identification and full length sequence of a homolog of the Drosophila gene Serrate , and identification and partial sequence of chick homologs of rat/mouse Notchl and Notch2 . Within the chick Serrate cDNA there is a single open reading frame predicted to encode a large transmembrane protein with 16 EGF repeats in its extracellular domain. It has a well conserved DSL motif suggesting that it would interact directly with Notch. The intracellular domain of chick Serrate exhibits no homology to anything in the current databases including the intracellular domains of Drosophila Delta and Serrate. It should he pointed out however that the intracellular domains of chick and human Serrate (see Section 12) are almost identical. The spatial distributions of C-Notch-1 and C-Serrate were investigated during early embryogenesis by in situ hybridization. C-Notch-1 and C-Serrate exhibit dynamic and complex patterns of expression including several regions in which they are coexpressed (CNS, ear, branchial region, lens, heart, nasal placodes and mesonephros) . The overlapping expression together with the finding that C-Serrate has a well conserved Notch binding domain suggests that this receptor/ligand interaction has been conserved from Drosophila through to vertebrates. In Drosophila , the Notch receptor is quite widely distributed and its ligands are found in overlapping but more restricted domains. In the chick a similar situation is observed. Fly Notch is necessary for many steps in the development of Drosophila; its role in lateral inhibition especially in the development of the central nervous system and peripheral sense organs being the best studied examples. However, Notch is a multifunctional receptor and can interact with different signalling molecules (including Delta and Serrate) and in developmental processes that do not easily fit within the framework of lateral inhibition. While available evidence implicates Delta as the signalling molecule in lateral inhibition there is no data to suggest that Serrate participates in lateral inhibition. Rather, Serrate appears to be necessary for development of the dorsal imaginal discs of the larva; that is, the humeral, haltere and wing discs. In the latter, the best studied of these processes, Serrate and Notch are important for the development of the dorsoventral wing margin, a structure necessary for the organization of wing development as a whole. That C-Serrate has a significant function can be inferred from the conservation of its sequence, in particular, of its Notch-binding domain. The expression patterns reported for C-Serrate in this paper provide the following information. First, since the Serrate gene is expressed in or next to sites where C-Notch-1 is expressed (possibly in conjunction with other Notch homologs) , it is highly probable that C-Serrate exerts its action by binding to C-Notch-1 (or to another chick Notch homolog with a similar expression pattern) . Second, the expression in the developing kidney, the vascular system and the limb buds might reflect an involvement in inductive signalling between mesoderm and ectoderm, which plays an important part in the development of all these organs. In the limb buds, for example, C-Serrate is expressed in the distal mesoderm, and C-Notch-1 is expressed in the overlying apical ectodermal ridge, whose maintenance is known to depend on a signal from the mesoderm below. In the cranial placodes, a similar role is possible, but the evidence for inductive signalling is weaker, and C-Serrate may equally be involved in communications between cells within the placodal epithelium, for example, in regulating the specialized modes of differentiation of the placodal calls. What might C-Serrate's function be within the curiously restricted domains of its expression in the CNS? One possibility is that it is involved in regulating the production of oligodendrocytes, which have likewise been reported to originate from narrow bands of tissue extending along the cranio-caudal axis of the neural tube. 9. ISOLATION AND CHARACTERIZATION OF HUMAN SERRATE HOMOLOGS Clones for the human Serrate sequence were obtained as described below. The polymerase chain reaction (PCR) was used to amplify DNA from a human placenta cDNA library. Degenerate oligonucleotide primers used in this reaction were designed based on amino-terminal regions of high homology between Drosophila Serrate and Drosophila Delta (see Fig. 5) ; this high homology region includes the 5' "DSL" domain, that is believed to code for the Notch-binding portion of Delta and Serrate. Two PCR products were isolated and used, one a 350 bp fragment, and one a 1.2 kb fragment. These PCR fragments were labeled with 32 P and used to screen a commercial human fetal brain cDNA library made from a 17-18 week old fetus (previously available from Stratagene) , in which the cDNAs were inserted into the _?coRI site of a λ-Zap vector. The 1.2 kb fragment hybridized to a single clone out of the 10 6 clones screened. We rescued this fragment from the λ DNA by converting the isolated phage λ clone to a plasmid via the manufacturer's instructions, yielding the Serrate-homologous cDNA as an insert in the J5.coRI site of the vector Bluescript KS- (Stratagene) . This plasmid was named "pBS39" and the gene corresponding to this cDNA clone was called Human Serrate-1 (also known as Human Jagged-1 ( "HJ1" ) ) . The isolated cDNA was 6464 nucleotides long and contained a complete open reading frame as well as 5' and 3' untranslated regions (Fig. 1) . Sequencing was carried out using the Sequenase® sequencing system (U.S. Biochemical Corp.) on 5 and 6% Sequagel acrylamide sequencing gels. The 350 bp fragment hybridized with two clones, containing cDNA inserts of approximately 1.1 and 3.1 kb in length; the plasmid constructs containing these inserts were named pBS14 and pBS15, respectively. Each clone was isolated, its respective insert rescued from the λ cDNA, and sequenced as above. The nucleotide sequence of the pBS14 insert was identical to a 1.1 kb stretch of sequence contained internally within the pBS15 cDNA insert and therefore, this clone was not characterized further. The sequence of the 3.1 kb pBS15 insert encoded a single open reading frame which spanned all but the 5' 20 nucleotides of the insert. The methionine located at the amino terminal residue of this predicted open reading was homologous to the start methionine encoded by the Human Serrate-1 (HJ1 ) cDNA clone in pBS39. The gene encoding the cDNA insert of pBS15 was named Human Serrate-2 and is also known as Human Jagged-2 ( "HJ2" ) . The pBS15 (HJ2 ) 3.1 kb insert was then labeled with 32 P and used to screen another human fetal brain library (from Clontech) , in which cDNA generated from a 25-26 week-old fetus was cloned into the EcoRl site of λgtll. This screen identified three potential positive clones. To isolate the cDNAs, λgtll DNA was prepared from a liquid lysate and purified over a DEAE column. The purified DNA was then cut with JϊcoRI and the cDNA inserts were isolated and subcloned into the _5σoRI site of Bluescript KS-. The bluescript constructs containing these cDNAs were named pBS3-15, pBS3-2, and pBS3-20. Two of these cDNA clones, pBS3-2 and pBS3-20, contained sequences that partially overlapped with pBS15 and were further characterized. pBS3-2 had a 3.2 kb insert extending from nucleotide 1210 of the pBS15 cDNA insert to just after the polyadenylation signal. The 2.6 kb insert of pBS3-20, was restriction mapped and partially sequenced to determine its 3' and 5' ends. This analysis indicated that the PBS3-20 insert had a nucleic acid sequence that was fully contained within the pBS3-2 cDNA insert and therefore, the pBS3-20 insert was not characterized further. The insert of pBS3-15 was determined to be a Bluescript vector fragment contaminant. Alignment of the deduced amino acid sequence (SEQ ID NO:4) of the "complete" Human Serrate-2 (HJ2 ) cDNA (SEQ ID NO:3) generated on the computer with the deduced amino acid sequence of Human Serrate-1 (HJ1) from pBS39 (SEQ ID NO:2) revealed a gap of about 120 bases, leading to a frameshift, in the region encoded by the pBS15 (HJ2 ) insert, between the putative signal sequence and the beginning of the DSL domain (Fig. 2) . The nucleotides missing in the gap of the pBS15 insert would be located between nucleotides 240 and 241 of SEQ ID NO:3. This missing region probably resulted from a cloning artifact in the construction of the Stratagene library. Attempts to clone the 5' end of HJ2 using anchored PCR, RACE, and Takara extended PCR techniques were unsuccessful. However, three human genomic clones potentially containing the 5' end of HJ " 2 were obtained from the screening of a human genomic cosmid library in which 30 kb fragments were cloned into a unique Xhol site introduced into the BatnHI site of a pWE15 vector (the unmodified vector is available from Stratagene) . This cosmid library was screened with a PCR fragment that had been amplified from the 5' end of pBS15 (HJ2 ) and three positive cosmid clones were isolated. Two different sets of primers were used to amplify DNA corresponding to the 5' end of pBS15 using the cosmid clones as a template, and both sets generated single bands that were subcloned, but which were determined to contain PCR artifacts. Portions of the cosmid clones are being subcloned directly without PCR, in order to obtain a portion of the cosmid clones that contains the 120 nucleotide stretch of DNA that is missing from pBS15. The pBS39 cDNA insert, encoding the Human Serrate-1 homolog (HJ1 ) , has been sequenced and contains the complete coding sequence for the gene product. The nucleotide (SEQ ID NO:l) and protein (SEQ ID NO:2) sequences are shown in Figure 1. The nucleotide sequence of Human Serrate-1 (HJ1 ) was translated using MacVector software (International Biotechnology Inc., New Haven, CT) . The coding region consists of nucleotide numbers 371-4024 of SEQ ID N0:1. The Protean protein analysis software program from DNAStar (Madison, WI) was used to predict signal peptide and transmembrane regions (based on hydrophobicity) . The signal peptide was predicted to consist of amino acids 14-29 of SEQ ID NO:2 (encoded by nucleotide numbers 410-457 of SEQ ID N0:1) , whereby the amino terminus of the mature protein was predicted to start with Gly at amino acid number 30. The transmembrane domain was predicted to be amino acid numbers 1068-1089 of SEQ ID NO:2, encoded by nucleotide numbers 3572-3637 of SEQ ID NO:l. The consensus (DSL) domain, the region of homology with Drosophila Delta and Serrate, predicted to mediate binding with Notch (in particular, Notch ELR 11 and 12) , spans amino acids 185-229 of SEQ ID NO:2, encoded by nucleotide numbers 923-1057 of SEQ ID NO:l. Epidermal growth factor-like (ELR) repeats in the amino acid sequence were identified by eye; 15 (full- length) ELRs were identified and 3 partial ELRs as follows: ELR 1: amino acid numbers 234 - 264 ELR 2: amino acid numbers 265 - 299 ELR 3: amino acid numbers 300 - 339 ELR 4: amino acid numbers 340 - 377 ELR 5: amino acid numbers 378 - 415 ELR 6: amino acid numbers 416 - 453 ELR 7: amino acid numbers 454 - 490 ELR 8: amino acid numbers 491 - 528 ELR 9: amino acid numbers 529 - 566 Partial ELR: amino acid numbers 567 - 598 Partial ELR: amino acid numbers 599 - 632 ELR 10: amino acid numbers 633 - 670 ELR 11: amino acid numbers 671 - 708 ELR 12: amino acid numbers 709 - 747 ELR 13: amino acid numbers 748 - 785 ELR 14: amino acid numbers 786 - 823 ELR 15: amino acid numbers 824 - 862 Partial ELR: amino acid numbers 863 - 879 Partial ELR: amino acid numbers 880 - 896 The total ELR domain is thus amino acid numbers 234 - 896 (encoded by nucleotide numbers 1070 - 3058 of SEQ ID NO:l) . The extracellular domain is thus predicted to be amino acid numbers 1 - 1067 of SEQ ID NO:2, encoded by nucleotide numbers 371 - 3571 of SEQ ID NO:l (amino acid numbers 30 - 1067 in the mature protein; encoded by nucleotides number 458 - 3571 of SEQ ID NO:l). The intracellular (cytoplasmic) domain is thus predicted to be amino acid numbers 1090 - 1218 of SEQ ID NO:2, encoded by nucleotide numbers 3638 - 4024 of SEQ ID NO:l. The expression of HJ1 in certain human tissues was established by probing a Clontech Human Multiple Tissue Northern blot with radio-labeled pBS39. The probe hybridized to a single band of about 6.6 kb, and was expressed in all of the tissue assayed, which included, heart, brain, placenta, lung, skeletal muscle, pancreas, liver and kidney. The observation that HJ1 was expressed in adult skeletal and heart muscle was particularly interesting, because adult muscle fibers are completely surrounded by a lamina of extracellular matrix, and it is unlikely, therefore, that the role of HJ1 in these cells is in direct cell-cell communication. The "complete" (containing an internal deletion) Human Serrate-2 (HJ2 ) cDNA nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4) generated on the computer are shown in Figure 2. The nucleotide sequence translated using MacVector software (International Biotechnology Inc., New Haven, CT) . The coding region consists of nucleotides number 332 - 4102 of SEQ ID NO: 3. The Protean protein analysis software program from DNAStar (Madison, WI) was used to predict signal peptide and transmembrane regions (based on hydrophobicity) . The transmembrane domain was predicted to be amino acid numbers 912-933 of SEQ ID NO:4, encoded by nucleotides numbers 3065-3130 of SEQ ID NO:3. The consensus (DSL) domain, the region of homology with Drosophila Delta and Serrate, predicted to mediate binding with Notch (in particular, Notch ELR 11 and 12), spans amino acids 26-70 of SEQ ID NO:4, encoded by nucleotide numbers 407 - 541 of SEQ ID NO: 3. Epidermal growth factor-like (ELR) repeats in the amino acid sequence were identified by eye; 15 (full-length) ELRs were identified and 3 partial ELRs as follows: ELR 1: amino acid numbers 75 - 105 ELR 2: amino acid numbers 106 - 140 ELR 3: amino acid numbers 141 - 180 ELR 4: amino acid numbers 181 - 218 ELR 5: amino acid numbers 219 - 256 ELR 6: amino acid numbers 257 - 294 ELR 7: amino acid numbers 295 - 331 ELR 8: amino acid numbers 332 - 369 ELR 9: amino acid numbers 370 - 407 Partial ELR: amino acid numbers 408 - 435 Partial ELR: amino acid numbers 436 - 469 ELR 10: amino acid numbers 470 - 507 ELR 11: amino acid numbers 508 - 545 ELR 12: amino acid numbers 546 - 584 ELR 13: amino acid numbers 585 - 622 ELR 14: amino acid numbers 623 - 660 ELR 15: amino acid numbers 664 - 701 Partial ELR: amino acid numbers 702 - 718 Partial ELR: amino acid numbers 719 - 735 The total ELR domain is thus amino acid numbers 75 - 735 (encoded by nucleotides number 554 - 2536 of SEQ ID NO:3). The extracellular domain is thus predicted to be amino acid numbers 1 - 912 of SEQ ID NO:4, encoded by nucleotides number 332 - 3064 of SEQ ID NO:3. The intracellular (cytoplasmic) domain is thus predicted to be amino acid numbers 934 - 1257 of SEQ ID NO:4, encoded by nucleotide numbers 3131 - 4102 of SEQ ID NO:3. Like Human Serrate-1 (HJ1 ) , the "complete" (with an internal deletion) Human Serrate-2 (HJ2 ) cDNA (SEQ ID NO:3) generated on the computer encodes a protein containing 16 complete and 2 interrupted EGF repeats as well as the diagnostic cryptic EGF repeat known as the DSL domain, which has been found only in putative Notch ligands. The open reading frame of the computer generated "complete" Human Serrate-2 (HJ2) is about 1400 amino acids long, approximately 182 amino acids longer than the carboxy terminus of HJ1 and the rat Serrate homologue Jagged. While there is significant homology between the complete HJ2 and HJ1 in the amino terminal portion of the protein, this homology is lost just before the putative transmembrane domain at about amino acid number 1029 of HJ1. This result is particularly interesting because the presence of a long COOH-terminal tail implies the possibility of some additional function or regulation of HJ2. The "complete" (with an internal deletion) Human Serrate-2 (HJ2 ) cDNA (SEQ ID NO:3) sequence can be constructed by taking advantage of the unique restriction sites for Accl, Drain, or BamHI present in the sequence overlap of pBS15 and pBS3-2, and which enzymes cleave the pBS15 insert at nucleotides 1431, 2648, and 2802, respectively. The expression of HJ2 in certain human tissues was established by probing a Clontech Human Multiple Tissue Northern blot with radio-labeled clone pBS15. This probe hybridized to a single band of about 5.2 kb and was expressed in heart, brain, placenta, lung, skeletal muscle, and pancreas, but was absent or nearly undetectable in liver and kidney. As in the case of HJ1 expression discussed supra, the observation that the pBSl5 insert component of HJ2 was expressed in adult skeletal and heart muscle was particularly interesting, because adult muscle fibers are completely surrounded by a lamina of extracellular matrix, and it is unlikely, therefore, that the role of HJ2 in these cells is in direct cell-cell communication. Expression constructs are made using the isolated clone(s) . The clone is excised from its vector as an _ScoRI restriction fragment(s) and subcloned into the EcoRI restriction site of an expression vector. This allows for the expression of the Human Serrate protein product from the subclone in the correct reading frame. Using this methodology, expression constructs in which the HJ " ! cDNA insert of pBS39 was cloned into an expression vector for expression under the control of a cytomegalovirus promoter have been generated and HJ1 has been expressed in both 3T3 and HAKAT human keratinocyte cell lines. 10. DEPOSIT OF MICROORGANISMS Plasmid pBS39, containing an EcoRI fragment encoding full-length Human Serrate-1 (HJ1) , was deposited on February 28, 1995 with the American Type Culture Collection, 1201 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned Accession No. 97068. Plasmid pBS15, containing a 3.1 kb EcoRI fragment encoding the amino terminus of Human Serrate-2 (HJ2) , cloned into the EcoRI site of Bluescript KS-, was deposited on March 5, 1996 with the American Type Culture Collection, 1201 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned Accession No. . Plasmid pBS3-2 containing an 3.2 kb EcoRI fragment encoding the carboxy terminus of Human Serrate-2 (HJ2) , cloned into the .EcoRI site of Bluescript KS-, was deposited on March 5, 1996 with the American Type Culture Collection, 1201 Parklawn Drive, Rockville, Maryland 20852, under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedures, and assigned Accession No. . The present invention is not to be limited in scope by the microorganisms deposited or the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims. Various references are cited herein, the disclosures of which are incorporated by reference in their entireties. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: ISH-HOROWICZ, DAVID HENRIQUE, DOMINGOS MANUEL PINTO LEWIS, JULIAN HART MYAT, ANNA MARY ARTAVANIS-TSAKONAS, SPYRIDON MANN, ROBERT S. GRAY, GRACE E. (ii) TITLE OF INVENTION: NUCLEOTIDE AND PROTEIN SEQUENCES OF VERTEBRATE SERRATE GENES AND METHODS BASED THEREON (iii) NUMBER OF SEQUENCES: 18 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Pennie & Edmonds (B) STREET: 1155 Avenue of the Americas (C) CITY: New York (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10036-2711 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: To Be Assigned (B) FILING DATE: On Even Date Herewith (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Misrock, S. Leslie (B) REGISTRATION NUMBER: 18,872 (C) REFERENCE/DOCKET NUMBER: 7326-037-228 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 790-9090 (B) TELEFAX: (212) 869-9741/8864 (C) TELEX: 66141 PENNIE (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6464 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 371.. 027 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: GAATTCCCCT CCCCCCTTTT TCCATGCAGC TGATCTAAAA GGGAATAAAA GGCTGCGCAT 60 AATCATAATA ATAAAAGAAG GGGAGCGCGA GAGAAGGAAA GAAAGCCGGG AGGTGGAAGA 120 GGAGGGGGAG CGTCTCAAAG AAGCGATCAG AATAATAAAA GGAGGCCGGG CTCTTTGCCT 180 TCTGGAACGG GCCGCTCTTG AAAGGGCTTT TGAAAAGTGG TGTTGTTTTC CAGTCGTGCA 240 TGCTCCAATC GGCGGAGTAT ATTAGAGCCG GGACGCGGCC GCAGGGGCAG CGGCGACGGC 300 AGCACCGGCG GCAGCACCAG CGCGAACAGC AGCGGCGGCG TCCCGAGTGC CCGCGGCGGC 360 GCGCGCAGCG ATG CGT TCC CCA CGG ACA CGC GGC CGG TCC GGG CGC CCC 409 Met Arg Ser Pro Arg Thr Arg Gly Arg Ser Gly Arg Pro 1 5 10 CTA AGC CTC CTG CTC GCC CTG CTC TGT GCC CTG CGA GCC AAG GTG TGT 457 Leu Ser Leu Leu Leu Ala Leu Leu Cys Ala Leu Arg Ala Lys Val Cys 15 20 25 GGG GCC TCG GGT CAG TTC GAG TTG GAG ATC CTG TCC ATG CAG AAC GTG 505 Gly Ala Ser Gly Gin Phe Glu Leu Glu lie Leu Ser Met Gin Asn Val 30 35 40 45 AAC GGG GAG CTG CAG AAC GGG AAC TGC TGC GGC GGC GCC CGG AAC CCG 553 Asn Gly Glu Leu Gin Asn Gly Asn Cys Cys Gly Gly Ala Arg Asn Pro 50 55 60 GGA GAC CGC AAG TGC ACC CGC GAC GAG TGT GAC ACA TAC TTC AAA GTG 601 Gly Asp Arg Lys Cys Thr Arg Asp Glu Cys Asp Thr Tyr Phe Lys Val 65 70 75 TGC CTC AAG GAG TAT CAG TCC CGC GTC ACG GCC GGG GGG CCC TGC AGC 649 Cys Leu Lys Glu Tyr Gin Ser Arg Val Thr Ala Gly Gly Pro Cys Ser 80 85 90 TTC GGC TCA GGG TCC ACG CCT GTC ATC GGG GGC AAC ACC TTC AAC CTC 697 Phe Gly Ser Gly Ser Thr Pro Val lie Gly Gly Asn Thr Phe Asn Leu 95 100 105 AAG GCC AGC CGC GGC AAC GAC CCG AAC CGC ATC GTG CTG CCT TTC AGT 745 Lys Ala Ser Arg Gly Asn Asp Pro Asn Arg lie Val Leu Pro Phe Ser 110 115 120 125 TTC GCC TGG CCG AGG TCC TAT ACG TTG CTT GTG GAG GCG TGG GAT TCC 793 Phe Ala Trp Pro Arg Ser Tyr Thr Leu Leu Val Glu Ala Trp Asp Ser 130 135 140 AGT AAT GAC ACC GTT CAA CCT GAC AGT ATT ATT GAA AAG GCT TCT CAC 841 Ser Asn Asp Thr Val Gin Pro Asp Ser lie lie Glu Lys Ala Ser His 145 150 155 TCG GGC ATG ATC AAC CCC AGC CGG CAG TGG CAG ACG CTG AAG CAG AAC 889 Ser Gly Met lie Asn Pro Ser Arg Gin Trp Gin Thr Leu Lys Gin Asn 160 165 170 ACG GGC GTT GCC CAC TTT GAG TAT CAG ATC CGC GTG ACC TGT GAT GAC 937 Thr Gly Val Ala His Phe Glu Tyr Gin lie Arg Val Thr Cys Asp Asp 175 180 185 TAC TAC TAT GGC TTT GGC TGT AAT AAG TTC TGC CGC CCC AGA GAT GAC 985 Tyr Tyr Tyr Gly Phe Gly Cys Asn Lys Phe Cys Arg Pro Arg Asp Asp 190 195 200 205 TTC TTT GGA CAC TAT GCC TGT GAC CAG AAT GGC AAC AAA ACT TGC ATG 1033 Phe Phe Gly Hie Tyr Ala Cys Asp Gin Asn Gly Asn Lys Thr Cys Met 210 215 220 GAA GGC TGG ATG GGC CCC GAA TGT AAC AGA GCT ATT TGC CGA CAA GGC 1081 Glu Gly Trp Met Gly Pro Glu Cys Asn Arg Ala lie Cys Arg Gin Gly 225 230 235 TGC AGT CCT AAG CAT GGG TCT TGC AAA CTC CCA GGT GAC TGC AGG TGC 1129 Cys Ser Pro Lys His Gly Ser Cys Lys Leu Pro Gly Asp Cys Arg Cys 240 245 250 CAG TAC GGC TGG CAA GGC CTG TAC TGT GAT AAG TGC ATC CCA CAC CCG 1177 Gin Tyr Gly Trp Gin Gly Leu Tyr Cys Asp Lys Cys lie Pro His Pro 255 260 265 GGA TGC GTC CAC GGC ATC TGT AAT GAG CCC TGG CAG TGC CTC TGT GAG 1225 Gly Cys Val His Gly lie Cys Asn Glu Pro Trp Gin Cys Leu Cys Glu 270 275 280 285 ACC AAC TGG GGC GGC CAG CTC TGT GAC AAA GAT CTC AAT TAC TGT GGG 1273 Thr Asn Trp Gly Gly Gin Leu Cys Asp Lys Asp Leu Asn Tyr Cys Gly 290 295 300 ACT CAT CAG CCG TGT CTC AAC GGG GGA ACT TGT AGC AAC ACA GGC CCT 1321 Thr His Gin Pro Cys Leu Asn Gly Gly Thr Cys Ser Asn Thr Gly Pro 305 310 315 GAC AAA TAT CAG TGT TCC TGC CCT GAG GGG TAT TCA GGA CCC AAC TGT 1369 Asp Lys Tyr Gin Cys Ser Cys Pro Glu Gly Tyr Ser Gly Pro Asn Cys 320 325 330 GAA ATT GCT GAG CAC GCC TGC CTC TCT GAT CCC TGT CAC AAC AGA GGC 1417 Glu lie Ala Glu His Ala Cys Leu Ser Asp Pro Cys His Asn Arg Gly 335 340 345 AGC TGT AAG GAG ACC TCC CTG GGC TTT GAG TGT GAG TGT TCC CCA GGC 1465 Ser Cys Lys Glu Thr Ser Leu Gly Phe Glu Cys Glu Cys Ser Pro Gly 350 355 360 365 TGG ACC GGC CCC ACA TGC TCT ACA AAC ATT GAT GAC TGT TCT CCT AAT 1513 Trp Thr Gly Pro Thr Cys Ser Thr Asn lie Asp Asp Cys Ser Pro Asn 370 375 380 AAC TGT TCC CAC GGG GGC ACC TGC CAG GAC CTG GTT AAC GGA TTT AAG 1561 Asn Cys Ser His Gly Gly Thr Cys Gin Asp Leu Val Asn Gly Phe Lys 385 390 395 TGT GTG TGC CCC CCA CAG TGG ACT GGG AAA ACG TGC CAG TTA GAT GCA 1609 Cys Val Cys Pro Pro Gin Trp Thr Gly Lys Thr Cys Gin Leu Asp Ala 400 405 410 AAT GAA TGT GAG GCC AAA CCT TGT GTA AAC GCC AAA TCC TGT AAG AAT 1657 Asn Glu Cys Glu Ala Lys Pro Cys Val Asn Ala Lys Ser Cys Lys Asn 415 420 425 CTC ATT GCC AGC TAC TAC TGC GAC TGT CTT CCC GGC TGG ATG GGT CAG 1705 Leu lie Ala Ser Tyr Tyr Cys Asp Cys Leu Pro Gly Trp Met Gly Gin 430 435 440 445 AAT TGT GAC ATA AAT ATT AAT GAC TGC CTT GGC CAG TGT CAG AAT GAC 1753 Asn Cys Asp lie Asn lie Asn Asp Cys Leu Gly Gin Cys Gin Asn Asp 450 455 460 GCC TCC TGT CGG GAT TTG GTT AAT GGT TAT CGC TGT ATC TGT CCA CCT 1801 Ala Ser Cys Arg Asp Leu Val Asn Gly Tyr Arg Cys lie Cys Pro Pro 465 470 475 GGC TAT GCA GGC GAT CAC TGT GAG AGA GAC ATC GAT GAA TGT GCC AGC 1849 Gly Tyr Ala Gly Asp His Cys Glu Arg Asp lie Asp Glu Cys Ala Ser 480 485 490 AAC CCC TGT TTG AAT GGG GGT CAC TGT CAG AAT GAA ATC AAC AGA TTC 1897 Asn Pro Cys Leu Asn Gly Gly His Cys Gin Asn Glu lie Asn Arg Phe 495 500 505 CAG TGT CTG TGT CCC ACT GGT TTC TCT GGA AAC CTC TGT CAG CTG GAC 1945 Gin Cys Leu Cys Pro Thr Gly Phe Ser Gly Asn Leu Cys Gin Leu Asp 510 515 520 525 ATC GAT TAT TGT GAG CCT AAT CCC TGC CAG AAC GGT GCC CAG TGC TAC 1993 lie Asp Tyr Cys Glu Pro Asn Pro Cys Gin Asn Gly Ala Gin Cys Tyr 530 535 540 AAC CGT GCC AGT GAC TAT TTC TGC AAG TGC CCC GAG GAC TAT GAG GGC 2041 Asn Arg Ala Ser Asp Tyr Phe Cys Lys Cys Pro Glu Asp Tyr Glu Gly 545 550 555 AAG AAC TGC TCA CAC CTG AAA GAC CAC TGC CGC ACG ACC CCC TGT GAA 2089 Lys Asn Cys Ser His Leu Lys Asp His Cys Arg Thr Thr Pro Cys Glu 560 565 570 GTG ATT GAC AGC TGC ACA GTG GCC ATG GCT TCC AAC GAC ACA CCT GAA 2137 Val lie Asp Ser Cys Thr Val Ala Met Ala Ser Asn Asp Thr Pro Glu 575 580 585 GGG GTG CGG TAT ATT TCC TCC AAC GTC TGT GGT CCT CAC GGG AAG TGC 2185 Gly Val Arg Tyr lie Ser Ser Asn Val Cys Gly Pro His Gly Lys Cys 590 595 600 605 AAG AGT CAG TCG GGA GGC AAA TTC ACC TGT GAC TGT AAC AAA GGC TTC 2233 Lys Ser Gin Ser Gly Gly Lys Phe Thr Cys Asp Cys Asn Lys Gly Phe 610 615 620 ACG GGA ACA TAC TGC CAT GAA AAT ATT AAT GAC TGT GAG AGC AAC CCT 2281 Thr Gly Thr Tyr Cys His Glu Asn lie Asn Asp Cys Glu Ser Asn Pro 625 630 635 TGT AGA AAC GGT GGC ACT TGC ATC GAT GGT GTC AAC TCC TAC AAG TGC 2329 Cys Arg Asn Gly Gly Thr Cys lie Asp Gly Val Asn Ser Tyr Lys Cys 640 645 650 ATC TGT AGT GAC GGC TGG GAG GGG GCC TAC TGT GAA ACC AAT ATT AAT 2377 lie Cys Ser Asp Gly Trp Glu Gly Ala Tyr Cys Glu Thr Asn lie Asn 655 660 665 GAC TGC AGC CAG AAC CCC TGC CAC AAT GGG GGC ACG TGT CGC GAC CTG 2425 Asp Cys Ser Gin Asn Pro Cys His Asn Gly Gly Thr Cys Arg Asp Leu 670 675 680 685 GTC AAT GAC TTC TAC TGT GAC TGT AAA AAT GGG TGG AAA GGA AAG ACC 2473 Val Asn Asp Phe Tyr Cys Asp Cys Lys Asn Gly Trp Lys Gly Lys Thr 690 695 700 TGC CAC TCA CGT GAC AGT CAG TGT GAT GAG GCC ACG TGC AAC AAC GGT 2521 Cys His Ser Arg Asp Ser Gin Cys Asp Glu Ala Thr Cys Asn Asn Gly 705 710 715 GGC ACC TGC TAT GAT GAG GGG GAT GCT TTT AAG TGC ATG TGT CCT GGC 2569 Gly Thr Cys Tyr Asp Glu Gly Asp Ala Phe Lys Cys Met Cys Pro Gly 720 725 730 GGC TGG GAA GGA ACA ACC TGT AAC ATA GCC CGA AAC AGT AGC TGC CTG 2617 Gly Trp Glu Gly Thr Thr Cys Asn lie Ala Arg Asn Ser Ser Cys Leu 735 740 745 CCC AAC CCC TGC CAT AAT GGG GGC ACA TGT GTG GTC AAC GGC GAG TCC 2665 Pro Asn Pro Cys His Asn Gly Gly Thr Cys Val Val Asn Gly Glu Ser 750 755 760 765 TTT ACG TGC GTC TGC AAG GAA GGC TGG GAG GGG CCC ATC TGT GCT CAG 2713 Phe Thr Cys Val Cys Lys Glu Gly Trp Glu Gly Pro He Cys Ala Gin 770 775 780 AAT ACC AAT GAC TGC AGC CCT CAT CCC TGT TAC AAC AGC GGC ACC TGT 2761 Asn Thr Asn Asp Cys Ser Pro His Pro Cys Tyr Asn Ser Gly Thr Cys 785 790 795 GTG GAT GGA GAC AAC TGG TAC CGG TGC GAA TGT GCC CCG GGT TTT GCT 2809 Val Asp Gly Asp Asn Trp Tyr Arg Cys Glu Cys Ala Pro Gly Phe Ala 800 805 810 GGG CCC GAC TGC AGA ATA AAC ATC AAT GAA TGC CAG TCT TCA CCT TGT 2857 Gly Pro Asp Cys Arg He Asn He Asn Glu Cys Gin Ser Ser Pro Cys 815 820 825 GCC TTT GGA GCG ACC TGT GTG GAT GAG ATC AAT GGC TAC CGG TGT GTC 2905 Ala Phe Gly Ala Thr Cys Val Asp Glu He Asn Gly Tyr Arg Cys Val 830 835 840 845 TGC CCT CCA GGG CAC AGT GGT GCC AAG TGC CAG GAA GTT TCA GGG AGA 2953 Cys Pro Pro Gly His Ser Gly Ala Lys Cys Gin Glu Val Ser Gly Arg 850 855 860 CCT TGC ATC ACC ATG GGG AGT GTG ATA CCA GAT GGG GCC AAA TGG GAT 3001 Pro Cys He Thr Met Gly Ser Val He Pro Asp Gly Ala Lys Trp Asp 865 870 875 GAT GAC TGT AAT ACC TGC CAG TGC CTG AAT GGA CGG ATC GCC TGC TCA 3049 Asp Asp Cys Asn Thr Cys Gin Cys Leu Asn Gly Arg He Ala Cys Ser 880 885 890 AAG GTC TGG TGT GGC CCT CGA CCT TGC CTG CTC CAC AAA GGG CAC AGC 3097 Lys Val Trp Cys Gly Pro Arg Pro Cys Leu Leu His Lys Gly His Ser 895 900 905 GAG TGC CCC AGC GGG CAG AGC TGC ATC CCC ATC CTG GAC GAC CAG TGC 3145 Glu Cys Pro Ser Gly Gin Ser Cys He Pro He Leu Asp Asp Gin Cys 910 915 920 925 TTC GTC CAC CCC TGC ACT GGT GTG GGC GAG TGT CGG TCT TCC AGT CTC 3193 Phe Val His Pro Cys Thr Gly Val Gly Glu Cys Arg Ser Ser Ser Leu 930 935 940 CAG CCG GTG AAG ACA AAG TGC ACC TCT GAC TCC TAT TAC CAG GAT AAC 3241 Gin Pro Val Lys Thr Lys Cys Thr Ser Asp Ser Tyr Tyr Gin Asp Asn 945 950 955 TGT GCG AAC ATC ACA TTT ACC TTT AAC AAG GAG ATG ATG TCA CCA GGT 3289 Cys Ala Asn He Thr Phe Thr Phe Asn Lys Glu Met Met Ser Pro Gly 960 965 970 CTT ACT ACG GAG CAC ATT TGC AGT GAA TTG AGG AAT TTG AAT ATT TTG 3337 Leu Thr Thr Glu His He Cys Ser Glu Leu Arg Asn Leu Asn He Leu 975 980 985 AAG AAT GTT TCC GCT GAA TAT TCA ATC TAC ATC GCT TGC GAG CCT TCC 3385 Lys Asn Val Ser Ala Glu Tyr Ser He Tyr He Ala Cys Glu Pro Ser 990 995 lOOO 1005 CCT TCA GCG AAC AAT GAA ATA CAT GTG GCC ATT TCT GCT GAA GAT ATA 3433 Pro Ser Ala Asn Asn Glu He His Val Ala He Ser Ala Glu Asp He 1010 1015 1020 CGG GAT GAT GGG AAC CCG ATC AAG GAA ATC ACT GAC AAA ATA ATC GAT 3481 Arg Asp Asp Gly Asn Pro He Lys Glu He Thr Asp Lys He He Asp 1025 1030 1035 CTT GTT ACT AAA CGT GAT GGA AAC AGC TCG CTG ATT GCT GCC GTT GAA 3529 Leu Val Thr Lys Arg Asp Gly Asn Ser Ser Leu He Ala Ala Val Glu 1040 1045 1050 GAA GTA AGA GTT CAG AGG CGG CCT CTG AAG AAC AGA ACA GAT TTC CTT 3577 Glu Val Arg Val Gin Arg Arg Pro Leu Lys Asn Arg Thr Asp Phe Leu 1055 1060 1065 GTT CCC TTG CTG AGC TCT GTC TTA ACT GTG GCT TGG ATC TGT TGC TTG 3625 Val Pro Leu Leu Ser Ser Val Leu Thr Val Ala Trp He Cys Cys Leu 1070 1075 1080 1085 GTG ACG GCC TTC TAC TGG TGC CTG CGG AAG CGG CGG AAG CCG GGC AGC 3673 Val Thr Ala Phe Tyr Trp Cys Leu Arg Lys Arg Arg Lys Pro Gly Ser 1090 1095 1100 CAC ACA CAC TCA GCC TCT GAG GAC AAC ACC ACC AAC AAC GTG CGG GAG 3721 His Thr His Ser Ala Ser Glu Asp Asn Thr Thr Asn Asn Val Arg Glu 1105 1110 1115 CAG CTG AAC CAG ATC AAA AAC CCC ATT GAG AAA CAT GGG GCC AAC ACG 3769 Gin Leu Asn Gin He Lys Asn Pro He Glu Lys His Gly Ala Asn Thr 1120 1125 1130 GTC CCC ATC AAG GAT TAC GAG AAC AAG AAC TCC AAA ATG TCT AAA ATA 3817 Val Pro He Lys Asp Tyr Glu Asn Lys Asn Ser Lys Met Ser Lys He 1135 1140 1145 AGG ACA CAC AAT TCT GAA GTA GAA GAG GAC GAC ATG GAC AAA CAC CAG 3865 Arg Thr His Asn Ser Glu Val Glu Glu Asp Asp Met Asp Lys His Gin 1150 1155 1160 1165 CAG AAA GCC CGG TTT GCC AAG CAG CCG GCG TAC ACG CTG GTA GAC AGA 3913 Gin Lys Ala Arg Phe Ala Lys Gin Pro Ala Tyr Thr Leu Val Asp Arg 1170 1175 1180 GAA GAG AAG CCC CCC AAC GGC ACG CCG ACA AAA CAC CCA AAC TGG ACA 3961 Glu Glu Lys Pro Pro Asn Gly Thr Pro Thr Lys His Pro Asn Trp Thr 1185 1190 1195 AAC AAA CAG GAC AAC AGA GAC TTG GAA AGT GCC CAG AGC TTA AAC CGA 4009 Asn Lys Gin Asp Asn Arg Asp Leu Glu Ser Ala Gin Ser Leu Asn Arg 1200 1205 1210 ATG GAG TAC ATC GTA TAG CAGACCGCGG GCACTGCCGC CGCTAGGTAG 4057 Met Glu Tyr He Val 1215 AGTCTGAGGG CTTGTAGTTC TTTAAACTGT CGTGTCATAC TCGAGTCTGA GGCCGTTGCT 4117 GACTTAGAAT CCCTGTGTTA ATTTAGTTTG ACAAGCTGGC TTACACTGGC AATGGTAGTT 4177 CTGTGGTTGG CTGGGAAATC GAGTGGCGCA TCTCACAGCT ATGCAAAAAG CTAGTCAACA 4237 GTACCCCTGG TTGTGTGTCC CCTTGCAGCC GACACGGTCT CGGATCAGGC TCCCAGGAGC 4297 TGCCCAGCCC CCTGGTACTT TGAGCTCCCA CTTCTGCCAG ATGTCTAATG GTGATGCAGT 4357 CTTAGATCAT AGTTTTATTT ATATTTATTG ACTCTTGAGT TGTTTTTGTA TATTGGTTTT 4417 ATGATGACGT ACAAGTAGTT CTGTATTTGA AAGTGCCTTT GCAGCTCAGA ACCACAGCAA 4477 CGATCACAAA TGACTTTATT ATTTATTTTT TTTAATTGTA TTTTTGTTGT TGGGGGAGGG 4537 GAGACTTTGA TGTCAGCAGT TGCTGGTAAA ATGAAGAATT TAAAGAAAAA ATGTCCAAAA 4597 GTAGAACTTT GTATAGTTAT GTAAATAATT CTTTTTTATT AATCACTGTG TATATTTGAT 4657 TTATTAACTT AATAATCAAG AGCCTTAAAA CATCATTCCT TTTTATTTAT ATGTATGTGT 4717 TTAGAATTGA AGGTTTTTGA TAGCATTGTA AGCGTATGGC TTTATTTTTT TGAACTCTTC 4777 TCATTACTTG TTGCCTATAA GCCAAAAAGG AAAGGGTGTT TTGAAAATAG TTTATTTTAA 4837 AACAATAGGA TGGGCTACAC GTACATAGGT AAATAATAGC ACCGTACTGG TTATGATGAT 4897 GAAAATAACT GGAAACTTGA AAGCTTGTGG TAATGGCAGA TAAAGATGGT TCACCTGGGA 4957 AATTAAAACT TGAATGGTTG TACAGAAAAG CACAGAGTGG AATGCACATC AATGACAGTA 5017 AGGGAGTTAG TTCTAGGAAC AGCTCCTGAA CAGTAAGATT CCCGCAATAG TCTCCGCCTC 5077 GTTCGTCTAT GGTATGCATC CCATTCATTT TCTTCTTCTG ATTATTGTCA TCTTTCCCTT 5137 TGCCAAATGG GCAGTTATTG TTTCAGGGAG AGAAGCTGCT CATTGGCCAA TCATTCTGGT 5197 GTGCAGTGCT CCATCGGATT CTACATGTCC AACAAGGCAT GTCTGGATGA TGCAATGTCT 5257 GTCTGACCCC CGGAATTCCG TGCAGAGACA ACATTCTAGA CAGATATACA CTTTTTATTA 5317 TTAACAAACT TTGGCCACAA CCTTTGATGT ATAAATTGCC GGATTTCCCC AGTCCTTTCA 5377 TTGTGGCTTT GGACAGGAGC AGGCTCACTT GTCTGCTTCA GGCTGCCTTT CTCTTGGGTT 5437 GCACCTCAGT TCTTACTTAT TTATTTATTT TGAGTGGAGC ATAGGGGCCT CTTCCAAAAT 5497 GGGTAGAGCT CAGGGGCTTT CTTATTGAAA TGGTCACATG ATAAAAACGG GCTGAAAAAG 5557 GAGAGTTCCA GGAGAAAAGC CCAGAAAAGG CCCCTCCTCA GAAGACAGCC TTTAAGCCTC 5617 TTGCTTACTG AAGGAAGCCC CACCTTCTAG CACTGAGGCC GGGTCTGATC TTCCAGAGGA 5677 GTTGGAGGAG TCCATGAGAA TGGCCACCAT TCTTGCTTGC TGCTGCTGAT GTTGCAGTTT 5737 TGAGAGAACA GCGGGATCCT TGTTGTCCTC TAGAGACTTG AGTCTGTCAC TGACATTTTT 5797 TCAGTTCCTT TGCTCATAGA CCATACGAGG AATTAGTGAT GTGTCAGTTG AGAGTTCACA 5857 ATCTCATTGT TCATTTAATT CACTTTAAAG TTGTCAATTT CTGTGTGAGT AACCTGTAAA 5917 AGACACCTTT CCAGAAGAGT TTTGCCGTCT GTTTGAAAAA AAAATCTTTA TAAACTTTCC 5977 TAAGTATCTG GATTTGGATT CCTTATTTGG AGAGAAAATG TACCCTGTCT CCACCAAAAA 6037 TACAAAAATT AGCCAGGCTT GGTGGTGCAC ACCGGTAATC CCAGCAACTC TGGAGACTAA 6097 GGCAGGAAGA ATCGCTTGAC CCAGGAGGGT CGAGGCTACA ATGAGTTGAA ACCGCGCCAC 6157 TGCACTCCAG CCTGGGCGAC AGTGCGAGGC CCTGTCTCAA AAATAAAATA AAATAAATAA 6217 ATAAATTAGC CAGATACTGT GTGCACGCCT GCAGTCCCAG CTATTCTGGA AGCTGAGGTG 6277 GGAAGATGGT TAAGCCTGAG AGGACAAAGC TGCAGTGAGT CATGTTTGCA TCACTGCACT 6337 CCAGCCTGGG TGACAGAGCA AGACCCTGTC TAAAAAACAA AAACAGGCCG GGTGTGGTGG 6397 CTCATGCCTG CCATCCCAGT GCTTTGGGAG GCAGAGGTTG GCATAATCCC AGCGCTCTGG 6457 GAATTCC 6464 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1219 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg Ser Pro Arg Thr Arg Gly Arg Ser Gly Arg Pro Leu Ser Leu 1 5 10 15 Leu Leu Ala Leu Leu Cys Ala Leu Arg Ala Lys Val Cys Gly Ala Ser 20 25 30 Gly Gin Phe Glu Leu Glu He Leu Ser Met Gin Asn Val Asn Gly Glu 35 40 45 Leu Gin Asn Gly Asn Cys Cys Gly Gly Ala Arg Asn Pro Gly Asp Arg 50 55 60 Lys Cys Thr Arg Asp Glu Cys Asp Thr Tyr Phe Lys Val Cys Leu Lys 65 70 75 80 Glu Tyr Gin Ser Arg Val Thr Ala Gly Gly Pro Cys Ser Phe Gly Ser 85 90 95 Gly Ser Thr Pro Val He Gly Gly Asn Thr Phe Asn Leu Lys Ala Ser 100 105 110 Arg Gly Asn Asp Pro Asn Arg He Val Leu Pro Phe Ser Phe Ala Trp 115 120 125 Pro Arg Ser Tyr Thr Leu Leu Val Glu Ala Trp Asp Ser Ser Asn Asp 130 135 140 Thr Val Gin Pro Asp Ser He He Glu Lys Ala Ser His Ser Gly Met 145 150 155 160 He Asn Pro Ser Arg Gin Trp Gin Thr Leu Lys Gin Asn Thr Gly Val 165 170 175 Ala His Phe Glu Tyr Gin He Arg Val Thr Cys Asp Asp Tyr Tyr Tyr 180 185 190 Gly Phe Gly Cys Asn Lys Phe Cys Arg Pro Arg Asp Asp Phe Phe Gly 195 200 205 His Tyr Ala Cys Asp Gin Asn Gly Asn Lys Thr Cys Met Glu Gly Trp 210 215 220 Met Gly Pro Glu Cys Asn Arg Ala He Cys Arg Gin Gly Cys Ser Pro 225 230 235 240 Lys His Gly Ser Cys Lys Leu Pro Gly Asp Cys Arg Cys Gin Tyr Gly 245 250 255 Trp Gin Gly Leu Tyr Cys Asp Lys Cys He Pro His Pro Gly Cys Val 260 265 270 His Gly He Cys Asn Glu Pro Trp Gin Cys Leu Cys Glu Thr Asn Trp 275 280 285 Gly Gly Gin Leu Cys Asp Lys Asp Leu Asn Tyr Cys Gly Thr His Gin 290 295 300 Pro Cys Leu Asn Gly Gly Thr Cys Ser Asn Thr Gly Pro Asp Lys Tyr 305 310 315 320 Gin Cys Ser Cys Pro Glu Gly Tyr Ser Gly Pro Asn Cys Glu He Ala 325 330 335 Glu His Ala Cys Leu Ser Asp Pro Cys His Asn Arg Gly Ser Cys Lys 340 345 350 Glu Thr Ser Leu Gly Phe Glu Cys Glu Cys Ser Pro Gly Trp Thr Gly 355 360 365 Pro Thr Cys Ser Thr Asn He Asp Asp Cys Ser Pro Asn Asn Cys Ser 370 375 380 His Gly Gly Thr Cys Gin Asp Leu Val Asn Gly Phe Lys Cys Val Cys 385 390 395 400 Pro Pro Gin Trp Thr Gly Lys Thr Cys Gin Leu Asp Ala Asn Glu Cys 405 410 415 Glu Ala Lys Pro Cys Val Asn Ala Lys Ser Cys Lys Asn Leu He Ala 420 425 430 Ser Tyr Tyr Cys Asp Cys Leu Pro Gly Trp Met Gly Gin Asn Cys Asp 435 440 445 He Asn He Asn Asp Cys Leu Gly Gin Cys Gin Asn Asp Ala Ser Cys 450 455 460 Arg Asp Leu Val Asn Gly Tyr Arg Cys He Cys Pro Pro Gly Tyr Ala 465 470 475 480 Gly Asp His Cys Glu Arg Asp He Asp Glu Cys Ala Ser Asn Pro Cys 485 490 495 Leu Asn Gly Gly His Cys Gin Asn Glu He Asn Arg Phe Gin Cys Leu 500 505 510 Cys Pro Thr Gly Phe Ser Gly Asn Leu Cys Gin Leu Asp He Asp Tyr 515 520 525 Cys Glu Pro Asn Pro Cys Gin Asn Gly Ala Gin Cys Tyr Asn Arg Ala 530 535 540 Ser Asp Tyr Phe Cys Lys Cys Pro Glu Asp Tyr Glu Gly Lys Asn Cys 545 550 555 560 Ser His Leu Lys Asp His Cys Arg Thr Thr Pro Cys Glu Val He Asp 565 570 575 Ser Cys Thr Val Ala Met Ala Ser Asn Asp Thr Pro Glu Gly Val Arg 580 585 590 Tyr He Ser Ser Asn Val Cys Gly Pro His Gly Lys Cys Lys Ser Gin 595 600 605 Ser Gly Gly Lys Phe Thr Cys Asp Cys Asn Lys Gly Phe Thr Gly Thr 610 615 620 Tyr Cys His Glu Asn He Asn Asp Cys Glu Ser Asn Pro Cys Arg Asn 625 630 635 640 Gly Gly Thr Cys He Asp Gly Val Asn Ser Tyr Lys Cys He Cys Ser 645 650 655 Aβp Gly Trp Glu Gly Ala Tyr Cys Glu Thr Asn He Asn Asp Cys Ser 660 665 670 Gin Asn Pro Cys His Asn Gly Gly Thr Cys Arg Asp Leu Val Asn Asp 675 680 685 Phe Tyr Cys Asp Cys Lys Asn Gly Trp Lys Gly Lys Thr Cys His Ser 690 695 700 Arg Asp Ser Gin Cys Asp Glu Ala Thr Cys Asn Asn Gly Gly Thr Cys 705 710 715 720 Tyr Asp Glu Gly Asp Ala Phe Lys Cys Met Cys Pro Gly Gly Trp Glu 725 730 735 Gly Thr Thr Cys Asn He Ala Arg Asn Ser Ser Cys Leu Pro Asn Pro 740 745 750 Cys His Asn Gly Gly Thr Cys Val Val Asn Gly Glu Ser Phe Thr Cys 755 760 765 Val Cys Lys Glu Gly Trp Glu Gly Pro He Cys Ala Gin Asn Thr Asn 770 775 780 Asp Cys Ser Pro His Pro Cys Tyr Asn Ser Gly Thr Cys Val Asp Gly 785 790 795 800 Asp Asn Trp Tyr Arg Cys Glu Cys Ala Pro Gly Phe Ala Gly Pro Asp 805 810 815 Cys Arg He Asn He Asn Glu Cys Gin Ser Ser Pro Cys Ala Phe Gly 820 825 830 Ala Thr Cys Val Asp Glu He Asn Gly Tyr Arg Cys Val Cys Pro Pro 835 840 845 Gly His Ser Gly Ala Lys Cys Gin Glu Val Ser Gly Arg Pro Cys He 850 855 860 Thr Met Gly Ser Val He Pro Asp Gly Ala Lys Trp Asp Asp Asp Cys 865 870 875 880 Asn Thr Cys Gin Cys Leu Asn Gly Arg He Ala Cys Ser Lys Val Trp 885 890 895 Cys Gly Pro Arg Pro Cys Leu Leu His Lys Gly His Ser Glu Cys Pro 900 905 910 Ser Gly Gin Ser Cys He Pro He Leu Asp Asp Gin Cys Phe Val His 915 920 925 Pro Cys Thr Gly Val Gly Glu Cys Arg Ser Ser Ser Leu Gin Pro Val 930 935 940 Lys Thr Lys Cys Thr Ser Asp Ser Tyr Tyr Gin Asp Asn Cys Ala Asn 945 950 955 960 He Thr Phe Thr Phe Asn Lys Glu Met Met Ser Pro Gly Leu Thr Thr 965 970 975 Glu His He Cys Ser Glu Leu Arg Asn Leu Asn He Leu Lys Asn Val 980 985 990 Ser Ala Glu Tyr Ser He Tyr He Ala Cys Glu Pro Ser Pro Ser Ala 995 1000 1005 Asn Asn Glu He His Val Ala He Ser Ala Glu Asp He Arg Asp Asp 1010 1015 1020 Gly Asn Pro He Lys Glu He Thr Asp Lys He He Asp Leu Val Thr 1025 1030 1035 1040 Lys Arg Asp Gly Asn Ser Ser Leu He Ala Ala Val Glu Glu Val Arg 1045 1050 1055 Val Gin Arg Arg Pro Leu Lys Asn Arg Thr Asp Phe Leu Val Pro Leu 1060 1065 1070 Leu Ser Ser Val Leu Thr Val Ala Trp He Cys Cys Leu Val Thr Ala 1075 1080 1085 Phe Tyr Trp Cys Leu Arg Lys Arg Arg Lys Pro Gly Ser His Thr His 1090 1095 1100 Ser Ala Ser Glu Asp Asn Thr Thr Asn Asn Val Arg Glu Gin Leu Asn 1105 1110 1115 1120 Gin He Lys Asn Pro He Glu Lys His Gly Ala Asn Thr Val Pro He 1125 1130 1135 Lys Asp Tyr Glu Asn Lys Asn Ser Lys Met Ser Lys He Arg Thr His 1140 1145 1150 Asn Ser Glu Val Glu Glu Asp Asp Met Asp Lys His Gin Gin Lys Ala 1155 1160 1165 Arg Phe Ala Lys Gin Pro Ala Tyr Thr Leu Val Asp Arg Glu Glu Lys 1170 1175 1180 Pro Pro Asn Gly Thr Pro Thr Lys His Pro Asn Trp Thr Asn Lys Gin 1185 1190 1195 1200 Asp Asn Arg Asp Leu Glu Ser Ala Gin Ser Leu Asn Arg Met Glu Tyr 1205 1210 1215 He Val (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 4483 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 332..4483 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: GGCCGGGGCC GGGCGGGCGG GTCGCGGGGG CAATGCGGGC GCAGGGCCGG GGGCGCCTTC 60 CCCGGCGGCT GCTGCTGCTG CTGGCGCTCT GGGTGCAGGC GGCGCGGCCC ATGGGCTATT 120 TCGAGCTGCA GCTGAGCGCG CTGCGGAACG TGAACGGGGA GCTGCTGAGC GGCGCCTGCT 180 GTGACGGCGA CGGCCGGACA ACGCGCGCGG GGGGCTGCGG CCACGACGAG TGCGACACCG 240 CTCCTTTACC CTCATCGTGG AGGCCTGGGA CTGGGACAAC GATACCACCC CGAATGAGGA 300 GCTGCTGATC GAGCGAGTGT CGCATGCCGG C ATG ATC AAC CCG GAG GAC CGC 352 Met He Asn Pro Glu Asp Arg 1 5 TGG AAG AGC CTG CAC TTC AGC GGC CAC GTG GCG CAC CTG GAG CTG CAG 400 Trp Lys Ser Leu His Phe Ser Gly His Val Ala His Leu Glu Leu Gin 10 15 20 ATC CGC GTG CGC TGC GAC GAG AAC TAC TAC AGC GCC ACT TGC AAC AAG 448 He Arg Val Arg Cys Asp Glu Asn Tyr Tyr Ser Ala Thr Cys Asn Lys 25 30 35 TTC TGC CGG CCC CGC AAT GAC TTT TTC GGC CAC TAC ACC TGC GAC CAG 496 Phe Cys Arg Pro Arg Asn Asp Phe Phe Gly His Tyr Thr Cys Asp Gin 40 45 50 55 TAC GGC AAC AAG GCC TGC ATG GAC GGC TGG ATG GGC AAG GAG TGC AAG 544 Tyr Gly Asn Lys Ala Cys Met Asp Gly Trp Met Gly Lys Glu Cys Lys 60 65 70 GAA GCT GTG TGT AAA CAA GGG TGT AAT TTG CTC CAC GGG GGA TGC ACC 592 Glu Ala Val Cys Lys Gin Gly Cys Asn Leu Leu His Gly Gly Cys Thr 75 80 85 GTG CCT GGG GAG TGC AGG TGC AGC TAC GGC TGG CAA GGG AGG TTC TGC 640 Val Pro Gly Glu Cys Arg Cys Ser Tyr Gly Trp Gin Gly Arg Phe Cys 90 95 100 GAT GAG TGT GTC CCC TAC CCC GGC TGC GTG CAT GGC AGT TGT GTG GAG 688 Asp Glu Cys Val Pro Tyr Pro Gly Cys Val His Gly Ser Cys Val Glu 105 110 115 CCC TGG CAG TGC AAC TGT GAG ACC AAC TGG GGC GGC CTG CTC TGT GAC 736 Pro Trp Gin Cys Asn Cys Glu Thr Asn Trp Gly Gly Leu Leu Cys Asp 120 125 130 135 AAA GAC CTG AAC TAC TGT GGC AGC CAC CAC CCC TGC ACC AAC GGA GGC 784 Lys Asp Leu Asn Tyr Cys Gly Ser His His Pro Cys Thr Asn Gly Gly 140 145 150 ACG TGC ATC AAC GCC GAG CCT GAC CAG TAC CGC TGC ACC TGC CCT GAC 832 Thr Cys He Asn Ala Glu Pro Asp Gin Tyr Arg Cys Thr Cys Pro Asp 155 160 165 GGC TAC TCG GGC AGG AAC TGT GAG AAG GCT GAG CAC GCC TGC ACC TCC 880 Gly Tyr Ser Gly Arg Asn Cys Glu Lys Ala Glu His Ala Cys Thr Ser 170 175 180 AAC CCG TGT GCC AAC GGG GGC TCT TGC CAT GAG GTG CCG TCC GGC TTC 928 Asn Pro Cys Ala Asn Gly Gly Ser Cys His Glu Val Pro Ser Gly Phe 185 190 195 GAA TGC CAC TGC CCA TCG GGC TGG AGC GGG CCC ACC TGT GCC CTT GAC 976 Glu Cys His Cys Pro Ser Gly Trp Ser Gly Pro Thr Cys Ala Leu Asp 200 205 210 215 ATC GAT GAG TGT GCT TCG AAC CCG TGT GCG GCC GGT GGC ACC TGT GTG 1024 He Asp Glu Cys Ala Ser Asn Pro Cys Ala Ala Gly Gly Thr Cys Val 220 225 230 GAC CAG GTG GAC GGC TTT GAG TGC ATC TGC CCC GAG CAG TGG GTG GGG 1072 Asp Gin Val Asp Gly Phe Glu Cys He Cys Pro Glu Gin Trp Val Gly 235 240 245 GCC ACC TGC CAG CTG GAC GCC AAT GAG TGT GAA GGG AAG CCA TGC CTT 1120 Ala Thr Cys Gin Leu Asp Ala Asn Glu Cys Glu Gly Lys Pro Cys Leu 250 255 260 AAC GCT TTT TCT TGC AAA AAC CTG ATT GGC GGC TAT TAC TGT GAT TGC 1168 Asn Ala Phe Ser Cys Lys Asn Leu He Gly Gly Tyr Tyr Cys Asp Cys 265 270 275 ATC CCG GGC TGG AAG GGC ATC AAC TGC CAT ATC AAC GTC AAC GAC TGT 1216 He Pro Gly Trp Lys Gly He Asn Cys His He Asn Val Asn Asp Cys 280 285 290 295 CGC GGG CAG TGT CAG CAT GGG GGC ACC TGC AAG GAC CTG GTG AAC GGG 1264 Arg Gly Gin Cys Gin His Gly Gly Thr Cys Lys Asp Leu Val Asn Gly 300 305 310 TAC CAG TGT GTG TGC CCA CGG GGC TTC GGA GGC CGG CAT TGC GAG CTG 1312 Tyr Gin Cys Val Cys Pro Arg Gly Phe Gly Gly Arg His Cys Glu Leu 315 320 325 GAA CGA GAC AAG TGT GCC AGC AGC CCC TGC CAC AGC GGC GGC CTC TGC 1360 Glu Arg Asp Lys Cys Ala Ser Ser Pro Cys His Ser Gly Gly Leu Cys 330 335 340 GAG GAC CTG GCC GAC GGC TTC CAC TGC CAC TGC CCC CAG GGC TTC TCC 1408 Glu Asp Leu Ala Asp Gly Phe His Cys His Cys Pro Gin Gly Phe Ser 345 350 355 GGG CCT CTC TGT GAG GTG GAT GTC GAC CTT TGT GAG CCA AGC CCC TGC 1456 Gly Pro Leu Cys Glu Val Asp Val Asp Leu Cys Glu Pro Ser Pro Cys 360 365 370 375 CGG AAC GGC GCT CGC TGC TAT AAC CTG GAG GGT GAC TAT TAC TGC GCC 1504 Arg Asn Gly Ala Arg Cys Tyr Asn Leu Glu Gly Asp Tyr Tyr Cys Ala 380 385 390 TGC CCT GAT GAC TTT GGT GGC AAG AAC TGC TCC GTG CCC CGC GAG CCG 1552 Cys Pro Asp Asp Phe Gly Gly Lys Asn Cys Ser Val Pro Arg Glu Pro 395 400 405 TGC CCT GGC GGG GCC TGC AGA GTG ATC GAT GGC TGC GGG TCA GAC GCG 1600 Cys Pro Gly Gly Ala Cys Arg Val He Asp Gly Cys Gly Ser Asp Ala 410 415 420 GGG CCT GGG ATG CCT GGC ACA GCA GCC TCC GGC GTG TGT GGC CCC CAT 1648 Gly Pro Gly Met Pro Gly Thr Ala Ala Ser Gly Val Cys Gly Pro His 425 430 435 GGA CGC TGC GTC AGC CAG CCA GGG GGC AAC TTT TCC TGC ATC TGT GAC 1696 Gly Arg Cys Val Ser Gin Pro Gly Gly Asn Phe Ser Cys He Cys Asp 440 445 450 455 AGT GGC TTT ACT GGC ACC TAC TGC CAT GAG AAC ATT GAC GAC TGC CTG 1744 Ser Gly Phe Thr Gly Thr Tyr Cys His Glu Asn He Asp Asp Cys Leu 460 465 470 GGC CAG CCC TGC CGC AAT GGG GGC ACA TGC ATC GAT GAG GTG GAC GCC 1792 Gly Gin Pro Cys Arg Asn Gly Gly Thr Cys He Asp Glu Val Asp Ala 475 480 485 TTC CGC TGC TTC TGC CCC AGC GGT TGG GAG GGC GAG CTC TGC GAC ACC 1840 Phe Arg Cys Phe Cys Pro Ser Gly Trp Glu Gly Glu Leu Cys Asp Thr 490 495 500 AAT CCC AAC GAC TGC CTT CCC GAT CCC TGC CAC AGC CGC GGC CGC TGC 1888 Asn Pro Asn Asp Cys Leu Pro Asp Pro Cys His Ser Arg Gly Arg Cys 505 510 515 TAC GAC CTG GTC AAT GAC TTC TAC TGT GCG TGC GAC GAC GGC TGG AAG 1936 Tyr Asp Leu Val Asn Asp Phe Tyr Cys Ala Cys Asp Asp Gly Trp Lys 520 525 530 535 GGC AAG ACC TGC CAC TCA CGC GAG TTC CAG TGC GAT GCC TAC ACC TGC 1984 Gly Lys Thr Cys His Ser Arg Glu Phe Gin Cys Asp Ala Tyr Thr Cys 540 545 550 AGC AAC GGT GGC ACC TGC TAC GAC AGC GGC GAC ACC TTC CGC TGC GCC 2032 Ser Asn Gly Gly Thr Cys Tyr Asp Ser Gly Asp Thr Phe Arg Cys Ala 555 560 565 TGC CCC CCC GGC TGG AAG GGC AGC ACC TGC GCC GTC GCC AAG AAC AGC 2080 Cys Pro Pro Gly Trp Lys Gly Ser Thr Cys Ala Val Ala Lys Asn Ser 570 575 580 AGC TGC CTG CCC AAC CCC TGT GTG AAT GGT GGC ACC TGC GTG GGC AGC 2128 Ser Cys Leu Pro Asn Pro Cys Val Asn Gly Gly Thr Cys Val Gly Ser 585 590 595 GGG GCC TCC TTC TCC TGC ATC TGC CGG GAC GGC TGG GAG GGT CGT ACT 2176 Gly Ala Ser Phe Ser Cys He Cys Arg Asp Gly Trp Glu Gly Arg Thr 600 605 610 615 TGC ACT CAC AAT ACC AAC GAC TGC AAC CCT CTG CCT TGC TAC AAT GGT 2224 Cys Thr His Asn Thr Aβn Asp Cys Asn Pro Leu Pro Cys Tyr Asn Gly 620 625 630 GGC ATC TGT GTT GAC GGC GTC AAC TGG TTC CGC TGC GAG TGT GCA CCT 2272 Gly He Cys Val Asp Gly Val Asn Trp Phe Arg Cys Glu Cys Ala Pro 635 640 645 GGC TTC GCG GGG CCT GAC TGC CGC ATC AAC ATC GAC GAG TGC CAG TCC 2320 Gly Phe Ala Gly Pro Asp Cys Arg He Asn He Asp Glu Cys Gin Ser 650 655 660 TCG CCC TGT GCC TAC GGG GCC ACG TGT GTG GAT GAG ATC AAC GGG TAT 2368 Ser Pro Cys Ala Tyr Gly Ala Thr Cys Val Asp Glu He Asn Gly Tyr 665 670 675 CGC TGT AGC TGC CCA CCC GGC CGA GCC GGC CCC CGG TGC CAG GAA GTG 2416 Arg Cys Ser Cys Pro Pro Gly Arg Ala Gly Pro Arg Cys Gin Glu Val 680 685 690 695 ATC GGG TTC GGG AGA TCC TGC TGG TCC CGG GGC ACT CCG TTC CCA CAC 2464 He Gly Phe Gly Arg Ser Cys Trp Ser Arg Gly Thr Pro Phe Pro His 700 705 710 GGA AGC TCC TGG GTG GAA GAC TGC AAC AGC TGC CGC TGC CTG GAT GGC 2512 Gly Ser Ser Trp Val Glu Asp Cys Asn Ser Cys Arg Cys Leu Asp Gly 715 720 725 CGC CGT GAC TGC AGC AAG GTG TGG TGC GGA TGG AAG CCT TGT CTG CTG 2560 Arg Arg Asp Cys Ser Lys Val Trp Cys Gly Trp Lys Pro Cys Leu Leu 730 735 740 GCC GGC CAG CCC GAG GCC CTG AGC GCC CAG TGC CCA CTG GGG CAA AGG 2608 Ala Gly Gin Pro Glu Ala Leu Ser Ala Gin Cys Pro Leu Gly Gin Arg 745 750 755 TGC CTG GAG AAG GCC CCA GGC CAG TGT CTG CGA CCA CCC TGT GAG GCC 2656 Cys Leu Glu Lys Ala Pro Gly Gin Cys Leu Arg Pro Pro Cys Glu Ala 760 765 770 775 TGG GGG GAG TGC GGC GCA GAA GAG CCA CCG AGC ACC CCC TGC CTG CCA 2704 Trp Gly Glu Cys Gly Ala Glu Glu Pro Pro Ser Thr Pro Cys Leu Pro 780 785 790 CGC TCC GGC CAC CTG GAC AAT AAC TGT GCC CGC CTC ACC TTG CAT TTC 2752 Arg Ser Gly His Leu Asp Asn Asn Cys Ala Arg Leu Thr Leu His Phe 795 800 805 AAC CGT GAC CAC GTG CCC CAG GGC ACC ACG GTG GGC GCC ATT TGC TCC 2800 Asn Arg Asp His Val Pro Gin Gly Thr Thr Val Gly Ala He Cys Ser 810 815 820 GGG ATC CGC TCC CTG CCA GCC ACA AGG GCT GTG GCA CGG GAC CGC CTG 2848 Gly He Arg Ser Leu Pro Ala Thr Arg Ala Val Ala Arg Asp Arg Leu 825 830 835 CTG GTG TTG CTT TGC GAC CGG GCG TCC TCG GGG GCC AGT GCT GTG GAG 2896 Leu Val Leu Leu Cys Asp Arg Ala Ser Ser Gly Ala Ser Ala Val Glu 840 845 850 855 GTG GCC GTG TCC TTC AGC CCT GCC AGG GAC CTG CCT GAC AGC AGC CTG 2944 Val Ala Val Ser Phe Ser Pro Ala Arg Asp Leu Pro Asp Ser Ser Leu 860 865 870 ATC CAG GGC GCG GCC CAC GCC ATC GTG GCC GCC ATC ACC CAG CGG GGG 2992 He Gin Gly Ala Ala His Ala He Val Ala Ala He Thr Gin Arg Gly 875 880 885 AAC AGC TCA CTG CTC CTG GCT GTC ACC GAG GTC AAG GTG GAG ACG GTT 3040 Asn Ser Ser Leu Leu Leu Ala Val Thr Glu Val Lys Val Glu Thr Val 890 895 900 GTT ACG GGC GGC TCT TCC ACA GGT CTG CTG GTG CCT GTG CTG TGT GGT 3088 Val Thr Gly Gly Ser Ser Thr Gly Leu Leu Val Pro Val Leu Cys Gly 905 910 915 GCC TTC AGC GTG CTG TGG CTG GCG TGC GTG GTC CTG TGC GTG TGG TGG 3136 Ala Phe Ser Val Leu Trp Leu Ala Cys Val Val Leu Cys Val Trp Trp 920 925 930 935 ACA CGC AAG CGC AGG AAA GAG CGG GAG AGG AGC CGG CTG CCG CGG GAG 3184 Thr Arg Lys Arg Arg Lys Glu Arg Glu Arg Ser Arg Leu Pro Arg Glu 940 945 950 GAG AGC GCC AAC AAC CAG TGG GCC CCG CTC AAC CCC ATC CGC AAC CCC 3232 Glu Ser Ala Asn Asn Gin Trp Ala Pro Leu Asn Pro He Arg Asn Pro 955 960 965 ATT GAG CGG CCG GGG GGG CAC AAG GAC GTG CTC TAC CAG TGC AAG AAC 3280 He Glu Arg Pro Gly Gly His Lys Asp Val Leu Tyr Gin Cys Lys Asn 970 975 980 TTC ACT CCA CCG CCG CGC AGG CGC TGC CCG GGC CGG CCG GCC ACG CGG 3328 Phe Thr Pro Pro Pro Arg Arg Arg Cys Pro Gly Arg Pro Ala Thr Arg 985 990 995 CCG TCA GGG AGG ATG AGG AGG ACG AGG ATC TTG GCC GCG GTG AGG AGG 3376 Pro Ser Gly Arg Met Arg Arg Thr Arg He Leu Ala Ala Val Arg Arg 1000 1005 1010 1015 ACT CCC TGG AGG CGG AGA AGT TCC TCT CAC ACA AAT TCA CCA AAG ATC 3424 Thr Pro Trp Arg Arg Arg Ser Ser Ser His Thr Asn Ser Pro Lys He 1020 1025 1030 CTG GCC GCT CGC CGG GGA GGC CGG CCC ACT GGG CCT CAG GCC CCA AAG 3472 Leu Ala Ala Arg Arg Gly Gly Arg Pro Thr Gly Pro Gin Ala Pro Lys 1035 1040 1045 TGG ACA ACC GCG CGG TCA GGA GCA TCA ATG AGG CCC GCT ACG TCG GCA 3520 Trp Thr Thr Ala Arg Ser Gly Ala Ser Met Arg Pro Ala Thr Ser Ala 1050 1055 1060 AGG GAA GTA GGG CGG CTG CAG CTG GGC CGG GAC CCA GGG CCC TCG GTG 3568 Arg Glu Val Gly Arg Leu Gin Leu Gly Arg Asp Pro Gly Pro Ser Val 1065 1070 1075 GGA GCC ATG CCG TCT GCC GGA CCC GGA GGC CGA GGC CAT GTG CAT AGT 3616 Gly Ala Met Pro Ser Ala Gly Pro Gly Gly Arg Gly Hiβ Val His Ser 1080 1085 1090 1095 TTC TTT ATT TTG TGT AAA AAA ACC ACC AAA AAC AAA AAC CAA ATG TTT 3664 Phe Phe He Leu Cys Lys Lys Thr Thr Lys Asn Lys Asn Gin Met Phe 1100 1105 1110 ATT TTC TAC GTT TCT TTA ACC TTG TAT AAA TTA TTC AGT AAC TGT CAG 3712 He Phe Tyr Val Ser Leu Thr Leu Tyr Lys Leu Phe Ser Asn Cys Gin 1115 1120 1125 GCT GAA AAC AAT GGA GTA TTC TCG GAT AGT TGC TAT TTT TGT AAA GTA 3760 Ala Glu Asn Asn Gly Val Phe Ser Asp Ser Cys Tyr Phe Cys Lys Val 1130 1135 1140 GCC GTG CGT GGC ACT CGC TGT ATG AAA GGA GAG AGC AAA GGG TGT CTG 3808 Ala Val Arg Gly Thr Arg Cys Met Lys Gly Glu Ser Lys Gly Cys Leu 1145 1150 1155 CGT CGT CAC CAA ATC GTC GCG TTT GTT ACC AGA GGT TGT GCA CTG TTT 3856 Arg Arg His Gin He Val Ala Phe Val Thr Arg Gly Cys Ala Leu Phe 1160 1165 1170 1175 ACA GAA TCT TCC TTT TAT TCC TCA CTC GGG TTT CTC TGT GCT CCA GGC 3904 Thr Glu Ser Ser Phe Tyr Ser Ser Leu Gly Phe Leu Cys Ala Pro Gly 1180 1185 1190 CAA AGT GCC GGT GAG ACC CAT GGC TGT GTT GGT GTG GCC CAT GGC TGT 3952 Gin Ser Ala Gly Glu Thr His Gly Cys Val Gly Val Ala His Gly Cys 1195 1200 1205 TGG TGG GAC CCG TGG CTG ATG GTG TGG CCT GTG GCT GTC GGT GGG ACT 4000 Trp Trp Asp Pro Trp Leu Met Val Trp Pro Val Ala Val Gly Gly Thr 1210 1215 1220 CGT GGC TGT CAA TGG GAC CTG TGG CTG TCG GTG GGA CCT ACG GTG GTC 4048 Arg Gly Cys Gin Trp Asp Leu Trp Leu Ser Val Gly Pro Thr Val Val 1225 1230 1235 GGT GGG ACC CTG GTT ATT GAT GTG GCC CTG GCT GCC GGC ACG GCC CGT 4096 Gly Gly Thr Leu Val He Asp Val Ala Leu Ala Ala Gly Thr Ala Arg 1240 1245 1250 1255 GGC TGT TG ACGCACCT GTGGTTGTTA GTGGGGCCTG AGGTCATCGGC GTGGCCCAAG 4154 Gly Cys GCCGGCAGGT CAACCTCGCG CTTGCTGGCC AGTCCACCCT GCCTGCCGTCT GTGCTTCCTC 4214 CTGCCCAGAA CGCCCGCTCC AGCGATCTCT CCACTGTGCT TTCAGAAGTGC CCTTCCTGCT 4274 GCGCAGTTCT CCCATCCTGG GACGGCGGCA GTATTGAAGC TCGTGACAAGT GCCTTCACAC 4334 AGACCCCTCG CAACTGTCCA CGCGTGCCGT GGCACCAGGC GCTGCCCACCT GCCGGCCCCG 4394 GCCGCCCCTC CTCGTGAAAG TGCATTTTTG TAAATGTGTA CATATTAAAGG AAGCACTCTG 4454 TATAAAAAAA AAAAACCGGA ATTCC 4483 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1384 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met He Asn Pro Glu Asp Arg Trp Lys Ser Leu His Phe Ser Gly His 1 5 10 15 Val Ala His Leu Glu Leu Gin He Arg Val Arg Cys Asp Glu Asn Tyr 20 25 30 Tyr Ser Ala Thr Cys Asn Lys Phe Cys Arg Pro Arg Asn Asp Phe Phe 35 40 45 Gly His Tyr Thr Cys Asp Gin Tyr Gly Asn Lys Ala Cys Met Asp Gly 50 55 60 Trp Met Gly Lys Glu Cys Lys Glu Ala Val Cys Lys Gin Gly Cys Asn 65 70 75 80 Leu Leu His Gly Gly Cys Thr Val Pro Gly Glu Cys Arg Cys Ser Tyr 85 90 95 Gly Trp Gin Gly Arg Phe Cys Asp Glu Cys Val Pro Tyr Pro Gly Cys 100 105 110 Val His Gly Ser Cys Val Glu Pro Trp Gin Cys Asn Cys Glu Thr Asn 115 120 125 Trp Gly Gly Leu Leu Cys Asp Lys Asp Leu Asn Tyr Cys Gly Ser His 130 135 140 His Pro Cys Thr Asn Gly Gly Thr Cys He Asn Ala Glu Pro Asp Gin 145 150 155 160 Tyr Arg Cys Thr Cys Pro Asp Gly Tyr Ser Gly Arg Asn Cys Glu Lys 165 170 175 Ala Glu His Ala Cys Thr Ser Asn Pro Cys Ala Asn Gly Gly Ser Cys 180 185 190 His Glu Val Pro Ser Gly Phe Glu Cys His Cys Pro Ser Gly Trp Ser 195 200 205 Gly Pro Thr Cys Ala Leu Asp He Asp Glu Cys Ala Ser Asn Pro Cys 210 215 220 Ala Ala Gly Gly Thr Cys Val Asp Gin Val Asp Gly Phe Glu Cys He 225 230 235 240 Cys Pro Glu Gin Trp Val Gly Ala Thr Cys Gin Leu Asp Ala Asn Glu 245 250 255 Cys Glu Gly Lys Pro Cys Leu Asn Ala Phe Ser Cys Lys Asn Leu He 260 265 270 Gly Gly Tyr Tyr Cys Asp Cys He Pro Gly Trp Lys Gly He Asn Cys 275 280 285 His He Asn Val Asn Asp Cys Arg Gly Gin Cys Gin His Gly Gly Thr 290 295 300 Cys Lys Asp Leu Val Asn Gly Tyr Gin Cys Val Cys Pro Arg Gly Phe 305 310 315 320 Gly Gly Arg His Cys Glu Leu Glu Arg Asp Lys Cys Ala Ser Ser Pro 325 330 335 Cys His Ser Gly Gly Leu Cys Glu Asp Leu Ala Asp Gly Phe His Cys 340 345 350 His Cys Pro Gin Gly Phe Ser Gly Pro Leu Cys Glu Val Asp Val Asp 355 360 365 Leu Cys Glu Pro Ser Pro Cys Arg Asn Gly Ala Arg Cys Tyr Asn Leu 370 375 380 Glu Gly Asp Tyr Tyr Cys Ala Cys Pro Asp Asp Phe Gly Gly Lys Asn 385 390 395 400 Cys Ser Val Pro Arg Glu Pro Cys Pro Gly Gly Ala Cys Arg Val He 405 410 415 Asp Gly Cyβ Gly Ser Asp Ala Gly Pro Gly Met Pro Gly Thr Ala Ala 420 425 430 Ser Gly Val Cys Gly Pro His Gly Arg Cys Val Ser Gin Pro Gly Gly 435 440 445 Aβn Phe Ser Cys He Cys Asp Ser Gly Phe Thr Gly Thr Tyr Cys His 450 455 460 Glu Asn He Asp Asp Cys Leu Gly Gin Pro Cys Arg Asn Gly Gly Thr 465 470 475 480 Cyβ He Asp Glu Val Asp Ala Phe Arg Cys Phe Cys Pro Ser Gly Trp 485 490 495 Glu Gly Glu Leu Cys Asp Thr Asn Pro Asn Asp Cys Leu Pro Asp Pro 500 505 510 Cys His Ser Arg Gly Arg Cys Tyr Asp Leu Val Asn Asp Phe Tyr Cys 515 520 525 Ala Cys Asp Asp Gly Trp Lys Gly Lys Thr Cys His Ser Arg Glu Phe 530 535 540 Gin Cys Asp Ala Tyr Thr Cys Ser Asn Gly Gly Thr Cys Tyr Asp Ser 545 550 555 560 Gly Asp Thr Phe Arg Cys Ala Cys Pro Pro Gly Trp Lys Gly Ser Thr 565 570 575 Cys Ala Val Ala Lys Asn Ser Ser Cys Leu Pro Asn Pro Cys Val Asn 580 585 590 Gly Gly Thr Cys Val Gly Ser Gly Ala Ser Phe Ser Cys He Cys Arg 595 600 605 Asp Gly Trp Glu Gly Arg Thr Cys Thr His Asn Thr Asn Asp Cys Asn 610 615 620 Pro Leu Pro Cys Tyr Asn Gly Gly He Cys Val Asp Gly Val Asn Trp 625 630 635 640 Phe Arg Cyβ Glu Cys Ala Pro Gly Phe Ala Gly Pro Aβp Cys Arg He 645 650 655 λβn He Asp Glu Cyβ Gin Ser Ser Pro Cys Ala Tyr Gly Ala Thr Cys 660 665 670 Val Asp Glu He Asn Gly Tyr Arg Cys Ser Cys Pro Pro Gly Arg Ala 675 680 685 Gly Pro Arg Cys Gin Glu Val He Gly Phe Gly Arg Ser Cys Trp Ser 690 695 700 Arg Gly Thr Pro Phe Pro His Gly Ser Ser Trp Val Glu Asp Cys Asn 705 710 715 720 Ser Cys Arg Cys Leu Asp Gly Arg Arg Asp Cys Ser Lys Val Trp Cys 725 730 735 Gly Trp Lye Pro Cys Leu Leu Ala Gly Gin Pro Glu Ala Leu Ser Ala 740 745 750 Gin Cys Pro Leu Gly Gin Arg Cys Leu Glu Lys Ala Pro Gly Gin Cys 755 760 765 Leu Arg Pro Pro Cys Glu Ala Trp Gly Glu Cys Gly Ala Glu Glu Pro 770 775 780 Pro Ser Thr Pro Cys Leu Pro Arg Ser Gly His Leu Asp Aβn Asn Cyβ 785 790 795 800 Ala Arg Leu Thr Leu His Phe Asn Arg Asp His Val Pro Gin Gly Thr 805 810 815 Thr Val Gly Ala He Cys Ser Gly He Arg Ser Leu Pro Ala Thr Arg 820 825 830 Ala Val Ala Arg Asp Arg Leu Leu Val Leu Leu Cys Asp Arg Ala Ser 835 840 845 Ser Gly Ala Ser Ala Val Glu Val Ala Val Ser Phe Ser Pro Ala Arg 850 855 860 Asp Leu Pro Aβp Ser Ser Leu He Gin Gly Ala Ala His Ala He Val 865 870 875 880 Ala Ala He Thr Gin Arg Gly Aβn Ser Ser Leu Leu Leu Ala Val Thr 885 890 895 Glu Val Lye Val Glu Thr Val Val Thr Gly Gly Ser Ser Thr Gly Leu 900 905 910 Leu Val Pro Val Leu Cys Gly Ala Phe Ser Val Leu Trp Leu Ala Cys 915 920 925 Val Val Leu Cys Val Trp Trp Thr Arg Lys Arg Arg Lys Glu Arg Glu 930 935 940 Arg Ser Arg Leu Pro Arg Glu Glu Ser Ala Asn Asn Gin Trp Ala Pro 945 950 955 960 Leu Aβn Pro He Arg Asn Pro He Glu Arg Pro Gly Gly His Lys Asp 965 970 975 Val Leu Tyr Gin Cys Lys Aβn Phe Thr Pro Pro Pro Arg Arg Arg Cys 980 985 990 Pro Gly Arg Pro Ala Thr Arg Pro Ser Gly Arg Met Arg Arg Thr Arg 995 1000 1005 He Leu Ala Ala Val Arg Arg Thr Pro Trp Arg Arg Arg Ser Ser Ser 1010 1015 1020 Hie Thr Aβn Ser Pro Lys He Leu Ala Ala Arg Arg Gly Gly Arg Pro 1025 1030 1035 1040 Thr Gly Pro Gin Ala Pro Lys Trp Thr Thr Ala Arg Ser Gly Ala Ser 1045 1050 1055 Met Arg Pro Ala Thr Ser Ala Arg Glu Val Gly Arg Leu Gin Leu Gly 1060 1065 1070 Arg Asp Pro Gly Pro Ser Val Gly Ala Met Pro Ser Ala Gly Pro Gly 1075 1080 1085 Gly Arg Gly His Val His Ser Phe Phe He Leu Cys Lys Lys Thr Thr 1090 1095 1100 Lye Asn Lys Asn Gin Met Phe He Phe Tyr Val Ser Leu Thr Leu Tyr 1105 1110 1115 1120 Lys Leu Phe Ser Asn Cys Gin Ala Glu Aβn Aβn Gly Val Phe Ser Aβp 1125 1130 1135 Ser Cyβ Tyr Phe Cys Lys Val Ala Val Arg Gly Thr Arg Cyβ Met Lye 1140 1145 1150 Gly Glu Ser Lys Gly Cys Leu Arg Arg His Gin He Val Ala Phe Val 1155 1160 1165 Thr Arg Gly Cys Ala Leu Phe Thr Glu Ser Ser Phe Tyr Ser Ser Leu 1170 1175 1180 Gly Phe Leu Cys Ala Pro Gly Gin Ser Ala Gly Glu Thr His Gly Cys 1185 1190 1195 1200 Val Gly Val Ala His Gly Cys Trp Trp Asp Pro Trp Leu Met Val Trp 1205 1210 1215 Pro Val Ala Val Gly Gly Thr Arg Gly Cys Gin Trp Asp Leu Trp Leu 1220 1225 1230 Ser Val Gly Pro Thr Val Val Gly Gly Thr Leu Val He Asp Val Ala 1235 1240 1245 Leu Ala Ala Gly Thr Ala Arg Gly Cys 1250 1255 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 3582 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..3582 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: CAG GTG GCG TCA GCA TCG GGA CAG TTC GAG CTG GAG ATC TTA TCC GTG 48 Gin Val Ala Ser Ala Ser Gly Gin Phe Glu Leu Glu He Leu Ser Val 1 5 10 15 CAG AAT GTG AAC GGC GTG CTG CAG AAC GGG AAC TGC TGC GAC GGC ACT 96 Gin Aβn Val Aβn Gly Val Leu Gin Asn Gly Asn Cys Cys Asp Gly Thr 20 25 30 CGA AAC CCC GGA GAT AAA AAG TGC ACC AGA GAT GAG TGT GAC ACC TAC 144 Arg Asn Pro Gly Asp Lys Lys Cys Thr Arg Asp Glu Cys Asp Thr Tyr 35 40 45 TTT AAA GTT TGC CTG AAG GAG TAC CAG TCG CGG GTC ACT GCT GGC GGC 192 Phe Lys Val Cys Leu Lys Glu Tyr Gin Ser Arg Val Thr Ala Gly Gly 50 55 60 CCT TGC AGC TTC GGA TCC AAA TCC ACC CCT GTC ATC GGC GGG AAT ACC 240 Pro Cys Ser Phe Gly Ser Lys Ser Thr Pro Val He Gly Gly Asn Thr 65 70 75 80 TTC AAT TTA AAG TAC AGC CGG AAT AAT GAA AAG AAC CGG ATT GTT ATC 288 Phe Asn Leu Lys Tyr Ser Arg Asn Asn Glu Lys Asn Arg He Val He 85 90 95 CCT TTC ACG TTC GCC TGG CCG AGA TCC TAC ACG TTG CTT GTT GAG GCA 336 Pro Phe Thr Phe Ala Trp Pro Arg Ser Tyr Thr Leu Leu Val Glu Ala 100 105 110 TGG GAT TAC AAT GAT AAC TCT ACT AAT CCC GAT CGC ATA ATT GAG AAG 384 Trp Aβp Tyr Aβn Aβp Asn Ser Thr Asn Pro Asp Arg He He Glu Lys 115 120 125 GCA TCC CAC TCT GGC ATG ATC AAT CCA AGC CGT CAG TGG CAG ACG TTG 432 Ala Ser His Ser Gly Met He Asn Pro Ser Arg Gin Trp Gin Thr Leu 130 135 140 AAA CAT AAC ACA GGA GCT GCC CAC TTT GAG TAT CAA ATC CGT GTG ACT 480 Lys His Aβn Thr Gly Ala Ala His Phe Glu Tyr Gin He Arg Val Thr 145 150 155 160 TGC GCA GAA CAT TAC TAT GGC TTT GGA TGC AAC AAG TTT TGT CGA CCG 528 Cys Ala Glu His Tyr Tyr Gly Phe Gly Cys Asn Lys Phe Cys Arg Pro 165 170 175 AGA GAT GAC TTC TTC ACT CAC CAT ACC TGT GAC CAG AAT GGC AAC AAA 576 Arg Aβp Aβp Phe Phe Thr His His Thr Cys Asp Gin Asn Gly Asn Lys 180 185 190 ACC TGC TTG GAA GGC TGG ACG GGA CCA GAA TGC AAC AAA GCT ATT TGT 624 Thr Cyβ Leu Glu Gly Trp Thr Gly Pro Glu Cyβ Aβn Lys Ala He Cys 195 200 205 CGT CAG GGA TGT AGC CCC AAG CAT GGT TCT TGC ACA GTT CCA GGA GAG 672 Arg Gin Gly Cyβ Ser Pro Lys His Gly Ser Cys Thr Val Pro Gly Glu 210 215 220 TGC AGG TGT CAG TAT GGA TGG CAA GGC CAG TAC TGT GAT AAG TGC ATT 720 Cyβ Arg Cyβ Gin Tyr Gly Trp Gin Gly Gin Tyr Cyβ Aβp Lys Cys He 225 230 235 240 CCA CAC CCG GGA TGT GTC CAT GGC ACT TGC ATT GAA CCA TGG CAG TGC 768 Pro Hie Pro Gly Cyβ Val His Gly Thr Cys He Glu Pro Trp Gin Cys 245 250 255 CTC TGT GAA ACC AAC TGG GGT GGT CAG CTC TGT GAC AAA GAC CTG AAC 816 Leu Cys Glu Thr Aβn Trp Gly Gly Gin Leu Cys Asp Lys Asp Leu Asn 260 265 270 TAC TGT GGA ACC CAC CCA CCC TGT TTG AAT GGT GGT ACC TGC AGC AAC 864 Tyr Cyβ Gly Thr His Pro Pro Cys Leu Asn Gly Gly Thr Cys Ser Asn 275 280 285 ACT GGC CCC GAT AAA TAC CAG TGT TCC TGC CCT GAG GGT TAC TCA GGA 912 Thr Gly Pro Asp Lys Tyr Gin Cys Ser Cys Pro Glu Gly Tyr Ser Gly 290 295 300 CAG AAC TGT GAA ATA GCG GAG CAT GCG TGC CTC TCT GAT CCG TGC CAC 960 Gin Asn Cys Glu He Ala Glu His Ala Cys Leu Ser Asp Pro Cys His 305 310 315 320 AAC GGA GGA AGC TGC CTA GAA ACG TCT ACA GGA TTT GAA TGT GTG TGT 1008 Asn Gly Gly Ser Cys Leu Glu Thr Ser Thr Gly Phe Glu Cys Val Cys 325 330 335 GCA CCT GGC TGG GCT GGA CCA ACT TGC ACT GAT AAT ATT GAT GAT TGT 1056 Ala Pro Gly Trp Ala Gly Pro Thr Cys Thr Asp Asn He Asp Asp Cyβ 340 345 350 TCT CCA AAT CCC TGT GGT CAT GGA GGA ACT TGC CAA GAT CTA GTT GAT 1104 Ser Pro Aβn Pro Cyβ Gly Hie Gly Gly Thr Cys Gin Aβp Leu Val Aβp 355 360 365 GGA TTT AAG TGT ATT TGC CCA CCT CAG TGG ACT GGC AAA ACA TGC CAG 1152 Gly Phe Lye Cys He Cys Pro Pro Gin Trp Thr Gly Lys Thr Cys Gin 370 375 380 CTA GAT GCG AAT GAA TGT GAG GGC AAA CCC TGT GTC AAT GCC AAC TCC 1200 Leu Asp Ala Aβn Glu Cyβ Glu Gly Lys Pro Cys Val Asn Ala Asn Ser 385 390 395 400 TGC AGG AAC TTG ATT GGC AGC TAC TAT TGT GAC TGC ATT ACT GGC TGG 1248 Cys Arg Asn Leu He Gly Ser Tyr Tyr Cys Asp Cys He Thr Gly Trp 405 410 415 TCT GGC CAC AAC TGT GAT ATA AAT ATT AAT GAT TGT CGT GGA CAA TGT 1296 Ser Gly His Asn Cys Asp He Asn He Asn Asp Cys Arg Gly Gin Cys 420 425 430 CAG AAT GGA GGA TCC TGT CGG GAC TTG GTT AAT GGT TAT CGG TGC ATC 1344 Gin Asn Gly Gly Ser Cyβ Arg Aβp Leu Val Aβn Gly Tyr Arg Cys He 435 440 445 TGT TCA CCT GGC TAT GCA GGA GAT CAC TGT GAG AAA GAC ATC AAT GAA 1392 Cyβ Ser Pro Gly Tyr Ala Gly Asp His Cys Glu Lye Asp He Asn Glu 450 455 460 TGT GCA AGT AAC CCT TGC ATG AAT GGG GGT CAC TGC CAG GAT GAA ATC 1440 Cys Ala Ser Aβn Pro Cys Met Asn Gly Gly His Cys Gin Asp Glu He 465 470 475 480 AAT GGA TTC CAA TGT CTG TGT CCT GCT GGT TTC TCA GGA AAC CTC TGT 1488 Asn Gly Phe Gin Cys Leu Cys Pro Ala Gly Phe Ser Gly Asn Leu Cys 485 490 495 CAG CTG GAT ATA GAC TAC TGT GAG CCA AAC CCT TGC CAG AAC GGT GCC 1536 Gin Leu Asp He Aβp Tyr Cyβ Glu Pro Aβn Pro Cys Gin Asn Gly Ala 500 505 510 CAG TGC TTC AAT CTT GCT ATG GAC TAT TTC TGT AAC TGC CCT GAA GAT 1584 Gin Cys Phe Aβn Leu Ala Met Aβp Tyr Phe Cyβ Aβn Cyβ Pro Glu Asp 515 520 525 TAC GAA GGC AAG AAC TGC TCC CAC CTG AAA GAT CAC TGC CGC ACA ACT 1632 Tyr Glu Gly Lys Asn Cys Ser His Leu Lys Asp His Cys Arg Thr Thr 530 535 540 CCT TGT GAA GTA ATC GAC AGC TGT ACA GTG GCA GTG GCT TCT AAC AGC 1680 Pro Cyβ Glu Val He Aβp Ser Cyβ Thr Val Ala Val Ala Ser Aβn Ser 545 550 555 560 ACA CCA GAA GGA GTT CGT TAC ATT TCT TCA AAT GTC TGT GGT CCT CAT 1728 Thr Pro Glu Gly Val Arg Tyr He Ser Ser Aβn Val Cyβ Gly Pro Hie 565 570 575 GGA AAA TGC AAG AGC CAA GCA GGT GGA AAA TTC ACC TGT GAA TGC AAC 1776 Gly Lys Cys Lye Ser Gin Ala Gly Gly Lys Phe Thr Cys Glu Cys Asn 580 585 590 AAA GGA TTC ACT GGC ACC TAC TGT CAT GAG AAT ATC AAT GAC TGT GAG 1824 Lys Gly Phe Thr Gly Thr Tyr Cyβ Hie Glu Aβn He Asn Asp Cys Glu 595 600 605 AGC AAC CCC TGT AAA AAT GGT GGC ACT TGT ATT GAC GGT GTA AAC TCC 1872 Ser Asn Pro Cys Lys Asn Gly Gly Thr Cys He Asp Gly Val Asn Ser 610 615 620 TAC AAA TGT ATT TGT AGT GAT GGA TGG GAA GGA ACA TAT TGT GAA ACA 1920 Tyr Lye Cyβ He Cyβ Ser Aβp Gly Trp Glu Gly Thr Tyr Cys Glu Thr 625 630 635 640 AAT ATT AAT GAC TGC AGT AAA AAC CCC TGC CAC AAT GGA GGA ACT TGC 1968 Aβn He Asn Asp Cyβ Ser Lys Asn Pro Cys His Asn Gly Gly Thr Cyβ 645 650 655 CGA GAC TTG GTC AAT GAC TTC TTC TGT GAA TGT AAA AAT GGG TGG AAA 2016 Arg Aβp Leu Val Asn Asp Phe Phe Cys Glu Cys Lys Asn Gly Trp Lys 660 665 670 GGA AAA ACT TGC CAC TCT CGT GAC AGC CAG TGT GAT GAG GCA ACA TGC 2064 Gly Lys Thr Cys His Ser Arg Asp Ser Gin Cys Asp Glu Ala Thr Cys 675 680 685 AAT AAT GGA GGA ACA TGT TAT GAT GAG GGG GAC ACT TTC AAG TGC ATG 2112 Asn Asn Gly Gly Thr Cyβ Tyr Asp Glu Gly Asp Thr Phe Lys Cys Met 690 695 700 TGT CCT GCA GGA TGG GAA GGA GCC ACT TGT AAT ATA GCA AGG AAC AGC 2160 Cys Pro Ala Gly Trp Glu Gly Ala Thr Cys Asn He Ala Arg Asn Ser 705 710 715 720 AGC TGC CTG CCA AAC CCC TGT CAC AAT GGT GGT ACC TGT GTA GTT AGT 2208 Ser Cys Leu Pro Aβn Pro Cyβ His Asn Gly Gly Thr Cys Val Val Ser 725 730 735 GGG GAT TCT TTC ACT TGT GTC TGC AAG GAG GGC TGG GAA GGA CCG ACA 2256 Gly Asp Ser Phe Thr Cyβ Val Cys Lys Glu Gly Trp Glu Gly Pro Thr 740 745 750 TGT ACT CAG AAC ACA AAT GAC TGC AGT CCT CAT CCT TGT TAC AAC AGT 2304 Cys Thr Gin Aβn Thr Asn Asp Cys Ser Pro His Pro Cys Tyr Asn Ser 755 760 765 GGT ACT TGT GTG GAT GGA GAC AAC TGG TAC CGC TGT GAG TGC GCT CCC 2352 Gly Thr Cyβ Val Aβp Gly Aβp Aβn Trp Tyr Arg Cys Glu Cys Ala Pro 770 775 780 GGC TTC GCA GGT CCC GAC TGT AGG ATC AAC ATC AAT GAA TGT CAG TCT 2400 Gly Phe Ala Gly Pro Aβp Cys Arg He Asn He Asn Glu Cys Gin Ser 785 790 795 800 TCA CCC TGT GCC TTT GGG GCT ACT TGT GTG GAT GAA ATT AAT GGG TAC 2448 Ser Pro Cys Ala Phe Gly Ala Thr Cys Val Asp Glu He Asn Gly Tyr 805 810 815 CGT TGC ATT TGT CCA CCG GGT CGC AGT GGT CCA GGA TGC CAG GAA GTT 2496 Arg Cyβ He Cyβ Pro Pro Gly Arg Ser Gly Pro Gly Cys Gin Glu Val 820 825 830 ACA GGG AGG CCT TGC TTT ACC AGT ATT CGA GTA ATG CCA GAC GGT GCT 2544 Thr Gly Arg Pro Cyβ Phe Thr Ser He Arg Val Met Pro Asp Gly Ala 835 840 845 AAG TGG GAT GAT GAC TGT AAT ACT TGT CAG TGT TTG AAT GGA AAA GTC 2592 Lye Trp Asp Asp Asp Cys Asn Thr Cyβ Gin Cys Leu Asn Gly Lys Val 850 855 860 ACC TGT TCT AAG GTT TGG TGT GGT CCT CGA CCT TGT ATA ATA CAT GCC 2640 Thr Cyβ Ser Lye Val Trp Cyβ Gly Pro Arg Pro Cys He He His Ala 865 870 875 880 AAA GGT CAT AAT GAA TGC CCA GCT GGA CAC GCT TGT GTT CCT GTT AAA 2688 Lys Gly His Aβn Glu Cys Pro Ala Gly His Ala Cyβ Val Pro Val Lye 885 890 895 GAA GAC CAT TGT TTC ACT CAT CCT TGT GCT GCA GTG GGT GAA TGC TGG 2736 Glu Asp His Cyβ Phe Thr Hie Pro Cys Ala Ala Val Gly Glu Cys Trp 900 905 910 CCT TCT AAT CAG CAG CCT GTG AAG ACC AAA TGC AAT TCT GAT TCT TAT 2784 Pro Ser Aβn Gin Gin Pro Val Lye Thr Lys Cys Asn Ser Aβp Ser Tyr 915 920 925 TAC CAA GAT AAT TGT GCC AAC ATC ACC TTC ACC TTT AAT AAG GAA ATG 2832 Tyr Gin Aβp Aβn Cys Ala Asn He Thr Phe Thr Phe Asn Lys Glu Met 930 935 940 ATG GCA CCA GGC CTT ACC ACG GAG CAC ATT TGC AGT GAA TTG AGG AAT 2880 Met Ala Pro Gly Leu Thr Thr Glu His He Cys Ser Glu Leu Arg Aβn 945 950 955 960 CTG AAT ATC CTG AAG AAT GTT TCT GCT GAA TAT TCC ATC TAT ATT ACC 2928 Leu Aβn He Leu Lye Aβn Val Ser Ala Glu Tyr Ser He Tyr He Thr 965 970 975 TGT GAG CCT TCA CAC TTG GCA AAT AAT GAA ATA CAT GTT GCT ATT TCT 2976 Cyβ Glu Pro Ser Hie Leu Ala Asn Asn Glu He His Val Ala He Ser 980 985 990 GCT GAA GAT ATA GGA GAA GAT GAA AAC CCA ATC AAG GAA ATC ACA GAT 3024 Ala Glu Aβp He Gly Glu Aβp Glu Aβn Pro He Lye Glu He Thr Aβp 995 1000 1005 AAG ATT ATT GAC CTT GTC AGT AAG CGT GAT GGA AAC AAC ACA CTA ATT 3072 Lye He He Aβp Leu Val Ser Lye Arg Asp Gly Asn Aβn Thr Leu He 1010 1015 1020 GCT GCA GTC GCA GAA GTC AGA GTA CAA AGG CGA CCA GTT AAG AAC AAA 3120 Ala Ala Val Ala Glu Val Arg Val Gin Arg Arg Pro Val Lys Asn Lys 1025 1030 1035 1040 ACA GAT TTC TTG GTG CCA TTA CTG AGC TCA GTC TTA ACA GTA GCC TGG 3168 Thr Asp Phe Leu Val Pro Leu Leu Ser Ser Val Leu Thr Val Ala Trp 1045 1050 1055 ATC TGC TGT CTG GTA ACT GTT TTC TAT TGG TGC ATT CAA AAG CGC AGA 3216 He Cys Cys Leu Val Thr Val Phe Tyr Trp Cys He Gin Lys Arg Arg 1060 1065 1070 AAG CAG AGC AGC CAT ACT CAC ACA GCA TCT GAT GAC AAC ACC ACC AAC 3264 Lys Gin Ser Ser Hie Thr Hie Thr Ala Ser Asp Asp Asn Thr Thr Aβn 1075 1080 1085 AAC GTA AGG GAG CAG CTG AAT CAG ATT AAA AAC CCC ATA GAG AAA CAC 3312 Asn Val Arg Glu Gin Leu Asn Gin He Lys Asn Pro He Glu Lys His 1090 1095 1100 GGA GCA AAT ACT GTT CCA ATT AAA GAC TAT GAA AAC AAA AAC TCT AAA 3360 Gly Ala Aβn Thr Val Pro He Lye Aβp Tyr Glu Asn Lys Asn Ser Lys 1105 1110 1115 1120 ATC GCC AAA ATA AGG ACG CAC AAT TCA GAA GTG GAG GAA GAT GAC ATG 3408 He Ala Lye He Arg Thr His Asn Ser Glu Val Glu Glu Asp Asp Met 1125 1130 1135 GAC AAA CAC CAG CAA AAG GCC CGG TTT GCC AAG CAG CCA GCG TAC ACT 3456 Asp Lys His Gin Gin Lye Ala Arg Phe Ala Lys Gin Pro Ala Tyr Thr 1140 1145 1150 TTG GTA GAC AGA GAT GAA AAG CCA CCC AAC AGC ACA CCC ACA AAA CAC 3504 Leu Val Aβp Arg Aβp Glu Lys Pro Pro Asn Ser Thr Pro Thr Lys His 1155 1160 1165 CCA AAC TGG ACA AAT AAA CAG GAC AAC AGA GAC TTG GAA AGT GCA CAA 3552 Pro Aβn Trp Thr Aβn Lye Gin Aβp Aβn Arg Asp Leu Glu Ser Ala Gin 1170 1175 1180 AGT TTA AAT AGA ATG GAG TAC ATT GTA Ser Leu Asn Arg Met Glu Tyr He Val 1185 1190 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1194 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Gin Val Ala Ser Ala Ser Gly Gin Phe Glu Leu Glu He Leu Ser Val 1 5 10 15 Gin Aβn Val Aβn Gly Val Leu Gin Asn Gly Asn Cys Cys Asp Gly Thr 20 25 30 Arg Aβn Pro Gly Aβp Lys Lys Cys Thr Arg Asp Glu Cys Asp Thr Tyr 35 40 45 Phe Lys Val Cyβ Leu Lye Glu Tyr Gin Ser Arg Val Thr Ala Gly Gly 50 55 60 Pro Cyβ Ser Phe Gly Ser Lys Ser Thr Pro Val He Gly Gly Asn Thr 65 70 75 80 Phe Aβn Leu Lye Tyr Ser Arg Aβn Aβn Glu Lye Aβn Arg He Val He 85 90 95 Pro Phe Thr Phe Ala Trp Pro Arg Ser Tyr Thr Leu Leu Val Glu Ala 100 105 110 Trp Asp Tyr Aβn Asp Asn Ser Thr Asn Pro Asp Arg He He Glu Lys 115 120 125 Ala Ser His Ser Gly Met He Asn Pro Ser Arg Gin Trp Gin Thr Leu 130 135 140 Lye Hie Aen Thr Gly Ala Ala His Phe Glu Tyr Gin He Arg Val Thr 145 150 155 160 Cys Ala Glu His Tyr Tyr Gly Phe Gly Cys Asn Lys Phe Cys Arg Pro 165 170 175 Arg Asp Aβp Phe Phe Thr His His Thr Cys Asp Gin Asn Gly Asn Lys 180 185 190 Thr Cyβ Leu Glu Gly Trp Thr Gly Pro Glu Cys Asn Lys Ala He Cys 195 200 205 Arg Gin Gly Cys Ser Pro Lys His Gly Ser Cys Thr Val Pro Gly Glu 210 215 220 Cys Arg Cys Gin Tyr Gly Trp Gin Gly Gin Tyr Cys Asp Lys Cys He 225 230 235 240 Pro His Pro Gly Cys Val His Gly Thr Cys He Glu Pro Trp Gin Cys 245 250 255 Leu Cyβ Glu Thr Aβn Trp Gly Gly Gin Leu Cyβ Aβp Lye Aβp Leu Aβn 260 265 270 Tyr Cyβ Gly Thr His Pro Pro Cys Leu Asn Gly Gly Thr Cys Ser Aβn 275 280 285 Thr Gly Pro Asp Lys Tyr Gin Cys Ser Cys Pro Glu Gly Tyr Ser Gly 290 295 300 Gin Asn Cys Glu He Ala Glu His Ala Cys Leu Ser Asp Pro Cys His 305 310 315 320 Asn Gly Gly Ser Cys Leu Glu Thr Ser Thr Gly Phe Glu Cys Val Cys 325 330 335 Ala Pro Gly Trp Ala Gly Pro Thr Cys Thr Asp Asn He Asp Asp Cys 340 345 350 Ser Pro Asn Pro Cys Gly His Gly Gly Thr Cys Gin Asp Leu Val Asp 355 360 365 Gly Phe Lys Cyβ He Cyβ Pro Pro Gin Trp Thr Gly Lye Thr Cys Gin 370 375 380 Leu Aβp Ala Aβn Glu Cys Glu Gly Lys Pro Cys Val Asn Ala Asn Ser 385 390 395 400 Cys Arg Asn Leu He Gly Ser Tyr Tyr Cys Asp Cys He Thr Gly Trp 405 410 415 Ser Gly His Asn Cys Asp He Asn He Asn Asp Cys Arg Gly Gin Cys 420 425 430 Gin Aβn Gly Gly Ser Cyβ Arg Aβp Leu Val Aen Gly Tyr Arg Cys He 435 440 445 Cys Ser Pro Gly Tyr Ala Gly Asp His Cys Glu Lys Asp He Asn Glu 450 455 460 Cys Ala Ser Asn Pro Cys Met Aβn Gly Gly Hie Cyβ Gin Aβp Glu He 465 470 475 480 Aβn Gly Phe Gin Cyβ Leu Cyβ Pro Ala Gly Phe Ser Gly Aβn Leu Cys 485 490 495 Gin Leu Aβp He Asp Tyr Cyβ Glu Pro Asn Pro Cys Gin Asn Gly Ala 500 505 510 Gin Cyβ Phe Aβn Leu Ala Met Aβp Tyr Phe Cys Asn Cys Pro Glu Asp 515 520 525 Tyr Glu Gly Lys Asn Cys Ser His Leu Lys Asp His Cys Arg Thr Thr 530 535 540 Pro Cys Glu Val He Asp Ser Cys Thr Val Ala Val Ala Ser Asn Ser 545 550 555 560 Thr Pro Glu Gly Val Arg Tyr He Ser Ser Asn Val Cys Gly Pro His 565 570 575 Gly Lye Cyβ Lys Ser Gin Ala Gly Gly Lys Phe Thr Cys Glu Cys Asn 580 585 590 Lys Gly Phe Thr Gly Thr Tyr Cys His Glu Asn He Asn Asp Cys Glu 595 600 605 Ser Asn Pro Cys Lys Asn Gly Gly Thr Cys He Asp Gly Val Asn Ser 610 615 620 Tyr Lys Cys He Cys Ser Aβp Gly Trp Glu Gly Thr Tyr Cyβ Glu Thr 625 630 635 640 Asn He Asn Aβp Cys Ser Lys Asn Pro Cys His Asn Gly Gly Thr Cys 645 650 655 Arg Aβp Leu Val Aβn Asp Phe Phe Cys Glu Cys Lys Asn Gly Trp Lys 660 665 670 Gly Lys Thr Cyβ Hie Ser Arg Asp Ser Gin Cys Asp Glu Ala Thr Cys 675 680 685 Aβn Aβn Gly Gly Thr Cys Tyr Asp Glu Gly Asp Thr Phe Lys Cys Met 690 695 700 Cys Pro Ala Gly Trp Glu Gly Ala Thr Cys Asn He Ala Arg Asn Ser 705 710 715 720 Ser Cys Leu Pro Asn Pro Cys His Asn Gly Gly Thr Cys Val Val Ser 725 730 735 Gly Aβp Ser Phe Thr Cys Val Cys Lys Glu Gly Trp Glu Gly Pro Thr 740 745 750 Cys Thr Gin Asn Thr Asn Asp Cys Ser Pro His Pro Cys Tyr Asn Ser 755 760 765 Gly Thr Cys Val Aβp Gly Aβp Aβn Trp Tyr Arg Cys Glu Cys Ala Pro 770 775 780 Gly Phe Ala Gly Pro Asp Cys Arg He Asn He Asn Glu Cys Gin Ser 785 790 795 800 Ser Pro Cys Ala Phe Gly Ala Thr Cys Val Asp Glu He Asn Gly Tyr 805 810 815 Arg Cys He Cyβ Pro Pro Gly Arg Ser Gly Pro Gly Cys Gin Glu Val 820 825 830 Thr Gly Arg Pro Cys Phe Thr Ser He Arg Val Met Pro Asp Gly Ala 835 840 845 Lye Trp Aβp Aβp Aβp Cyβ Asn Thr Cys Gin Cys Leu Asn Gly Lys Val 850 855 860 Thr Cyβ Ser Lys Val Trp Cys Gly Pro Arg Pro Cys He He His Ala 865 870 875 880 Lye Gly Hie Asn Glu Cys Pro Ala Gly His Ala Cys Val Pro Val Lys 885 890 895 Glu Asp His Cyβ Phe Thr Hie Pro Cyβ Ala Ala Val Gly Glu Cys Trp 900 905 910 Pro Ser Asn Gin Gin Pro Val Lye Thr Lys Cys Asn Ser Asp Ser Tyr 915 920 925 Tyr Gin Aβp Aβn Cys Ala Aβn He Thr Phe Thr Phe Aβn Lye Glu Met 930 935 940 Met Ala Pro Gly Leu Thr Thr Glu His He Cys Ser Glu Leu Arg Asn 945 950 955 960 Leu Asn He Leu Lye Aβn Val Ser Ala Glu Tyr Ser He Tyr He Thr 965 970 975 Cyβ Glu Pro Ser Hie Leu Ala Aβn Aβn Glu He Hie Val Ala He Ser 980 985 990 Ala Glu Aβp He Gly Glu Aβp Glu Aen Pro He Lye Glu He Thr Asp 995 1000 1005 Lye He He Aβp Leu Val Ser Lye Arg Aep Gly Aβn Aen Thr Leu He 1010 1015 1020 Ala Ala Val Ala Glu Val Arg Val Gin Arg Arg Pro Val Lys Asn Lys 1025 1030 1035 1040 Thr Asp Phe Leu Val Pro Leu Leu Ser Ser Val Leu Thr Val Ala Trp 1045 1050 1055 He Cys Cys Leu Val Thr Val Phe Tyr Trp Cys He Gin Lys Arg Arg 1060 1065 1070 Lys Gin Ser Ser His Thr His Thr Ala Ser Asp Asp Asn Thr Thr Asn 1075 1080 1085 Aβn Val Arg Glu Gin Leu Aβn Gin He Lys Asn Pro He Glu Lys His 1090 1095 1100 Gly Ala Aβn Thr Val Pro He Lye Aβp Tyr Glu Asn Lys Asn Ser Lys 1105 1110 1115 1120 He Ala Lys He Arg Thr His Asn Ser Glu Val Glu Glu Asp Asp Met 1125 1130 1135 Aβp Lye Hie Gin Gin Lys Ala Arg Phe Ala Lys Gin Pro Ala Tyr Thr 1140 1145 1150 Leu Val Aβp Arg Aβp Glu Lye Pro Pro Asn Ser Thr Pro Thr Lys His 1155 1160 1165 Pro Asn Trp Thr Asn Lye Gin Aβp Aβn Arg Aβp Leu Glu Ser Ala Gin 1170 1175 1180 Ser Leu Aβn Arg Met Glu Tyr He Val 1185 1190 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 236 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met His Trp He Lys Cys Leu Leu Thr Ala Phe He Cys Phe Thr Val 1 5 10 15 He Val Gin Val His Ser Ser Gly Ser Phe Glu Leu Arg Leu Lys Tyr 20 25 30 Phe Ser Asn Asp His Gly Arg Aβp Asn Glu Gly Arg Cys Cys Ser Gly 35 40 45 Glu Ser Asp Gly Ala Thr Gly Lys Cys Leu Gly Ser Cys Lys Thr Arg 50 55 60 Phe Arg Val Cys Leu Lys His Tyr Gin Ala Thr He Asp Thr Thr Ser 65 70 75 80 Gin Cys Thr Tyr Gly Asp Val He Thr Pro He Leu Gly Glu Asn Ser 85 90 95 Val Aβn Leu Thr Asp Ala Gin Arg Phe Gin Asn Lys Gly Phe Thr Asn 100 105 110 Pro He Gin Phe Pro Phe Ser Phe Ser Trp Pro Gly Thr Phe Ser Leu 115 120 125 He Val Glu Ala Trp His Asp Thr Asn Asn Ser Gly Asn Ala Arg Thr 130 135 140 Asn Lys Leu Leu He Gin Arg Leu Leu Val Gin Gin Val Leu Glu Val 145 150 155 160 Ser Ser Glu Trp Lys Thr Asn Lys Ser Glu Ser Gin Tyr Thr Ser Leu 165 170 175 Glu Tyr Aβp Phe Arg Val Thr Cys Asp Leu Asn Tyr Tyr Gly Ser Gly 180 185 190 Cyβ Ala Lye Phe Cys Arg Pro Arg Asp Asp Ser Phe Gly His Ser Thr 195 200 205 Cyβ Ser Glu Thr Gly Glu He He Cyβ Leu Thr Gly Trp Gin Gly Aep 210 215 220 Tyr Cyβ Hie He Pro Lye Cys Ala Lys Gly Cys Glu 225 230 235 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1405 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Phe Arg Lys His Phe Arg Arg Lys Pro Ala Thr Ser Ser Ser Leu 1 5 10 15 Glu Ser Thr He Glu Ser Ala Asp Ser Leu Gly Met Ser Lys Lys Thr 20 25 30 Ala Thr Lye Arg Gin Arg Pro Arg Hie Arg Val Pro Lys He Ala Thr 35 40 45 Leu Pro Ser Thr He Arg Asp Cys Arg Ser Leu Lys Ser Ala Cys Asn 50 55 60 Leu He Ala Leu He Leu He Leu Leu Val His Lys He Ser Ala Ala 65 70 75 80 Gly Asn Phe Glu Leu Glu He Leu Glu He Ser Asn Thr Asn Ser His 85 90 95 Leu Leu Aβn Gly Tyr Cys Cys Gly Met Pro Ala Glu Leu Arg Ala Thr 100 105 110 Lys Thr He Gly Cys Ser Pro Cys Thr Thr Ala Phe Arg Leu Cys Leu 115 120 125 Lye Glu Tyr Gin Thr Thr Glu Gin Gly Ala Ser He Ser Thr Gly Cyβ 130 135 140 Ser Phe Gly Asn Ala Thr Thr Lye He Leu Gly Gly Ser Ser Phe Val 145 150 155 160 Leu Ser Aβp Pro Gly Val Gly Ala He Val Leu Pro Phe Thr Phe Arg 165 170 175 Trp Thr Lye Ser Phe Thr Leu He Leu Gin Ala Leu Asp Met Tyr Asn 180 185 190 Thr Ser Tyr Pro Asp Ala Glu Arg Leu He Glu Glu Thr Ser Tyr Ser 195 200 205 Gly Val He Leu Pro Ser Pro Glu Trp Lys Thr Leu Asp His He Gly 210 215 220 Arg Asn Ala Arg He Thr Tyr Arg Val Arg Val Gin Cys Ala Val Thr 225 230 235 240 Tyr Tyr Asn Thr Thr Cyβ Thr Thr Phe Cyβ Arg Pro Arg Asp Asp Gin 245 250 255 Phe Gly His Tyr Ala Cys Gly Ser Glu Gly Gin Lys Leu Cys Leu Asn 260 265 270 Gly Trp Gin Gly Val Asn Cys Glu Glu Ala He Cys Lys Ala Gly Cys 275 280 285 Aβp Pro Val His Gly Lys Cys Asp Arg Pro Gly Glu Cys Glu Cys Arg 290 295 300 Pro Gly Trp Arg Gly Pro Leu Cys Asn Glu Cys Met Val Tyr Pro Gly 305 310 315 320 Cys Lys His Gly Ser Cys Asn Gly Ser Ala Trp Lys Cys Val Cys Asp 325 330 335 Thr Aβn Trp Gly Gly He Leu Cyβ Aβp Gin Aβp Leu Aβn Phe Cys Gly 340 345 350 Thr Hie Glu Pro Cye Lye Hie Gly Gly Thr Cyβ Glu Aβn Thr Ala Pro 355 360 365 Aβp Lye Tyr Arg Cyβ Thr Cys Ala Glu Gly Leu Ser Gly Glu Gin Cys 370 375 380 Glu He Val Glu His Pro Cyβ Ala Thr Arg Pro Cys Arg Asn Gly Gly 385 390 395 400 Thr Cys Thr Leu Lye Thr Ser Aβn Arg Thr Gin Ala Gin Val Tyr Arg 405 410 415 Thr Ser Hie Gly Arg Ser Aβn Met Gly Arg Pro Val Arg Arg Ser Ser 420 425 430 Ser Met Arg Ser Leu Asp Hie Leu Arg Pro Glu Gly Gin Ala Leu Aβn 435 440 445 Gly Ser Ser Ser Ser Gly Leu Val Ser Leu Gly Ser Leu Gin Leu Gin 450 455 460 Gin Gin Leu Ala Pro Aβp Phe Thr Cys Asp Cys Ala Ala Gly Trp Thr 465 470 475 480 Gly Pro Thr Cys Glu He Asn He Asp Glu Cys Ala Gly Gly Pro Cys 485 490 495 Glu His Gly Gly Thr Cys He Asp Leu He Gly Gly Phe Arg Cys Glu 500 505 510 Cys Pro Pro Glu Trp His Gly Asp Val Cys Gin Val Asp Val Asn Glu 515 520 525 Cys Glu Ala Pro His Ser Ala Gly He Ala Ala Asn Ala Leu Leu Thr 530 535 540 Thr Thr Ala Thr Ala He He Gly Ser Asn Leu Ser Ser Thr Ala Leu 545 550 555 560 Leu Ala Ala Leu Thr Ser Ala Val Ala Ser Thr Ser Leu Ala He Gly 565 570 575 Pro Cys He Asn Ala Lys Glu Cys Arg Asn Gin Pro Gly Ser Phe Ala 580 585 590 Cys He Cyβ Lys Glu Gly Trp Gly Gly Val Thr Cys Ala Glu Asn Leu 595 600 605 Aβp Asp Cyβ Val Gly Gin Cyβ Arg Aβn Gly Ala Thr Cys He Asp Leu 610 615 620 Val Aβn Aβp Tyr Arg Cys Ala Cys Ala Ser Gly Phe Thr Gly Arg Asp 625 630 635 640 Cys Glu Thr Asp He Asp Glu Cys Ala Thr Ser Pro Cys Arg Asn Gly 645 650 655 Gly Glu Cys Val Asp Met Val Gly Lys Phe Asn Cys He Cys Pro Leu 660 665 670 Gly Tyr Ser Gly Ser Leu Cys Glu Glu Ala Lys Glu Asn Cys Thr Pro 675 680 685 Ser Pro Cys Leu Glu Gly His Cys Leu Asn Thr Pro Glu Gly Tyr Tyr 690 695 700 Cyβ Hie Cyβ Pro Pro Aβp Arg Ala Gly Lys His Cys Glu Gin Leu Arg 705 710 715 720 Pro Leu Cyβ Ser Gin Pro Pro Cys Asn Glu Gly Cys Phe Ala Asn Val 725 730 735 Ser Leu Ala Thr Ser Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr Ala 740 745 750 Thr Thr Thr Arg Lys Met Ala Lys Pro Ser Gly Leu Pro Cys Ser Gly 755 760 765 Hie Gly Ser Cyβ Glu Met Ser Asp Val Gly Thr Phe Cys Lys Cys His 770 775 780 Val Gly His Thr Gly Thr Phe Cys Glu His Asn Leu Asn Glu Cys Ser 785 790 795 800 Pro Aβn Pro Cyβ Arg Aβn Gly Gly He Cys Leu Asp Gly Asp Gly Asp 805 810 815 Phe Thr Cys Glu Cys Met Ser Gly Trp Thr Gly Lys Arg Cys Ser Glu 820 825 830 Arg Ala Thr Gly Cys Tyr Ala Gly Gin Cys Gin Asn Gly Gly Thr Cys 835 840 845 Met Pro Gly Ala Pro Asp Lys Ala Leu Gin Pro His Cys Arg Cys Ala 850 855 860 Pro Gly Trp Thr Gly Leu Phe Cys Ala Glu Ala He Asp Gin Cys Arg 865 870 875 880 Gly Gin Pro Cys His Aβn Gly Gly Thr Cys Glu Ser Gly Ala Gly Trp 885 890 895 Phe Arg Cys Val Cys Ala Gin Gly Phe Ser Gly Pro Asp Cys Arg He 900 905 910 Asn Val Asn Glu Cys Ser Pro Gin Pro Cys Gin Gly Gly Ala Thr Cys 915 920 925 He Aβp Gly He Gly Gly Tyr Ser Cys He Cys Pro Pro Gly Arg His 930 935 940 Gly Leu Arg Cys Glu He Leu Leu Ser Asp Pro Lys Ser Ala Cys Gin 945 950 955 960 Aen Ala Ser Aβn Thr He Ser Pro Tyr Thr Ala Leu Asn Arg Ser Gin 965 970 975 Asn Trp Leu Asp He Ala Leu Thr Gly Arg Thr Glu Asp Asp Glu Asn 980 985 990 Cyβ Aβn Ala Cyβ Val Cyβ Glu Aβn Gly Thr Ser Arg Cys Thr Asn Leu 995 1000 1005 Trp Cys Gly Leu Pro Asn Cys Tyr Lys Val Asp Pro Leu Ser Lys Ser 1010 1015 1020 Ser Aβn Leu Ser Gly Val Cys Lys Gin His Glu Val Cys Val Pro Ala 1025 1030 1035 1040 Leu Ser Glu Thr Cys Leu Ser Ser Pro Cys Asn Val Arg Gly Asp Cys 1045 1050 1055 Arg Ala Leu Glu Pro Ser Arg Arg Val Ala Pro Pro Arg Leu Pro Ala 1060 1065 1070 Lye Ser Ser Cyβ Trp Pro Aβn Gin Ala Val Val Aen Glu Aβn Cys Ala 1075 1080 1085 Arg Leu Thr He Leu Leu Ala Leu Glu Arg Val Gly Lys Gly Ala Ser 1090 1095 1100 Val Glu Gly Leu Cys Ser Leu Val Arg Val Leu Leu Ala Ala Gin Leu 1105 1110 1115 1120 He Lys Lye Pro Ala Ser Thr Phe Gly Gin Aβp Pro Gly Met Leu Met 1125 1130 1135 Val Leu Cyβ Aβp Leu Lye Thr Gly Thr Aβn Aβp Thr Val Glu Leu Thr 1140 1145 1150 Val Ser Ser Ser Lys Leu Asn Asp Pro Gin Leu Pro Val Ala Val Gly 1155 1160 1165 Leu Leu Gly Glu Leu Leu Ser Ser Arg Gin Leu Asn Gly He Gin Arg 1170 1175 1180 Arg Lys Glu Leu Glu Leu Gin His Ala Lys Leu Ala Ala Leu Thr Ser 1185 1190 1195 1200 He Val Glu Val Lys Leu Glu Thr Ala Arg Val Ala Asp Gly Ser Gly 1205 1210 1215 His Ser Leu Leu He Gly Val Leu Cys Gly Val Phe He Val Leu Val 1220 1225 1230 Gly Phe Ser Val Phe He Ser Leu Tyr Trp Lys Gin Arg Leu Ala Tyr 1235 1240 1245 Arg Thr Ser Ser Gly Met Asn Leu Thr Pro Ser Leu Asp Ala Leu Arg 1250 1255 1260 Hie Glu Glu Glu Lye Ser Asn Asn Leu Gin Asn Glu Glu Asn Leu Arg 1265 1270 1275 1280 Arg Tyr Thr Asn Pro Leu Lys Gly Ser Thr Ser Ser Leu Arg Ala Ala 1285 1290 1295 Thr Gly Met Glu Leu Ser Leu Asn Pro Ala Pro Glu Leu Ala Ala Ser 1300 1305 1310 Ala Ala Ser Ser Ser Ala Leu His Arg Ser Gin Pro Leu Phe Pro Pro 1315 1320 1325 Cys Aep Phe Glu Arg Glu Leu Aβp Ser Ser Thr Gly Leu Lys Gin Ala 1330 1335 1340 His Lye Arg Ser Ser Gin He Leu Leu His Lys Thr Gin Asn Ser Asp 1345 1350 1355 1360 Met Arg Lys Aβn Thr Val Gly Ser Leu Asp Ser Pro Arg Lys Asp Phe 1365 1370 1375 Gly Lys Arg Ser He Asn Cys Lys Ser Met Pro Pro Ser Ser Gly Asp 1380 1385 1390 Glu Gly Ser Asp Val Leu Ala Thr Thr Val Met Val 1395 1400 (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: modified_baβe (B) LOCATION: 3 (D) OTHER INFORMATION: /mod_baβe= i (ix) FEATURE: (A) NAME/KEY: modified_baβe (B) LOCATION: 12 (D) OTHER INFORMATION: /mod_baβe= i (i ) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 18 (D) OTHER INFORMATION: /mod_base= i (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: CGNYTTTGCY TNAARSANTA YCA 23 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acidβ (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label= A /note= "X=histidine or glutamic acid" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: Arg Leu Cys Cys Lys Xaa Tyr Gin 1 5 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 3 (D) OTHER INFORMATION: /mod_base= i (ix) FEATURE: (A) NAME/KEY: modified_baβe (B) LOCATION: 9 (D) OTHER INFORMATION: /mod_baβe= i (ix) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 12 (D) OTHER INFORMATION: /mod_base= i (ix) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 15 (D) OTHER INFORMATION: /mod_baβe= i (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: TCNATGCANG TNCCNCCRTT 20 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 163 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2..163 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: G TCC CGC GTC ACT GCC GGG GGA CCC TGC AGC TTC GGC TCA GGG TCT 46 Ser Arg Val Thr Ala Gly Gly Pro Cys Ser Phe Gly Ser Gly Ser 1 5 10 15 ACG CCT GTC ATC GGG GGT AAC ACC TTC AAT CTC AAG GCC AGC CGT GGC 94 Thr Pro Val He Gly Gly Asn Thr Phe Asn Leu Lys Ala Ser Arg Gly 20 25 30 AAC GAC CGT AAT CGC ATC GTA CTG CCT TTC AGT TTC ACC TGG CCG AGG 142 Asn Aβp Arg Aβn Arg He Val Leu Pro Phe Ser Phe Thr Trp Pro Arg 35 40 45 TCC TAC ACT TTG CTG GTG GAG 163 Ser Tyr Thr Leu Leu Val Glu 50 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 54 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: Ser Arg Val Thr Ala Gly Gly Pro Cys Ser Phe Gly Ser Gly Ser Thr 1 5 10 15 Pro Val He Gly Gly Asn Thr Phe Asn Leu Lys Ala Ser Arg Gly Asn 20 25 30 Aβp Arg Asn Arg He Val Leu Pro Phe Ser Phe Thr Trp Pro Arg Ser 35 40 45 Tyr Thr Leu Leu Val Glu 50 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 135 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..135 (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: TCT TCT AAC GTC TGT GGT CCC CAT GGC AAG TGC AAG AGC CAG TCG GCA 48 Ser Ser Aβn Val Cys Gly Pro His Gly Lys Cys Lys Ser Gin Ser Ala 1 5 10 15 GGC AAA TTC ACC TGT GAC TGT AAC AAA GGC TTC ACC GGC ACC TAC TGC 96 Gly Lys Phe Thr Cyβ Asp Cys Asn Lys Gly Phe Thr Gly Thr Tyr Cys 20 25 30 CAT GAA AAT ATC AAC GAC TGC GAG AGC AAC CCC TGT AAA 135 Hie Glu Asn He Asn Aβp Cyβ Glu Ser Aβn Pro Cys Lys 35 40 45 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: Ser Ser Asn Val Cys Gly Pro His Gly Lys Cys Lys Ser Gin Ser Ala 1 5 10 15 Gly Lys Phe Thr Cys Aβp Cyβ Asn Lys Gly Phe Thr Gly Thr Tyr Cys 20 25 30 His Glu Aβn He Asn Asp Cys Glu Ser Asn Pro Cys Lys 35 40 45 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (ix) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 3 (D) OTHER INFORMATION: /mod_base= i (ix) FEATURE: (A) NAME/KEY: modified_baβe (B) LOCATION: 6 (D) OTHER INFORMATION: /mod_baβe= i (ix) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 12 (D) OTHER INFORMATION: /mod_base= i (ix) FEATURE: (A) NAME/KEY: modified_base (B) LOCATION: 18 (D) OTHER INFORMATION: /mod_base= i (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: CGNYTNTGCY TNAARSANTA YCA 23 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (ix) FEATURE: (A) NAME/KEY: Modified-site (B) LOCATION: 6 (D) OTHER INFORMATION: /label* A /note= "X-glutamic acid or hiβtidine" (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: Arg Leu Cys Leu Lys Xaa Tyr Gin 1 5 International Application No: PCT/ MICROORGANISMS Optional Sheet in connection with the microorganism referred to on page 86-87, lines 1- Q of the description ' A. IDENTIFICATION OF DEPOSIT ' Further deposits are identified on an additional sheet Name of depositary institution ' American Type Culture Collection Address of depositary institution (including postal code and country) 12301 Parklawn Drive Rockville. MD 208S2 US Date of deposit ' February 28, 1995 Accession Number • 97068 B. ADDITIONAL INDICATIONS ' (leave blank if not applicable). This information u continued on a separate -niched sheet C. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE ' ore.. D. SEPARATE FURNISHING OF INDICATIONS ' (leave blank if not applicable) The indication* Hated below will be submitted to the International Bureau later ' (Specify the oeneral nature of the indications e.g., "Acceaaion Number of Deposit") E. D This sheet was received with the International application when filed (to be checked by the receiving Office) (Authorized Officer) D The date of receipt (from the applicant) by the International Bureau ' (Authorized Officer) Form PCT/RO/134 (January 19S1. International Application No: PCT/ Form PCT/RO/134 (cont.) American Type Culture Collection 12301 Parklawn Drive Rockville, MD 20852 US Accession No. Date of Deposit March 5, 1996 March 5, 1996

Claims: WHAT IS CLAIMED IS: 1. A purified vertebrate Serrate protein. 2. The protein of claim 1 which is a human protein. The protein of claim 1 which is a mammalian protein. 4. The protein of claim 2 which comprises the amino acid sequence substantially as set forth in amino acid numbers 30 - 1218 of SEQ ID NO:2. 5. The protein of claim 2 which comprises the amino acid sequence substantially as set forth in amino acid numbers 1 - 1257 of SEQ ID NO:4. 6. A purified human protein encoded by a nucleic acid hybridizable to plasmid SerFL or the Serrate sequence therein as deposited with the ATCC and assigned accession number 68876. 7. The protein of claim 2 which is encoded by plasmid pBS39 as deposited with the ATCC and assigned accession number 97068. 8. The protein of claim 2 which comprises the Serrate amino acid sequence encoded by plasmid pBS15 as deposited with the ATCC and assigned accession number . 9. The protein of claim 2 which comprises the Serrate amino acid sequence encoded by plasmid pBS3-2 as deposited with the ATCC and assigned accession number 10. A purified fragment of the protein of claim 1, which is able to display one or more functional activities of a Serrate protein. 11. A purified fragment of the protein of claim 2, which is able to display one or more functional activities of a human or D . melanogaster Serrate protein. 12. A purified fragment of the protein of claim 2 or 7, which is able to be bound by an antibody directed against a human Serrate protein. 13. A molecule comprising the fragment of claim 10. 14. A purified fragment of a vertebrate Serrate protein comprising a domain of the protein selected from the group consisting of the extracellular domain, DSL domain, epidermal growth factor-like repeat domain, cysteine-rich domain, transmembrane domain, and intracellular domain. 15. A purified fragment of a vertebrate Serrate protein comprising the DSL domain of the protein. 16. A purified fragment of a vertebrate Serrate protein comprising an epidermal growth factor-homologous repeat of the protein. 17. The fragment of claim 14 in which the Serrate protein is a human Serrate protein. 18. A purified fragment of a vertebrate Serrate protein comprising a region homologous to a Notch protein or a Delta protein, and consisting of at least ten amino acids. 19. A chimeric protein comprising a fragment of a vertebrate Serrate protein consisting of at least ten amino acids fused via a covalent bond to an amino acid sequence of a second protein, in which the second protein is not a Serrate protein. 20. The chimeric protein of claim 19 in which the fragment of a Serrate protein is a fragment capable of being bound by an anti-Serrate antibody. 21. The chimeric protein of claim 19 in which the Serrate protein is a human protein. 22. The chimeric protein of claim 19 which is able to display one or more functional activities of a Serrate protein. 23. A purified fragment of a vertebrate Serrate protein which fragment (a) is capable of being bound by an anti-Serrate antibody; (b) lacks the transmembrane and intracellular domains of the protein; and (c) consists of at least ten amino acids of the Serrate protein. 24. A purified fragment of a vertebrate Serrate protein which fragment (a) is capable of being bound by an anti-Serrate antibody; (b) lacks the extracellular domain of the protein; and (c) consists of at least ten amino acids of the Serrate protein. 25. A purified fragment of a vertebrate Serrate protein which is able to bind to a Notch protein. 26. The fragment of claim 25, which lacks the epidermal growth factor-like repeats of the Serrate protein. 27. The fragment of claim 23, 24, 25 or 26 in which the Serrate protein is a human Serrate protein. 28. The fragment of claim 29, which is a fragment of SEQ ID NO:2 or SEQ ID NO:4. 29. A molecule comprising the fragment of claim 25. 30. An antibody which is capable of binding the Serrate protein of claim 1 and which does not bind a Drosophila Serrate protein. 31. An antibody which is capable of binding the Serrate protein of claim 2 and which does not bind a Drosophila Serrate protein. 32. The antibody of claim 30 which is monoclonal. 33. A molecule comprising a fragment of the antibody of claim 32, which fragment is capable of binding a vertebrate Serrate protein. 34. An isolated nucleic acid comprising a nucleotide sequence encoding a vertebrate Serrate protein. 35. The nucleic acid of claim 34 which is DNA. 36. An isolated nucleic acid comprising a nucleotide sequence absolutely complementary to the nucleotide sequence of claim 34. 37. An isolated nucleic acid comprising a nucleotide sequence encoding the Serrate protein of claim 2. 38. An isolated nucleic acid comprising the Serrate coding sequence contained in plasmid pBS39 as deposited with the ATCC and assigned accession number 97068. 39. An isolated human nucleic acid hybridizable to plasmid SerFL or the Serrate sequence therein as deposited with the ATCC and assigned accession number 68876. 40. An isolated nucleic acid comprising the Serrate coding sequence contained in plasmid pBS3-2 as deposited with the ATCC and assigned accession number . 41. An isolated nucleic acid comprising the Serrate coding sequence contained in plasmid pBS15 as deposited with the ATCC and assigned accession number . 42. An isolated nucleic acid comprising a nucleotide sequence encoding a protein, said protein comprising amino acid numbers 1 - 1257 of SEQ ID NO:4. 43. An isolated nucleic acid comprising a fragment of a vertebrate Serrate gene consisting of at least 8 nucleotides. 44. An isolated nucleic acid comprising a nucleotide sequence encoding the fragment of claim 14, 15, 16 or 25. 45. The nucleic acid of claim 44 in which the fragment is a fragment of a human Serrate protein. 46. An isolated nucleic acid comprising a nucleotide sequence encoding the fragment of claim 12. 47. An isolated nucleic acid comprising a nucleotide sequence encoding a protein, said protein comprising amino acid numbers 30 - 1218 of SEQ ID NO:2. 48. An isolated nucleic acid comprising a nucleotide sequence encoding the protein of claim 21. 49. A recombinant cell containing the nucleic acid of claim 34, 37 or 43. 50. A recombinant cell containing the nucleic acid of claim 38, 40 or 41. 51. A method of producing a Serrate protein comprising growing a recombinant cell containing the nucleic acid of claim 34 or 37 such that the encoded Serrate protein is expressed by the cell, and recovering the expressed Serrate protein. 52. A method of producing a Serrate protein comprising growing a recombinant cell containing the nucleic acid of claim 38, 40 or 41 such that the encoded Serrate protein is expressed by the cell, and recovering the expressed Serrate protein. 53. A method of producing a Serrate protein comprising growing a recombinant cell containing the nucleic acid of claim 45 such that the encoded protein is expressed by the cell, and recovering the expressed protein. 54. A method of producing a protein comprising a fragment of a Serrate protein, which method comprises growing a recombinant cell containing the nucleic acid of claim 46 such that the encoded protein is expressed by the cell, and recovering the expressed protein. 55. The product of the process of claim 51. 56. The product of the process of claim 52. 57. The product of the process of claim 53. 58. The product of the process of claim 54. 59. A pharmaceutical composition comprising a therapeutically effective amount of a vertebrate Serrate protein; and a pharmaceutically acceptable carrier. 60. The composition of claim 59 in which the Serrate protein is a human Serrate protein. 61. A pharmaceutical composition comprising a therapeutically effective amount of the fragment of claim 14, 15, 16 or 25; and a pharmaceutically acceptable carrier. 62. A pharmaceutical composition comprising a therapeutically effective amount of the fragment of claim 12; and a pharmaceutically acceptable carrier. 63. A pharmaceutical composition comprising a therapeutically effective amount of a molecule comprising a fragment of a vertebrate Serrate protein, which derivative or analog is characterized by the ability to bind to a Notch protein or to a molecule comprising the epidermal growth factor-like repeats 11 and 12 of a Notch protein. 64. A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of claim 34, 36 or 37; and a pharmaceutically acceptable carrier. 65. A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of claim 44; and a pharmaceutically acceptable carrier. 66. A pharmaceutical composition comprising a therapeutically effective amount of the nucleic acid of claim 46; and a pharmaceutically acceptable carrier. 67. A pharmaceutical composition comprising a therapeutically effective amount of the antibody of claim 30; and a pharmaceutically acceptable carrier. 68. A pharmaceutical composition comprising a therapeutically effective amount of a fragment or derivative of the antibody of claim 30 containing the binding domain of the antibody; and a pharmaceutically acceptable carrier. 69. A method of treating or preventing a disease or disorder in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a vertebrate Serrate protein or derivative thereof which is able to bind to a Notch protein. 70. The method according to claim 69 in which the disease or disorder is a malignancy characterized by increased Notch activity or increased expression of a Notch protein or of a Notch derivative capable of being bound by an anti-Notch antibody, relative to said Notch activity or expression in an analogous non-malignant sample. 71. The method according to claim 69 in which the disease or disorder is selected from the group consisting of cervical cancer, breast cancer, colon cancer, melanoma, seminoma, and lung cancer. 72. The method according to claim 69 in which the subject is a human. 73. The method according to claim 69 in which the Serrate protein is a human Serrate protein. 74. A method of treating or preventing a disease or disorder in a subject comprising administering to a subject in which such treatment or prevention is desired a therapeutically effective amount of a molecule, in which the molecule is an oligonucleotide which (a) comprises ten nucleotides; (b) comprises a sequence absolutely complementary to an at least ten nucleotide portion of an RNA transcript specific to a vertebrate Serrate gene; and (c) is hybridizable to the RNA transcript. 75. A method of treating or preventing a disease or disorder in a subject comprising administering to a subject in which such treatment or prevention is desired an effective amount of the nucleic acid of claim 34, 37 or 46. 76. A method of treating or preventing a disease or disorder in a subject comprising administering to a subject in which such treatment or prevention is desired an effective amount of the antibody of claim 32. 77. The method according to claim 73 in which the disease or disorder is a disease or disorder of the central nervous system. 78. An isolated oligonucleotide comprising ten nucleotides, and comprising a sequence absolutely complementary to an at least ten nucleotide portion of an RNA transcript specific to a vertebrate Serrate gene, which oligonucleotide is hybridizable to the RNA transcript. 79. A pharmaceutical composition comprising the oligonucleotide of claim 78; and a pharmaceutically acceptable carrier. 80. A method of inhibiting the expression of a nucleic acid sequence encoding a Serrate protein in a cell comprising providing the cell with an effective amount of the oligonucleotide of claim 78. 81. A method of diagnosing a disease or disorder characterized by an aberrant level of Notch-Serrate protein binding activity in a patient, comprising measuring the ability of a Notch protein in a sample derived from the patient to bind to a vertebrate Serrate protein, in which an increase or decrease in the ability of the Notch protein to bind to the Serrate protein, relative to the ability found in an analogous sample from a normal individual, indicates the presence of the disease or disorder in the patient. 82. A method of diagnosing a disease or disorder characterized by an aberrant level of Serrate protein in a patient, comprising measuring the levels of a vertebrate Serrate protein in a sample derived from the patient, in which an increase or decrease in the levels of the Serrate protein, relative to the levels of the Serrate protein found in an analogous sample from a normal individual, indicates the presence of the disease or disorder in the patient.

Inventors: ARTAVANIS-TSAKONAS SPYRIDON, GRAY GRACE E, HENRIQUE DOMINGOS M P, ISH-HOROWICZ DAVID, LEWIS JULIAN H, MANN ROBERT S, MYAT ANNA M, ARTAVANIS-TSAKONAS, SPYRIDON, GRAY, GRACE, E., HENRIQUE, DOMINGOS, M., P., ISH-HOROWICZ, DAVID, LEWIS, JULIAN, H., MANN, ROBERT, S., MYAT, ANNA, M.
Applicants: ARTAVANIS TSAKONAS SPYRIDON, GRAY GRACE E, HENRIQUE DOMINGOS M P, IMP CANCER RES TECH, ISH HOROWICZ DAVID, LEWIS JULIAN H, MANN ROBERT S, MYAT ANNA M, UNIV YALE, ARTAVANIS-TSAKONAS, SPYRIDON, GRAY, GRACE, E., HENRIQUE, DOMINGOS, M., P., IMPERIAL CANCER RESEARCH TECHNOLOGY, LTD., ISH-HOROWICZ, DAVID, LEWIS, JULIAN, H., MANN, ROBERT, S., MYAT, ANNA, M., YALE UNIVERSITY
Application year: 1996
Main classification: C07K14
IPC codes: A61K31, A61K38, A61K39, A61K48, A61P25, A61P35, C07K14, C07K16, C07K19, C12N5, C12N15, C12P21, C12Q1, G01N33